50_CD
Hikma_NN
Pharmaceuticals_NN
PLC_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
1_CD
._.
Corporate_JJ
restructuring_GER
During_PIN
the_DT
period_NN
the_DT
Group_NN
carried_VBD
out_PIN
a_DT
corporate_JJ
restructuring_GER
including_VBG [WZPRES]
the_DT
introduction_NOMZ
of_PIN
a_DT
new_JJ
holding_VBG [PRIV]
company_NN
,_,
Hikma_NN
Pharma_NN
PLC_NN
,_,
incorporated_VBN [PASTP]
in_PIN
Great_NN
Britain_NN
as_IN
a_DT
public_JJ
limited_JJ
company_NN
on_PIN
8_CD
September_NN
2005_CD
._.
Hikma_NN
Pharma_NN
PLC_NN
changed_VBD
its_PIT
name_NN
to_PIN
Hikma_NN
Pharmaceuticals_NN
PLC_NN
on_PIN
19_CD
September_NN
2005_CD
and_CC
on_PIN
31_CD
October_NN
2005_CD
Hikma_NN
Pharmaceuticals_NN
PLC_NN
acquired_VBD
the_DT
issued_VBN
share_NN
capital_NN
of_PIN
Hikma_NN
Pharma_NN
Limited_NN
,_,
the_DT
former_JJ
holding_VBG [PRIV]
company_NN
,_,
for_PIN
the_DT
issue_NN
of_PIN
shares_NN
to_PIN
shareholders_NN
on_PIN
the_DT
basis_NN
of_PIN
four_CD
shares_NN
for_PIN
every_QUAN
one_CD
share_NN
held_VBN [PRIV] [WZPAST]
in_PIN
Hikma_NN
Pharma_NN
Limited_NN
._.
Prior_RB
to_PIN
31_CD
October_NN
2005_CD
,_,
Hikma_NN
Pharmaceuticals_NN
PLC_NN
had_VBD [PEAS]
not_XX0
commenced_VBN
trading_GER
or_CC
made_VBN
any_QUAN
profits_NN
or_CC
losses_NN
._.
On_PIN
1_CD
November_NN
2005_CD
the_DT
shares_NN
of_PIN
Hikma_NN
Pharmaceuticals_NN
PLC_NN
were_VBD [PASS]
listed_VBN
on_PIN
the_DT
London_NN
Stock_NN
Exchange_NN
._.
The_DT
corporate_JJ
restructuring_GER
was_VBD [PASS]
accounted_VBN
for_PIN
using_VBG
merger_NN
accounting_GER
principles_NN
._.
The_DT
results_NN
of_PIN
the_DT
Company_NN
and_CC
its_PIT
subsidiaries_NN
have_VPRT [PEAS]
been_VBN [PASS]
presented_VBN
on_PIN
a_DT
pro_PIN
forma_FW
basis_NN
for_PIN
the_DT
years_NN
ended_VBN
31_CD
December_NN
2005_CD
and_CC
31_CD
December_NN
2004_CD
as_IN
the_DT
Directors_NN
believe_VPRT [PRIV]
this_DEMO
information_NOMZ
is_VPRT [BEMA]
more_EMPH
meaningful_PRED
to_PIN
readers_NN
than_PIN
information_NOMZ
for_PIN
the_DT
period_NN
from_PIN
8_CD
September_NN
2005_CD
to_PIN
31_CD
December_NN
2005_CD
._.
The_DT
Directors_NN
believe_VPRT [PRIV] [THATD]
that_DEMP
this_DEMO
presentation_NOMZ
is_VPRT [BEMA]
necessary_PRED
to_TO
present_VB
a_DT
true_JJ
and_PHC
fair_JJ
view_NN
of_PIN
the_DT
results_NN
of_PIN
the_DT
Company_NN
and_CC
its_PIT
subsidiaries_NN
for_PIN
the_DT
period_NN
._.
The_DT
Hikma_NN
Pharmaceuticals_NN
PLC_NN
consolidated_JJ
statutory_JJ
income_NN
statement_NOMZ
and_PHC
cash_NN
flow_NN
statement_NOMZ
for_PIN
the_DT
period_NN
from_PIN
8_CD
September_NN
2005_CD
,_,
the_DT
date_NN
of_PIN
incorporation_NOMZ
,_,
to_PIN
31_CD
December_NN
2005_CD
is_VPRT [PASS]
presented_VBN
in_PIN
Note_NN
44_CD
,_,
in_PIN
order_NN
to_TO
comply_VB
with_PIN
Section_NOMZ
226_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
._.
Significant_JJ
accounting_GER
policies_NN
Basis_NN
of_PIN
accounting_GER
Hikma_NN
Pharmaceuticals_NN
PLCs_NN
consolidated_JJ
financial_JJ
statements_NOMZ
are_VPRT [PASS]
prepared_VBN
in_PIN
accordance_NN
with_PIN
International_NN
Financial_NN
Reporting_GER
Standards_NN
IFRS_NN
issued_VBN [WZPAST]
by_PIN
the_DT
International_NN
Accounting_GER
Standards_NN
Board_NN
._.
The_DT
financial_JJ
statements_NOMZ
have_VPRT [SPAU] [PEAS]
also_RB
been_VBN [PASS]
prepared_VBN
in_PIN
accordance_NN
with_PIN
IFRS_NN
adopted_VBD
for_PIN
use_NN
in_PIN
the_DT
European_NN
Union_NN
and_ANDC
therefore_CONJ
comply_VB
with_PIN
Article_NN
4_CD
of_PIN
the_DT
EU_NN
IAS_NN
Regulation_NOMZ
._.
The_DT
financial_JJ
statements_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
under_IN
the_DT
historical_JJ
cost_NN
convention_NOMZ
,_,
except_PIN
for_PIN
the_DT
revaluation_NOMZ
to_PIN
market_NN
of_PIN
certain_JJ
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
._.
The_DT
Groups_NN
previously_TIME
published_VBN
financial_JJ
statements_NOMZ
were_VBD [SPAU] [PASS]
also_RB
prepared_VBN
in_PIN
accordance_NN
with_PIN
International_NN
Financial_NN
Reporting_GER
Standards_NN
._.
These_DEMO
International_NN
Financial_NN
Reporting_GER
Standards_NN
have_VPRT [PEAS]
been_VBN [BEMA]
subject_PRED
to_PIN
amendment_NOMZ
and_PHC
interpretation_NOMZ
by_PIN
the_DT
International_NN
Accounting_GER
Standards_NN
Board_NN
and_CC
the_DT
financial_JJ
statements_NOMZ
presented_VBN [WZPAST]
for_PIN
the_DT
years_NN
ended_VBN
31_CD
December_NN
2004_CD
and_CC
31_CD
December_NN
2005_CD
have_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
in_PIN
accordance_NN
with_PIN
those_DEMP
revised_VBN
standards_NN
._.
Unless_COND
stated_VBN [PUBV]
otherwise_CONJ
these_DEMO
policies_NN
are_VPRT [BEMA]
in_PIN
accordance_NN
with_PIN
the_DT
revised_VBN
standards_NN
that_TSUB
have_VPRT [PEAS]
been_VBN [PASS]
applied_VBN
throughout_PIN
the_DT
year_NN
and_CC
prior_JJ
years_NN
presented_VBN [WZPAST]
in_PIN
this_DEMO
financial_JJ
statements_NOMZ
._.
The_DT
currency_NN
used_VBN [WZPAST]
in_PIN
the_DT
preparation_NOMZ
of_PIN
the_DT
accompanying_VBG
consolidated_JJ
financial_JJ
statements_NOMZ
is_VPRT [BEMA]
the_DT
US_FPP1
Dollar_NN
as_IN
the_DT
majority_NOMZ
of_PIN
the_DT
Companys_NN
business_NOMZ
is_VPRT [PASS]
conducted_VBN
in_PIN
US_FPP1
Dollars_NN
$_$
._.
The_DT
significant_JJ
accounting_GER
policies_NN
are_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
._.
Restatement_NOMZ
of_PIN
prior_JJ
year_NN
income_NN
statement_NOMZ
comparatives_VPRT
The_DT
following_JJ
restatements_NOMZ
had_VBD
no_SYNE
effect_NN
on_PIN
the_DT
profit_NN
for_PIN
the_DT
2004_CD
financial_JJ
year_NN
or_CC
on_PIN
the_DT
net_JJ
assets_NN
of_PIN
the_DT
Group_NN
at_PIN
31_CD
December_NN
2004_CD
._.
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2005_CD
,_,
the_DT
Groups_NN
share_NN
of_PIN
results_NN
of_PIN
associates_NN
has_VPRT [PEAS]
been_VBN [PASS]
included_VBN
within_PIN
operating_GER
profit_NN
as_IN
the_DT
Directors_NN
consider_VPRT [PRIV]
these_DEMO
activities_NOMZ
to_TO
be_VB [BEMA]
operational_JJ
activities_NOMZ
and_CC
the_DT
2004_CD
comparative_JJ
has_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
._.
Accordingly_RB
,_,
management_NOMZ
fees_NN
receivable_JJ
from_PIN
associates_NN
of_PIN
$_$
1,016,000_CD
2004_CD
:_:
$_$
333,000_CD
are_VPRT [PASS]
included_VBN
in_PIN
other_JJ
operating_GER
income_NN
._.
In_PIN
2004_CD
the_DT
management_NOMZ
fees_NN
were_VBD [PASS]
included_VBN
in_PIN
other_JJ
income_NN
._.
Flotation_NOMZ
costs_NN
totalling_VBG [WZPRES]
$_$
425,000_CD
incurred_VBN
in_PIN
2004_CD
were_VBD [PASS]
classified_VBN
as_IN
general_JJ
and_PHC
administrative_JJ
expenses_NN
._.
Following_VBG
flotation_NOMZ
,_,
the_DT
2004_CD
comparatives_NN
have_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
to_TO
reflect_VB [PRIV]
these_DEMO
costs_NN
as_IN
non_NN
operational_JJ
._.
The_DT
prior_JJ
year_NN
comparatives_NN
for_PIN
revenue_NN
,_,
sales_NN
and_PHC
marketing_GER
costs_NN
,_,
and_ANDC
general_JJ
and_PHC
administrative_JJ
expenses_NN
have_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
to_TO
reflect_VB [PRIV]
a_DT
change_NN
in_PIN
accounting_GER
policy_NN
for_PIN
Medicaid_NN
rebates_NN
and_CC
associated_VBN
administrative_JJ
charges_NN
paid_VBN [WZPAST]
to_PIN
the_DT
wholesale_JJ
customers_NN
of_PIN
the_DT
Generics_NN
division_NN
._.
The_DT
restatement_NOMZ
has_VPRT [PEAS]
resulted_VBN
in_PIN
revenue_NN
,_,
sales_NN
and_PHC
marketing_GER
costs_NN
,_,
and_ANDC
general_JJ
and_PHC
administrative_JJ
expenses_NN
being_VBG [WZPRES] [BYPA]
decreased_VBN
by_PIN
$_$
1,771,000_CD
,_,
$_$
1,334,000_CD
and_CC
$_$
437,000_CD
respectively_RB
._.
This_DEMO
restatement_NOMZ
had_VBD
no_SYNE
effect_NN
on_PIN
operating_VBG
profits_NN
for_PIN
the_DT
period_NN
._.
Significant_JJ
accounting_GER
policies_NN
continued_VBD
Basis_NN
of_PIN
consolidation_NOMZ
The_DT
consolidated_JJ
financial_JJ
statements_NOMZ
incorporate_VPRT
the_DT
results_NN
of_PIN
Hikma_NN
Pharmaceuticals_NN
PLC_NN
the_DT
Company_NN
and_PHC
entities_NOMZ
controlled_VBN [WZPAST]
by_PIN
the_DT
Company_NN
together_RB
the_DT
Group_NN
._.
Control_NN
is_VPRT [PASS]
achieved_VBN
where_RB
the_DT
Company_NN
has_VPRT
the_DT
power_NN
to_TO
govern_VB
the_DT
financial_JJ
and_CC
operating_VBG
policies_NN
of_PIN
an_DT
investee_NN
entity_NOMZ
so_RB
as_IN
to_TO
obtain_VB
benefits_NN
from_PIN
its_PIT
activities_NOMZ
._.
On_PIN
acquisition_NOMZ
,_,
the_DT
assets_NN
and_PHC
liabilities_NOMZ
and_CC
contingent_JJ
liabilities_NOMZ
of_PIN
a_DT
subsidiary_NN
are_VPRT [PASS]
measured_VBN
at_PIN
their_TPP3
fair_JJ
values_NN
at_PIN
the_DT
date_NN
of_PIN
acquisition_NOMZ
._.
Any_QUAN
excess_NN
of_PIN
the_DT
cost_NN
of_PIN
acquisition_NOMZ
over_IN
the_DT
fair_JJ
values_NN
of_PIN
the_DT
identifiable_JJ
net_JJ
assets_NN
acquired_VBN [WZPAST]
is_VPRT [PASS]
recognized_VBN [PRIV]
as_IN
goodwill_NN
._.
The_DT
interest_NN
of_PIN
minority_NOMZ
shareholders_NN
is_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
the_DT
minoritys_NN
proportion_NOMZ
of_PIN
the_DT
fair_JJ
values_NN
of_PIN
the_DT
assets_NN
and_PHC
liabilities_NOMZ
recognized_VBN [PRIV]
._.
Subsequently_TIME
,_,
any_QUAN
losses_NN
applicable_JJ
to_PIN
the_DT
minority_NOMZ
interest_NN
in_PIN
excess_NN
of_PIN
the_DT
minority_NOMZ
interest_NN
are_VPRT [PASS]
allocated_VBN
against_PIN
the_DT
interests_NN
of_PIN
the_DT
parent_NN
._.
The_DT
results_NN
of_PIN
subsidiaries_NN
acquired_VBN
or_CC
disposed_VBN
of_PIN
during_PIN
the_DT
year_NN
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
consolidated_JJ
income_NN
statement_NOMZ
from_PIN
the_DT
effective_JJ
date_NN
of_PIN
acquisition_NOMZ
or_CC
up_RB
to_PIN
the_DT
effective_JJ
date_NN
of_PIN
disposal_NN
,_,
as_IN
appropriate_JJ
._.
Where_RB
necessary_JJ
,_,
adjustments_NOMZ
are_VPRT [PASS]
made_VBN
to_PIN
the_DT
financial_JJ
statements_NOMZ
of_PIN
subsidiaries_NN
to_TO
bring_VB
the_DT
accounting_GER
policies_NN
used_VBN [WZPAST]
in_PIN
line_NN
with_PIN
those_DEMP
used_VBN
by_PIN
the_DT
Group_NN
._.
All_QUAN
intra-Group_JJ
transactions_NOMZ
,_,
balances_NN
,_,
income_NN
and_PHC
expenses_NN
are_VPRT [PASS]
eliminated_VBN
on_PIN
consolidation_NOMZ
._.
Business_NOMZ
combinations_NOMZ
The_DT
acquisition_NOMZ
of_PIN
subsidiaries_NN
is_VPRT [PASS]
accounted_VBN
for_PIN
using_VBG
the_DT
purchase_NN
method_NN
._.
The_DT
cost_NN
of_PIN
the_DT
acquisition_NOMZ
is_VPRT [PASS]
measured_VBN
at_PIN
the_DT
aggregate_NN
of_PIN
the_DT
fair_JJ
values_NN
,_,
at_PIN
the_DT
date_NN
of_PIN
exchange_NN
,_,
of_PIN
assets_NN
given_VBN
,_,
liabilities_NOMZ
incurred_VBN
or_CC
assumed_VBN [PRIV]
,_,
and_ANDC
equity_NOMZ
instruments_NOMZ
issued_VBN [WZPAST]
by_PIN
the_DT
Group_NN
in_PIN
exchange_NN
for_PIN
control_NN
of_PIN
the_DT
acquiree_NN
,_,
plus_PIN
any_QUAN
costs_NN
directly_RB
attributable_JJ
to_PIN
the_DT
business_NOMZ
combination_NOMZ
._.
The_DT
acquirees_NN
identifiable_JJ
assets_NN
,_,
liabilities_NOMZ
and_CC
contingent_JJ
liabilities_NOMZ
that_TSUB
meet_VPRT
the_DT
conditions_NOMZ
for_PIN
recognition_NOMZ
under_IN
IFRS_NN
3_CD
are_VPRT [PASS]
recognized_VBN [PRIV]
at_PIN
their_TPP3
fair_JJ
value_NN
at_PIN
the_DT
acquisition_NOMZ
date_NN
._.
Goodwill_NN
arising_VBG [WZPRES]
on_PIN
acquisition_NOMZ
is_VPRT [PASS]
recognized_VBN [PRIV]
as_IN
an_DT
asset_NN
and_CC
initially_TIME
measured_VBN
at_PIN
cost_NN
,_,
being_VBG [PRESP] [BEMA]
the_DT
excess_NN
of_PIN
the_DT
cost_NN
of_PIN
the_DT
business_NOMZ
combination_NOMZ
over_IN
the_DT
Groups_NN
interest_NN
in_PIN
the_DT
net_JJ
fair_JJ
value_NN
of_PIN
the_DT
identifiable_JJ
assets_NN
,_,
liabilities_NOMZ
and_CC
contingent_JJ
liabilities_NOMZ
recognized_VBN [PRIV]
._.
If_COND
,_,
after_IN
reassessment_NOMZ
,_,
the_DT
Groups_NN
interest_NN
in_PIN
the_DT
net_JJ
fair_JJ
value_NN
of_PIN
the_DT
acquirees_NN
identifiable_JJ
assets_NN
,_,
liabilities_NOMZ
and_CC
contingent_JJ
liabilities_NOMZ
exceeds_VPRT
the_DT
cost_NN
of_PIN
the_DT
business_NOMZ
combination_NOMZ
,_,
the_DT
excess_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
immediately_TIME
in_PIN
profit_NN
or_CC
loss_NN
._.
The_DT
interest_NN
of_PIN
minority_NOMZ
shareholders_NN
in_PIN
the_DT
acquiree_NN
is_VPRT [SPAU] [PASS]
initially_TIME
measured_VBN
at_PIN
the_DT
minoritys_NN
proportion_NOMZ
of_PIN
the_DT
net_JJ
fair_JJ
value_NN
of_PIN
the_DT
assets_NN
,_,
liabilities_NOMZ
and_CC
contingent_JJ
liabilities_NOMZ
recognized_VBN [PRIV]
._.
Investments_NOMZ
in_PIN
associates_NN
An_DT
associate_NN
is_VPRT [BEMA]
an_DT
entity_NOMZ
over_IN
which_WDT
the_DT
Group_NN
is_VPRT [BEMA]
in_PIN
a_DT
position_NOMZ
to_TO
exercise_VB
significant_JJ
influence_NN
,_,
but_CC
not_XX0
control_VB
or_CC
joint_JJ
control_NN
,_,
through_PIN
participation_NOMZ
in_PIN
the_DT
financial_JJ
and_CC
operating_GER
policy_NN
decisions_NN
of_PIN
the_DT
investee_NN
._.
The_DT
results_NN
and_PHC
assets_NN
and_PHC
liabilities_NOMZ
of_PIN
associates_NN
are_VPRT [PASS]
incorporated_VBN
in_PIN
the_DT
financial_JJ
statements_NOMZ
using_VBG [WZPRES]
the_DT
equity_NOMZ
method_NN
of_PIN
accounting_GER
except_PIN
when_RB
classified_VBN
as_IN
held_VBN [PRIV]
for_PIN
sale_NN
._.
Investments_NOMZ
in_PIN
associates_NN
are_VPRT [PASS]
carried_VBN
in_PIN
the_DT
balance_NN
sheet_NN
at_PIN
cost_NN
as_IN
adjusted_VBN
by_PIN
post-acquisition_JJ
changes_NN
in_PIN
the_DT
Groups_NN
share_NN
of_PIN
the_DT
net_JJ
assets_NN
of_PIN
the_DT
associate_NN
,_,
less_JJ
any_QUAN
impairment_NOMZ
in_PIN
the_DT
value_NN
of_PIN
individual_JJ
investments_NOMZ
._.
Losses_NN
of_PIN
the_DT
associates_NN
in_PIN
excess_NN
of_PIN
the_DT
Groups_NN
interest_NN
in_PIN
those_DEMO
associates_NN
are_VPRT [PASS]
not_XX0
recognized_VBN [PRIV]
._.
Any_QUAN
excess_NN
of_PIN
the_DT
cost_NN
of_PIN
acquisition_NOMZ
over_IN
the_DT
Groups_NN
share_NN
of_PIN
the_DT
fair_JJ
values_NN
of_PIN
the_DT
identifiable_JJ
net_JJ
assets_NN
of_PIN
the_DT
associate_NN
at_PIN
the_DT
date_NN
of_PIN
acquisition_NOMZ
is_VPRT [PASS]
recognized_VBN [PRIV]
as_IN
goodwill_NN
._.
Where_RB
a_DT
Group_NN
company_NN
transacts_VPRT
with_PIN
an_DT
associate_NN
of_PIN
the_DT
Group_NN
,_,
profits_NN
and_PHC
losses_NN
are_VPRT [PASS]
eliminated_VBN
to_PIN
the_DT
extent_NN
of_PIN
the_DT
Groups_NN
interest_NN
in_PIN
the_DT
relevant_JJ
associate_NN
._.
52_CD
Hikma_NN
Pharmaceuticals_NN
PLC_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
continued_VBD
2_CD
._.
Significant_JJ
accounting_GER
policies_NN
continued_VBD
Intangible_JJ
assets_NN
Intangible_JJ
assets_NN
are_VPRT [PASS]
valued_VBN
at_PIN
cost_NN
and_CC
reviewed_VBN
at_PIN
least_JJ
annually_RB
for_PIN
any_QUAN
impairment_NOMZ
._.
Any_QUAN
resulting_VBG
impairment_NOMZ
loss_NN
is_VPRT [PASS]
recorded_VBN
in_PIN
the_DT
income_NN
statement_NOMZ
under_IN
general_JJ
and_PHC
administrative_JJ
expenses_NN
._.
a_DT
Goodwill_NN
:_:
Goodwill_NN
arising_VBG [WZPRES]
on_PIN
consolidation_NOMZ
represents_VPRT
the_DT
excess_NN
of_PIN
the_DT
cost_NN
of_PIN
acquisition_NOMZ
over_IN
the_DT
Groups_NN
interest_NN
in_PIN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
identifiable_JJ
assets_NN
and_PHC
liabilities_NOMZ
of_PIN
a_DT
subsidiary_NN
at_PIN
the_DT
date_NN
of_PIN
acquisition_NOMZ
._.
Goodwill_NN
is_VPRT [SPAU] [PASS]
initially_TIME
recognized_VBN [PRIV]
as_IN
an_DT
asset_NN
at_PIN
cost_NN
and_CC
is_VPRT [SPAU] [PASS]
subsequently_TIME
measured_VBN
at_PIN
cost_NN
less_JJ
any_QUAN
accumulated_VBN
impairment_NOMZ
losses_NN
._.
Goodwill_NN
which_WDT [WHSUB]
is_VPRT [PASS]
recognized_VBN [PRIV]
as_IN
an_DT
asset_NN
is_VPRT [PASS]
reviewed_VBN
for_PIN
impairment_NOMZ
at_PIN
least_JJ
annually_RB
._.
Any_QUAN
impairment_NOMZ
is_VPRT [PASS]
recognized_VBN [PRIV]
immediately_TIME
in_PIN
profit_NN
or_CC
loss_NN
and_CC
is_VPRT
not_XX0
subsequently_TIME
reversed_PRED
._.
For_PIN
the_DT
purpose_NN
of_PIN
impairment_NOMZ
testing_GER
,_,
goodwill_NN
is_VPRT [PASS]
allocated_VBN
to_PIN
each_QUAN
of_PIN
the_DT
Groups_NN
cash-generating_JJ
units_NN
._.
Cash-generating_VBG
units_NN
to_PIN
which_WDT [PIRE]
goodwill_NN
has_VPRT [PEAS]
been_VBN [PASS]
allocated_VBN
are_VPRT [PASS]
tested_VBN
for_PIN
impairment_NOMZ
annually_RB
,_,
or_CC
more_EMPH
frequently_RB
when_RB
there_EX
is_VPRT
an_DT
indication_NOMZ
that_TOBJ
the_DT
unit_NN
may_POMD
be_VB [PASS]
impaired_VBN
._.
If_COND
the_DT
recoverable_JJ
amount_NN
of_PIN
the_DT
cash-generating_JJ
unit_NN
is_VPRT [BEMA]
less_PRED
than_PIN
the_DT
carrying_VBG
amount_NN
of_PIN
the_DT
unit_NN
,_,
the_DT
impairment_NOMZ
loss_NN
is_VPRT [PASS]
allocated_VBN
first_RB
to_TO
reduce_VB
the_DT
carrying_VBG
amount_NN
of_PIN
any_QUAN
goodwill_NN
allocated_VBN [WZPAST]
to_PIN
the_DT
unit_NN
and_CC
then_RB
to_PIN
the_DT
other_JJ
assets_NN
of_PIN
the_DT
unit_NN
pro_PIN
rata_JJ
on_PIN
the_DT
basis_NN
of_PIN
the_DT
carrying_VBG
amount_NN
of_PIN
each_QUAN
asset_NN
in_PIN
the_DT
unit_NN
._.
An_DT
impairment_NOMZ
loss_NN
recognized_VBN [PRIV] [WZPAST]
for_PIN
goodwill_NN
is_VPRT [PASS]
not_XX0
reversed_VBN
in_PIN
a_DT
subsequent_JJ
period_NN
._.
On_PIN
disposal_NN
of_PIN
a_DT
subsidiary_NN
,_,
the_DT
attributable_JJ
amount_NN
of_PIN
goodwill_NN
is_VPRT [PASS]
included_VBN
in_PIN
the_DT
determination_NOMZ
of_PIN
the_DT
profit_NN
or_CC
loss_NN
on_PIN
disposal_NN
._.
b_NN
Marketing_GER
rights_NN
:_:
are_VPRT [PASS]
amortised_VBN
over_IN
their_TPP3
useful_JJ
lives_NN
commencing_VBG [WZPRES]
in_PIN
the_DT
year_NN
in_PIN
which_WDT [PIRE]
the_DT
rights_NN
first_RB
generate_VPRT
sales_NN
._.
c_NN
Product_NN
files_NN
:_:
product_NN
files_NN
are_VPRT [PASS]
assigned_VBN
indefinite_JJ
useful_JJ
lives_NN
which_WDT [WHSUB]
are_VPRT [PASS]
reviewed_VBN
for_PIN
impairment_NOMZ
at_PIN
least_JJ
annually_RB
:_:
any_QUAN
impairment_NOMZ
is_VPRT [PASS]
recognized_VBN [PRIV]
immediately_TIME
in_PIN
profit_NN
and_PHC
loss_NN
and_CC
is_VPRT
not_XX0
subsequently_TIME
reversed_PRED
._.
d_LS
Purchased_VBN
software_NN
:_:
is_VPRT [PASS]
amortised_VBN
over_IN
three_CD
years_NN
._.
Foreign_NN
currencies_NN
For_PIN
the_DT
purpose_NN
of_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
,_,
the_DT
results_NN
and_CC
financial_JJ
position_NOMZ
of_PIN
each_QUAN
Group_NN
company_NN
are_VPRT [PASS]
expressed_VBN
in_PIN
US_FPP1
Dollars_NN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
the_DT
functional_JJ
currency_NN
of_PIN
the_DT
Group_NN
,_,
and_ANDC
the_DT
presentation_NOMZ
currency_NN
for_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
._.
Transactions_NOMZ
in_PIN
currencies_NN
other_JJ
than_PIN
local_JJ
currency_NN
are_VPRT [PASS]
recorded_VBN
at_PIN
the_DT
rates_NN
of_PIN
exchange_NN
prevailing_VBG [WZPRES]
on_PIN
the_DT
dates_NN
of_PIN
the_DT
transactions_NOMZ
._.
At_PIN
each_QUAN
balance_NN
sheet_NN
date_NN
,_,
monetary_JJ
assets_NN
and_PHC
liabilities_NOMZ
that_TSUB
are_VPRT [PASS]
denominated_VBN
in_PIN
foreign_JJ
currencies_NN
are_VPRT [PASS]
retranslated_VBN
at_PIN
the_DT
rates_NN
prevailing_VBG [WZPRES]
on_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
Non-monetary_JJ
assets_NN
and_PHC
liabilities_NOMZ
carried_VBD
at_PIN
fair_JJ
value_NN
that_TSUB
are_VPRT [PASS]
denominated_VBN
in_PIN
foreign_JJ
currencies_NN
are_VPRT [PASS]
translated_VBN
at_PIN
the_DT
rates_NN
prevailing_VBG [WZPRES]
at_PIN
the_DT
date_NN
when_RB
the_DT
fair_JJ
value_NN
was_VBD [PASS]
determined_VBN [SUAV] [PRIV]
._.
Non-monetary_JJ
items_NN
that_TSUB
are_VPRT [PASS]
measured_VBN
in_PIN
terms_NN
of_PIN
historical_JJ
cost_NN
in_PIN
a_DT
foreign_JJ
currency_NN
are_VPRT [PASS]
not_XX0
retranslated_VBN
._.
Gains_NN
and_PHC
losses_NN
arising_VBG [WZPRES]
on_PIN
retranslation_NOMZ
are_VPRT [PASS]
included_VBN
in_PIN
net_JJ
profit_NN
or_CC
loss_NN
for_PIN
the_DT
period_NN
,_,
except_PIN
for_PIN
exchange_NN
differences_NN
arising_VBG [WZPRES]
on_PIN
non-monetary_JJ
assets_NN
and_PHC
liabilities_NOMZ
where_RB
the_DT
changes_NN
in_PIN
fair_JJ
value_NN
and_CC
the_DT
related_VBN
foreign_JJ
exchange_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
directly_RB
in_PIN
equity_NOMZ
._.
On_PIN
consolidation_NOMZ
,_,
the_DT
assets_NN
and_PHC
liabilities_NOMZ
of_PIN
the_DT
Groups_NN
overseas_PLACE
operations_NOMZ
are_VPRT [PASS]
translated_VBN
at_PIN
exchange_NN
rates_NN
prevailing_VBG [WZPRES]
on_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
Income_NN
and_PHC
expense_NN
items_NN
are_VPRT [PASS]
translated_VBN
at_PIN
the_DT
average_JJ
exchange_NN
rates_NN
for_PIN
the_DT
period_NN
._.
Exchange_NN
differences_NN
arising_VBG [WZPRES]
,_,
if_COND
any_QUAN
,_,
are_VPRT [PASS]
classified_VBN
as_IN
equity_NOMZ
and_CC
transferred_VBN
to_PIN
the_DT
Groups_NN
translation_NOMZ
reserve_NN
._.
Such_JJ
cumulative_JJ
translation_NOMZ
differences_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
as_IN
income_NN
or_CC
as_IN
expenses_NN
in_PIN
the_DT
period_NN
in_PIN
which_WDT [PIRE]
the_DT
operation_NOMZ
is_VPRT [PASS]
disposed_VBN
._.
Revenue_NN
recognition_NOMZ
Revenue_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
income_NN
statement_NOMZ
when_RB
goods_NN
or_CC
services_NN
are_VPRT [PASS]
supplied_VBN
or_CC
made_VBN
available_JJ
to_PIN
external_JJ
customers_NN
against_PIN
orders_NN
received_VBN
and_ANDC
when_RB
title_NN
and_PHC
risk_NN
of_PIN
loss_NN
passes_VPRT
to_PIN
the_DT
customer_NN
._.
Turnover_NN
represents_VPRT
net_JJ
invoice_NN
value_NN
after_IN
the_DT
deduction_NOMZ
of_PIN
discounts_NN
and_PHC
allowances_NN
given_VBN
and_CC
accruals_NN
for_PIN
estimated_JJ
future_JJ
rebates_NN
and_PHC
returns_NN
._.
The_DT
methodology_NN
and_PHC
assumptions_NOMZ
used_VBN
to_TO
estimate_VB [PRIV]
rebates_NN
and_PHC
returns_NN
are_VPRT [PASS]
monitored_VBN
and_PHC
adjusted_VBN
regularly_RB
in_PIN
the_DT
light_NN
of_PIN
contractual_JJ
and_PHC
historical_JJ
information_NOMZ
and_CC
past_JJ
experience_NN
._.
Value_NN
added_VBD [PUBV]
tax_NN
and_CC
other_JJ
sales_NN
taxes_NN
are_VPRT [PASS]
excluded_VBN
from_PIN
revenue_NN
._.
Significant_JJ
accounting_GER
policies_NN
continued_VBD
Charge_NN
backs_VPRT
The_DT
provision_NN
for_PIN
charge_NN
backs_NN
is_VPRT [BEMA]
the_DT
most_EMPH
significant_JJ
and_PHC
complex_JJ
estimate_NN
used_VBN [WZPAST]
in_PIN
the_DT
recognition_NOMZ
of_PIN
revenue_NN
._.
In_PIN
the_DT
USA_NN
the_DT
Group_NN
sells_VPRT
its_PIT
products_NN
directly_RB
to_PIN
wholesale_JJ
distributors_NN
,_,
generic_JJ
distributors_NN
,_,
retail_JJ
pharmacy_NN
chains_NN
and_CC
mail-order_JJ
pharmacies_NN
._.
The_DT
Group_NN
also_RB
sells_VPRT
its_PIT
products_NN
indirectly_RB
to_PIN
independent_JJ
pharmacies_NN
,_,
managed_VBD
care_NN
organizations_NOMZ
,_,
hospitals_NN
,_,
and_ANDC
Group_NN
purchasing_VBG [WZPRES]
organizations_NOMZ
,_,
collectively_RB
referred_VBD
to_PIN
as_IN
indirect_JJ
customers_NN
._.
The_DT
Group_NN
enters_VPRT
into_PIN
agreements_NOMZ
with_PIN
its_PIT
indirect_JJ
customers_NN
to_TO
establish_VB [PRIV]
pricing_GER
for_PIN
certain_JJ
products_NN
._.
The_DT
indirect_JJ
customers_NN
then_RB
independently_RB
select_VB
a_DT
wholesaler_NN
from_PIN
which_WDT [PIRE]
they_TPP3
purchase_VPRT
the_DT
products_NN
at_PIN
agreed-upon_PIN
prices_NN
._.
The_DT
Group_NN
will_PRMD
provide_VB
credit_NN
to_PIN
the_DT
wholesaler_NN
for_PIN
the_DT
difference_NN
between_PIN
the_DT
agreed-upon_PIN
price_NN
with_PIN
the_DT
indirect_JJ
customer_NN
and_CC
the_DT
wholesalers_NN
invoice_VPRT
price_NN
._.
This_DEMO
credit_NN
is_VPRT [PASS]
called_VBN
a_DT
charge_NN
back_RB
._.
The_DT
provision_NN
for_PIN
charge_NN
backs_NN
is_VPRT [PASS]
based_VBN
on_PIN
historical_JJ
sell-through_PIN
levels_NN
by_PIN
the_DT
Groups_NN
wholesale_JJ
customers_NN
to_PIN
the_DT
indirect_JJ
customers_NN
,_,
and_ANDC
estimated_VBD [PRIV]
wholesaler_NN
inventory_NN
levels_NN
._.
As_IN
sales_NN
are_VPRT [PASS]
made_VBN
to_PIN
the_DT
large_JJ
wholesale_JJ
customers_NN
,_,
the_DT
Group_NN
continually_RB
monitors_VPRT
the_DT
reserve_NN
for_PIN
chargebacks_NN
and_CC
makes_VPRT
adjustments_NOMZ
when_RB
it_PIT
believes_VPRT [PRIV]
that_THVC
actual_JJ
charge_NN
backs_NN
may_POMD
differ_VB
from_PIN
estimated_VBN [PRIV]
reserves_NN
._.
Returns_NN
and_PHC
rebates_NN
In_PIN
certain_JJ
countries_NN
and_CC
consistent_JJ
with_PIN
industry_NN
practice_NN
,_,
the_DT
Group_NN
has_VPRT
a_DT
product_NN
return_NN
policy_NN
that_TSUB
allows_VPRT [SUAV]
selected_VBN
customers_NN
to_TO
return_VB
the_DT
product_NN
within_PIN
a_DT
specified_JJ
period_NN
prior_RB
to_TO
and_CC
subsequent_JJ
to_PIN
the_DT
expiration_NOMZ
date_NN
,_,
in_PIN
exchange_NN
for_PIN
a_DT
credit_NN
to_TO
be_VB [PASS]
applied_VBN
to_PIN
future_JJ
purchases_NN
._.
The_DT
Group_NN
estimates_VPRT [PRIV]
its_PIT
provision_NN
for_PIN
returns_NN
and_PHC
rebates_NN
based_VBN [WZPAST]
on_PIN
historical_JJ
experience_NN
,_,
changes_NN
to_PIN
business_NOMZ
practices_NN
and_PHC
credit_NN
terms_NN
._.
While_OSUB
such_JJ
experience_NN
has_VPRT [PEAS]
allowed_VBN [SUAV]
for_PIN
reasonable_JJ
estimations_NOMZ
in_PIN
the_DT
past_NN
,_,
history_NN
may_POMD
not_XX0
always_RB
be_VB [BEMA]
an_DT
accurate_JJ
indicator_NN
of_PIN
future_JJ
returns_NN
._.
The_DT
Group_NN
continually_RB
monitors_VPRT
the_DT
provisions_NN
for_PIN
returns_NN
and_PHC
rebates_NN
,_,
and_ANDC
makes_VPRT
adjustments_NOMZ
when_RB
it_PIT
believes_VPRT [PRIV]
that_THVC
actual_JJ
product_NN
returns_NN
may_POMD
differ_VB
from_PIN
established_VBN [PRIV]
reserves_NN
._.
Generally_RB
,_,
the_DT
reserve_NN
for_PIN
returns_NN
and_PHC
rebates_NN
increases_NN
as_IN
net_JJ
sales_NN
increase_NN
._.
Price_NN
adjustments_NOMZ
Price_NN
adjustments_NOMZ
,_,
also_RB
known_VBN [PRIV]
as_IN
shelf_NN
stock_NN
adjustments_NOMZ
,_,
are_VPRT [PASS]
credits_NN
issued_VBN
to_TO
reflect_VB [PRIV]
decreases_VPRT
in_PIN
the_DT
selling_GER
prices_NN
of_PIN
the_DT
Groups_NN
products_NN
that_TOBJ
customers_NN
have_VPRT
remaining_VBG
in_PIN
their_TPP3
inventories_NN
at_PIN
the_DT
time_NN
of_PIN
the_DT
price_NN
reduction_NOMZ
._.
Decreases_NN
in_PIN
selling_VBG
prices_NN
are_VPRT [BEMA]
discretionary_JJ
decisions_NN
made_VBN [WZPAST]
by_PIN
Group_NN
management_NOMZ
to_TO
reflect_VB [PRIV]
competitive_JJ
market_NN
conditions_NOMZ
._.
Amounts_NN
recorded_VBD
for_PIN
estimated_VBN [PRIV]
shelf_NN
stock_NN
adjustments_NOMZ
are_VPRT [PASS]
based_VBN
upon_PIN
specified_VBN
terms_NN
with_PIN
direct_JJ
customers_NN
,_,
estimated_VBN [PRIV]
declines_NN
in_PIN
market_NN
prices_NN
and_PHC
estimates_NN
of_PIN
inventory_NN
held_VBN [PRIV] [WZPAST]
by_PIN
customers_NN
._.
The_DT
Group_NN
regularly_RB
monitors_VPRT
these_DEMP
and_CC
other_JJ
factors_NN
and_CC
re-evaluates_VPRT
the_DT
reserve_NN
as_IN
additional_JJ
information_NOMZ
becomes_VPRT
available_JJ
._.
Borrowing_GER
costs_NN
Borrowing_VBG [WZPRES]
costs_NN
directly_RB
attributable_JJ
to_PIN
the_DT
acquisition_NOMZ
,_,
construction_NOMZ
or_CC
production_NOMZ
of_PIN
qualifying_VBG
assets_NN
,_,
which_WDT [SERE]
are_VPRT
assets_NN
that_TSUB
necessarily_RB
take_VB
a_DT
substantial_JJ
period_NN
of_PIN
time_NN
to_TO
get_VB
ready_JJ
for_PIN
their_TPP3
intended_VBN [SUAV]
use_NN
or_CC
sale_NN
,_,
are_VPRT [PASS]
added_VBN [PUBV]
to_PIN
the_DT
cost_NN
of_PIN
those_DEMO
assets_NN
,_,
until_IN
such_JJ
time_NN
as_IN
the_DT
assets_NN
are_VPRT [BEMA]
substantially_RB
ready_PRED
for_PIN
their_TPP3
intended_VBN [SUAV]
use_NN
or_CC
sale_NN
._.
Investment_NOMZ
income_NN
earned_VBN [WZPAST]
on_PIN
the_DT
temporary_JJ
investment_NOMZ
of_PIN
specific_JJ
borrowings_GER
pending_VBG [WZPRES]
their_TPP3
expenditure_NN
on_PIN
qualifying_VBG
assets_NN
is_VPRT [PASS]
deducted_VBN
from_PIN
the_DT
borrowing_GER
costs_VPRT
eligible_JJ
for_PIN
capitalization_NOMZ
._.
All_QUAN
other_JJ
borrowing_GER
costs_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
profit_NN
or_CC
loss_NN
in_PIN
the_DT
period_NN
in_PIN
which_WDT [PIRE]
they_TPP3
are_VPRT [PASS]
incurred_VBN
._.
Dividend_NN
income_NN
Income_NN
from_PIN
investments_NOMZ
is_VPRT [PASS]
recognized_VBN [PRIV]
when_RB [WHCL]
the_DT
shareholders_NN
rights_NN
to_TO
receive_VB
payment_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
established_VBN [PRIV]
._.
Leasing_GER
Leases_NN
are_VPRT [PASS]
classified_VBN
as_IN
capital_NN
leases_NN
whenever_RB
the_DT
terms_NN
of_PIN
the_DT
lease_NN
transfer_NN
substantially_RB
all_QUAN
the_DT
risks_NN
and_PHC
rewards_NN
of_PIN
ownership_NN
to_PIN
the_DT
lessee_NN
._.
All_QUAN
other_JJ
leases_NN
are_VPRT [PASS]
classified_VBN
as_IN
operating_VBG
leases_NN
._.
Rentals_NN
payable_JJ
under_IN
operating_VBG
leases_NN
are_VPRT [PASS]
charged_VBN
to_PIN
income_NN
on_PIN
a_DT
straight-line_JJ
basis_NN
over_IN
the_DT
term_NN
of_PIN
the_DT
operating_GER
lease_NN
._.
Assets_NN
held_VBN [PRIV]
under_IN
capital_NN
leases_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
as_IN
assets_NN
of_PIN
the_DT
Group_NN
at_PIN
their_TPP3
fair_JJ
value_NN
or_CC
,_,
if_COND
lower_JJ
,_,
at_PIN
the_DT
present_JJ
value_NN
of_PIN
the_DT
minimum_NN
lease_NN
payments_NOMZ
,_,
each_QUAN
determined_VBN [SUAV] [PRIV]
at_PIN
the_DT
inception_NOMZ
of_PIN
the_DT
lease_NN
._.
The_DT
corresponding_JJ
liability_NOMZ
to_PIN
the_DT
lessor_NN
is_VPRT [PASS]
included_VBN
in_PIN
the_DT
balance_NN
sheet_NN
as_IN
a_DT
capital_NN
lease_NN
obligation_NOMZ
._.
Lease_NN
payments_NOMZ
are_VPRT [PASS]
apportioned_VBN
between_PIN
finance_NN
charges_NN
and_PHC
reduction_NOMZ
of_PIN
the_DT
lease_NN
obligation_NOMZ
so_RB
as_IN
to_TO
achieve_VB
a_DT
constant_JJ
rate_NN
of_PIN
interest_NN
on_PIN
the_DT
remaining_VBG
balance_NN
of_PIN
the_DT
liability_NOMZ
._.
54_CD
Hikma_NN
Pharmaceuticals_NN
PLC_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
continued_VBD
2_CD
._.
Significant_JJ
accounting_GER
policies_NN
continued_VBD
Government_NOMZ
grants_NN
Government_NOMZ
grants_NN
relating_VBG [WZPRES]
to_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
are_VPRT [PASS]
treated_VBN
as_IN
deferred_JJ
income_NN
and_CC
released_VBN
to_PIN
the_DT
income_NN
statement_NOMZ
over_IN
the_DT
expected_VBN [PRIV]
useful_JJ
lives_NN
of_PIN
the_DT
assets_NN
concerned_VBN
._.
Research_NN
and_PHC
development_NOMZ
Research_NN
and_PHC
development_NOMZ
expenses_NN
are_VPRT [SPAU] [PASS]
fully_AMP
charged_VBN
to_PIN
the_DT
income_NN
statement_NOMZ
,_,
as_IN
the_DT
Group_NN
considers_VPRT [PRIV]
that_THVC
the_DT
regulatory_JJ
and_PHC
other_JJ
uncertainties_NN
inherent_JJ
in_PIN
the_DT
development_NOMZ
of_PIN
its_PIT
products_NN
generally_RB
mean_VPRT [PRIV]
that_THVC
the_DT
recognition_NOMZ
criteria_NN
in_PIN
IAS_NN
38_CD
Intangible_JJ
assets_NN
are_VPRT [PASS]
not_XX0
met_VBN
._.
Where_RB
,_,
however_CONJ
the_DT
recognition_NOMZ
criteria_NN
are_VPRT [PASS]
met_VBN
,_,
intangible_JJ
assets_NN
will_PRMD
be_VB [PASS]
capitalized_VBN
and_PHC
amortised_VBN
over_IN
their_TPP3
useful_JJ
economic_JJ
life_NN
._.
Retirement_NOMZ
benefit_NN
costs_NN
Payments_NOMZ
to_TO
defined_VBN
contribution_NOMZ
retirement_NOMZ
benefit_NN
schemes_NN
are_VPRT [PASS]
charged_VBN
as_IN
an_DT
expense_NN
as_IN
they_TPP3
fall_VPRT
due_JJ
._.
Payments_NOMZ
made_VBD
to_PIN
state-managed_JJ
retirement_NOMZ
benefit_NN
schemes_NN
are_VPRT [PASS]
dealt_VBN
with_PIN
as_IN
payments_NOMZ
to_TO
defined_VBN
contribution_NOMZ
schemes_NN
where_RB
the_DT
Groups_NN
obligations_NOMZ
under_IN
the_DT
schemes_NN
are_VPRT [BEMA]
equivalent_PRED
to_PIN
those_DEMP
arising_VBG
in_PIN
a_DT
defined_VBN
contribution_NOMZ
retirement_NOMZ
benefit_NN
scheme_NN
._.
Tax_NN
The_NN
Group_NN
provides_VPRT
for_PIN
income_NN
tax_NN
according_VBG [WZPRES]
to_PIN
the_DT
laws_NN
and_PHC
regulations_NOMZ
prevailing_VBG [WZPRES]
in_PIN
the_DT
countries_NN
where_RB
the_DT
Group_NN
operates_VPRT
._.
Furthermore_CONJ
,_,
the_DT
Group_NN
computes_NN
and_PHC
records_NN
deferred_VBN
tax_NN
assets_NN
according_VBG [WZPRES]
to_PIN
IAS_NN
12_CD
Income_NN
Taxes_NN
._.
The_DT
tax_NN
expense_NN
represents_VPRT
the_DT
sum_NN
of_PIN
the_DT
tax_NN
currently_RB
payable_JJ
and_PHC
deferred_JJ
tax_NN
._.
The_DT
tax_NN
currently_RB
payable_JJ
is_VPRT [PASS]
based_VBN
on_PIN
taxable_JJ
profit_NN
for_PIN
the_DT
year_NN
._.
Taxable_JJ
profit_NN
differs_VPRT
from_PIN
net_JJ
profit_NN
as_IN
reported_VBN [PUBV]
in_PIN
the_DT
income_NN
statements_NOMZ
because_CAUS
it_PIT
excludes_VPRT
items_NN
of_PIN
income_NN
or_CC
expense_NN
that_TSUB
are_VPRT [BEMA]
taxable_PRED
or_CC
deductible_JJ
in_PIN
other_JJ
years_NN
and_CC
it_PIT
further_RB
excludes_VPRT
items_NN
that_TSUB
are_VPRT [BEMA]
never_RB
taxable_PRED
or_CC
deductible_JJ
._.
The_DT
Groups_NN
liability_NOMZ
for_PIN
current_JJ
tax_NN
is_VPRT [PASS]
calculated_VBN [PRIV]
using_VBG
tax_NN
rates_NN
that_TSUB
have_VPRT [PEAS]
been_VBN [PASS]
enacted_VBN
or_CC
substantively_RB
enacted_VBN
by_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
Deferred_JJ
tax_NN
is_VPRT [BEMA]
the_DT
tax_NN
expected_VBN [PRIV]
to_TO
be_VB [BEMA]
payable_PRED
or_CC
recoverable_JJ
on_PIN
differences_NN
between_PIN
the_DT
carrying_VBG
amounts_NN
of_PIN
assets_NN
and_PHC
liabilities_NOMZ
in_PIN
the_DT
financial_JJ
statements_NOMZ
and_CC
the_DT
corresponding_JJ
tax_NN
bases_NN
used_VBN [WZPAST]
in_PIN
the_DT
computation_NOMZ
of_PIN
taxable_JJ
profit_NN
,_,
and_ANDC
is_VPRT [PASS]
accounted_VBN
for_PIN
using_VBG
the_DT
balance_NN
sheet_NN
liability_NOMZ
method_NN
._.
Deferred_JJ
tax_NN
liabilities_NOMZ
are_VPRT [SPAU] [PASS]
generally_RB
recognized_VBN [PRIV]
for_PIN
all_QUAN
taxable_JJ
temporary_JJ
differences_NN
and_CC
deferred_VBN
tax_NN
assets_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
to_PIN
the_DT
extent_NN
that_TOBJ
it_PIT
is_VPRT [BEMA]
probable_PRED
that_THAC
taxable_JJ
profits_NN
will_PRMD
be_VB [BEMA]
available_PRED
against_PIN
which_WDT [PIRE]
deductible_JJ
temporary_JJ
differences_NN
can_POMD
be_VB [PASS]
utilised_VBN
._.
Such_JJ
assets_NN
and_PHC
liabilities_NOMZ
are_VPRT [PASS]
not_XX0
recognized_VBN [PRIV]
if_COND
the_DT
temporary_JJ
difference_NN
arises_VPRT
from_PIN
goodwill_NN
or_CC
from_PIN
the_DT
initial_JJ
recognition_NOMZ
other_JJ
than_PIN
in_PIN
a_DT
business_NOMZ
combination_NOMZ
of_PIN
other_JJ
assets_NN
and_PHC
liabilities_NOMZ
in_PIN
a_DT
transaction_NOMZ
that_TSUB
affects_VPRT
neither_SYNE
the_DT
tax_NN
profit_NN
nor_SYNE
the_DT
accounting_GER
profit_NN
._.
Deferred_JJ
tax_NN
liabilities_NOMZ
are_VPRT [PASS]
recognized_VBN [PRIV]
for_PIN
taxable_JJ
temporary_JJ
differences_NN
arising_VBG [WZPRES]
on_PIN
investments_NOMZ
in_PIN
subsidiaries_NN
and_PHC
associates_NN
,_,
and_ANDC
interests_NN
in_PIN
joint_JJ
ventures_NN
,_,
except_PIN
where_RB
the_DT
Group_NN
is_VPRT [BEMA]
able_PRED
to_TO
control_VB
the_DT
reversal_NN
of_PIN
the_DT
temporary_JJ
difference_NN
and_CC
it_PIT
is_VPRT [BEMA]
probable_PRED
that_THAC
the_DT
temporary_JJ
difference_NN
will_PRMD
not_XX0
reverse_VB
in_PIN
the_DT
foreseeable_JJ
future_NN
._.
The_DT
carrying_VBG
amount_NN
of_PIN
deferred_JJ
tax_NN
assets_NN
is_VPRT [PASS]
reviewed_VBN
at_PIN
each_QUAN
balance_NN
sheet_NN
date_NN
and_CC
reduced_VBN
to_PIN
the_DT
extent_NN
that_TOBJ
it_PIT
is_VPRT
no_RB
longer_RB
probable_JJ
that_THAC
sufficient_JJ
taxable_JJ
profits_NN
will_PRMD
be_VB [BEMA]
available_PRED
to_TO
allow_VB [SUAV]
all_QUAN
or_CC
part_NN
of_PIN
the_DT
asset_NN
to_TO
be_VB [PASS]
recovered_VBN
._.
Deferred_JJ
tax_NN
is_VPRT [PASS]
calculated_VBN [PRIV]
at_PIN
the_DT
tax_NN
rates_NN
that_TSUB
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
apply_VB
in_PIN
the_DT
period_NN
when_RB
the_DT
liability_NOMZ
is_VPRT [PASS]
settled_VBN
or_CC
the_DT
asset_NN
is_VPRT [PASS]
realized_VBN [PRIV]
._.
Deferred_JJ
tax_NN
is_VPRT [PASS]
charged_VBN
or_CC
credited_VBN
in_PIN
the_DT
income_NN
statement_NOMZ
,_,
except_PIN
when_RB
it_PIT
relates_VPRT
to_PIN
items_NN
charged_VBN
or_CC
credited_VBN
directly_RB
to_PIN
equity_NOMZ
,_,
in_PIN
which_WDT [PIRE]
case_NN
the_DT
deferred_JJ
tax_NN
is_VPRT [SPAU] [PASS]
also_RB
dealt_VBN
with_PIN
in_PIN
equity_NOMZ
._.
Share-based_JJ
payment_NOMZ
transactions_NOMZ
Employees_NN
including_VBG [WZPRES]
Directors_NN
of_PIN
the_DT
Group_NN
receive_VPRT
remuneration_NOMZ
in_PIN
the_DT
form_NN
of_PIN
share-based_JJ
payments_NOMZ
,_,
whereby_OSUB
employees_NN
render_VB
services_NN
in_PIN
exchange_NN
for_PIN
shares_NN
or_CC
rights_NN
over_IN
shares_NN
equity-settled_JJ
transactions_NOMZ
._.
Significant_JJ
accounting_GER
policies_NN
continued_VBD
Equity-settled_JJ
transactions_NOMZ
The_DT
cost_NN
of_PIN
equity-settled_JJ
transactions_NOMZ
with_PIN
employees_NN
is_VPRT [BYPA]
measured_VBN
by_PIN
reference_NN
to_PIN
the_DT
fair_JJ
value_NN
at_PIN
the_DT
date_NN
at_PIN
which_WDT [PIRE]
the_DT
share-based_JJ
payments_NOMZ
are_VPRT [PASS]
granted_VBN [SUAV]
._.
The_DT
fair_JJ
value_NN
is_VPRT [PASS]
determined_VBN [SUAV] [PRIV]
using_VBG
a_DT
binomial_JJ
model_NN
._.
The_DT
expected_VBN [PRIV] [THATD]
life_NN
used_VBN [WZPAST]
in_PIN
the_DT
model_NN
has_VPRT [PEAS]
been_VBN [PASS]
adjusted_VBN
,_,
based_VBN [PASTP]
on_PIN
managements_NOMZ
best_JJ
estimate_NN
,_,
for_PIN
the_DT
effects_NN
of_PIN
non-transferability_NOMZ
,_,
exercise_NN
restrictions_NOMZ
,_,
and_ANDC
behavioural_JJ
considerations_NOMZ
further_RB
details_NN
are_VPRT [PASS]
given_VBN
in_PIN
Note_NN
36_CD
._.
In_PIN
valuing_VBG
equity-settled_JJ
transactions_NOMZ
,_,
no_SYNE
account_NN
is_VPRT [PASS]
taken_VBN
of_PIN
any_QUAN
performance_NN
conditions_NOMZ
,_,
other_JJ
than_PIN
conditions_NOMZ
linked_VBN [WZPAST]
to_PIN
the_DT
market_NN
price_NN
of_PIN
the_DT
shares_NN
of_PIN
Hikma_NN
Pharmaceuticals_NN
PLC._NN
._.
The_DT
cost_NN
of_PIN
equity-settled_JJ
transactions_NOMZ
is_VPRT [PASS]
recognized_VBN [PRIV]
,_,
together_RB
with_PIN
a_DT
corresponding_JJ
increase_NN
in_PIN
equity_NOMZ
,_,
on_PIN
a_DT
straight-line_JJ
basis_NN
over_IN
the_DT
vesting_JJ
period_NN
based_VBN [WZPAST]
on_PIN
the_DT
Groups_NN
estimate_NN
of_PIN
shares_NN
that_TSUB
will_PRMD
eventually_TIME
vest_NN
._.
No_SYNE
expense_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
for_PIN
awards_NN
that_TSUB
do_VPRT
not_XX0
ultimately_RB
vest_NN
._.
Where_RB
the_DT
terms_NN
of_PIN
an_DT
equity-settled_JJ
award_NN
are_VPRT [PASS]
modified_VBN
,_,
as_IN
a_DT
minimum_NN
an_DT
expense_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
as_IN
if_COND
the_DT
terms_NN
had_VBD [PEAS]
not_XX0
been_VBN [PASS]
modified_VBN
._.
In_CONJ
addition_NULL
,_,
an_DT
expense_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
for_PIN
any_QUAN
increase_NN
in_PIN
the_DT
value_NN
of_PIN
the_DT
transaction_NOMZ
as_CONJ
a_NULL
result_NULL
of_PIN
the_DT
modification_NOMZ
,_,
as_IN
measured_VBN
at_PIN
the_DT
modification_NOMZ
date_NN
._.
Where_RB
an_DT
equity-settled_JJ
award_NN
is_VPRT [PASS]
canceled_VBN
,_,
it_PIT
is_VPRT [PASS]
treated_VBN
as_IN
if_COND
it_PIT
had_VBD [PEAS]
vested_VBN
on_PIN
the_DT
date_NN
of_PIN
cancellation_NOMZ
,_,
and_ANDC
any_QUAN
expense_NN
not_XX0
yet_RB
recognized_VBN [PRIV]
for_PIN
the_DT
award_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
immediately_TIME
._.
However_CONJ
,_,
if_COND
a_DT
new_JJ
award_NN
is_VPRT [PASS]
substituted_VBN
for_PIN
a_DT
canceled_VBN
award_NN
,_,
and_ANDC
designated_VBN
as_IN
a_DT
replacement_NOMZ
award_NN
on_PIN
the_DT
date_NN
that_TOBJ
it_PIT
is_VPRT [PASS]
granted_VBN [SUAV]
,_,
the_DT
canceled_VBN
and_CC
new_JJ
awards_NN
are_VPRT [PASS]
treated_VBN
as_IN
if_COND
they_TPP3
were_VBD [BEMA]
a_DT
modification_NOMZ
of_PIN
the_DT
original_JJ
award_NN
,_,
as_IN
described_VBN
in_PIN
the_DT
previous_JJ
paragraph_NN
._.
The_DT
dilutive_JJ
effect_NN
of_PIN
outstanding_JJ
options_NOMZ
is_VPRT [PASS]
reflected_VBN [PRIV]
as_IN
additional_JJ
share_NN
dilution_NOMZ
in_PIN
the_DT
computation_NOMZ
of_PIN
diluted_JJ
earnings_GER
per_PIN
share_NN
._.
IFRS_NN
2_CD
Share-based_JJ
Payment_NOMZ
requires_VPRT [SUAV]
an_DT
expense_NN
to_TO
be_VB [PASS]
recognized_VBN [PRIV]
when_RB [WHCL]
the_DT
Group_NN
buys_VPRT
goods_NN
or_CC
services_NN
in_PIN
exchange_NN
for_PIN
share_NN
or_CC
rights_NN
over_IN
shares_NN
equity-settled_JJ
transactions_NOMZ
or_CC
in_PIN
exchange_NN
for_PIN
other_JJ
equivalent_JJ
assets_NN
._.
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
valued_VBN
at_PIN
cost_NN
of_PIN
acquisition_NOMZ
and_CC
are_VPRT [PASS]
depreciated_VBN
,_,
except_PIN
for_PIN
land_NN
,_,
on_PIN
a_DT
straight-line_JJ
basis_NN
at_PIN
the_DT
following_VBG
depreciation_NOMZ
rates_NN
:_:
Buildings_GER
2_CD
%_NN
to_PIN
4_CD
%_NN
Vehicles_NN
10_CD
%_NN
to_PIN
20_CD
%_NN
Machinery_NN
and_PHC
equipment_NOMZ
5_CD
%_NN
to_PIN
20_CD
%_NN
Fixtures_NN
and_PHC
equipment_NOMZ
8_CD
%_NN
to_PIN
33_CD
%_NN
Any_QUAN
additional_JJ
costs_NN
that_TSUB
extend_VPRT
the_DT
useful_JJ
life_NN
of_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
are_VPRT [PASS]
capitalized_VBN
._.
Financing_GER
costs_NN
associated_VBN [WZPAST]
with_PIN
the_DT
construction_NOMZ
of_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
are_VPRT [PASS]
not_XX0
capitalized_VBN
._.
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
which_WDT [WHSUB]
are_VPRT [BYPA]
financed_VBN
by_PIN
leases_NN
giving_VBG [WZPRES]
Hikma_NN
Pharmaceuticals_NN
PLC_NN
substantially_RB
all_QUAN
the_DT
risks_NN
and_PHC
rewards_NN
of_PIN
ownership_NN
are_VPRT [PASS]
capitalized_VBN
at_PIN
the_DT
lower_JJ
of_PIN
the_DT
fair_JJ
value_NN
of_PIN
leased_VBN
property_NN
and_CC
the_DT
present_JJ
value_NN
of_PIN
the_DT
minimum_NN
lease_NN
payments_NOMZ
at_PIN
the_DT
inception_NOMZ
of_PIN
the_DT
lease_NN
,_,
and_ANDC
depreciated_VBD
in_PIN
the_DT
same_JJ
manner_NN
as_IN
other_JJ
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
over_IN
the_DT
shorter_JJ
of_PIN
the_DT
lease_NN
term_NN
or_CC
their_TPP3
useful_JJ
life_NN
._.
Whenever_NN
the_DT
recoverable_JJ
amount_NN
of_PIN
an_DT
asset_NN
is_VPRT [PASS]
impaired_VBN
,_,
the_DT
carrying_VBG
value_NN
is_VPRT [PASS]
reduced_VBN
to_PIN
the_DT
recoverable_JJ
amount_NN
and_CC
the_DT
impairment_NOMZ
loss_NN
is_VPRT [PASS]
taken_VBN
to_PIN
the_DT
income_NN
statement_NOMZ
._.
Projects_NN
under_IN
construction_NOMZ
are_VPRT [PASS]
carried_VBN
at_PIN
cost_NN
,_,
less_JJ
any_QUAN
recognized_VBN [PRIV]
impairment_NOMZ
loss_NN
._.
Depreciation_NOMZ
of_PIN
these_DEMO
assets_NN
,_,
on_PIN
the_DT
same_JJ
basis_NN
as_IN
other_JJ
property_NN
assets_NN
,_,
commences_NN
when_RB
the_DT
assets_NN
are_VPRT [BEMA]
ready_PRED
for_PIN
their_TPP3
intended_VBN [SUAV]
use_NN
._.
The_DT
gain_NN
or_CC
loss_NN
arising_VBG [WZPRES]
on_PIN
the_DT
disposal_NN
or_CC
retirement_NOMZ
of_PIN
an_DT
asset_NN
is_VPRT [PASS]
determined_VBN [SUAV] [PRIV]
as_IN
the_DT
difference_NN
between_PIN
the_DT
sales_NN
proceeds_NN
and_CC
the_DT
carrying_VBG
amount_NN
of_PIN
the_DT
asset_NN
and_CC
is_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
income_NN
statement_NOMZ
._.
Inventories_NN
Inventories_NN
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
the_DT
lower_JJ
of_PIN
cost_NN
and_CC
net_JJ
realisable_JJ
value_NN
._.
Purchased_JJ
products_NN
are_VPRT [PASS]
valued_VBN
at_PIN
acquisition_NOMZ
cost_NN
and_CC
all_QUAN
other_JJ
costs_NN
incurred_VBN [WZPAST]
in_PIN
bringing_VBG
each_QUAN
product_NN
to_PIN
its_PIT
present_JJ
location_NOMZ
and_PHC
condition_NOMZ
._.
Cost_NN
of_PIN
own-manufactured_JJ
products_NN
comprises_VPRT
direct_JJ
materials_NN
and_CC
,_,
where_RB
applicable_JJ
,_,
direct_JJ
labor_NN
costs_NN
and_CC
those_DEMO
overheads_NN
that_TSUB
have_VPRT [PEAS]
been_VBN [PASS]
incurred_VBN
in_PIN
bringing_VBG
the_DT
inventories_NN
to_PIN
their_TPP3
present_JJ
location_NOMZ
and_PHC
condition_NOMZ
._.
In_PIN
the_DT
balance_NN
sheets_NN
,_,
inventory_NN
is_VPRT [SPAU] [PASS]
primarily_RB
valued_VBN
at_PIN
standard_JJ
cost_NN
,_,
which_WDT [SERE]
approximates_VPRT
to_PIN
historical_JJ
cost_NN
determined_VBN [SUAV] [PRIV] [WZPAST]
on_PIN
a_DT
moving_VBG [SUAV]
average_JJ
basis_NN
,_,
and_ANDC
this_DEMO
value_NN
is_VPRT [PASS]
used_VBN
to_TO
determine_VB [SUAV] [PRIV]
the_DT
cost_NN
of_PIN
sales_NN
in_PIN
the_DT
income_NN
statement_NOMZ
._.
Net_JJ
realisable_JJ
value_NN
represents_VPRT
the_DT
estimated_VBN [PRIV]
selling_GER
price_NN
in_PIN
the_DT
ordinary_JJ
course_NN
of_PIN
business_NOMZ
,_,
less_JJ
all_QUAN
estimated_VBN [PRIV]
costs_NN
of_PIN
completion_NOMZ
and_CC
all_QUAN
estimated_VBN [PRIV]
costs_NN
necessary_JJ
to_TO
make_VB
the_DT
sale_NN
._.
Provisions_NN
are_VPRT [PASS]
made_VBN
for_PIN
inventories_NN
with_PIN
net_JJ
realisable_JJ
value_NN
lower_JJ
than_PIN
cost_NN
or_CC
for_PIN
slow_JJ
moving_VBG [SUAV]
inventory_NN
._.
56_CD
Hikma_NN
Pharmaceuticals_NN
PLC_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
continued_VBD
2_CD
._.
Significant_JJ
accounting_GER
policies_NN
continued_VBD
Financial_JJ
instruments_NOMZ
Financial_JJ
assets_NN
and_CC
financial_JJ
liabilities_NOMZ
are_VPRT [PASS]
recognized_VBN [PRIV]
on_PIN
the_DT
Groups_NN
balance_NN
sheet_NN
when_RB
the_DT
Group_NN
becomes_VPRT
a_DT
party_NN
to_PIN
the_DT
contractual_JJ
provisions_NN
of_PIN
the_DT
instrument_NOMZ
._.
Derivative_JJ
financial_JJ
instruments_NOMZ
are_VPRT [PASS]
used_VBN
to_TO
manage_VB
exposure_NN
to_PIN
market_NN
risks_NN
from_PIN
treasury_NN
operations_NOMZ
._.
The_DT
principal_JJ
derivative_NN
instruments_NOMZ
used_VBN [WZPAST]
by_PIN
the_DT
Group_NN
are_VPRT
interest_NN
rate_NN
swaps_NN
and_CC
forward_RB
foreign_JJ
exchange_NN
contracts_NN
._.
The_DT
Group_NN
does_VPRT
not_XX0
hold_VB [PRIV]
or_CC
issue_VB
derivative_JJ
financial_JJ
instruments_NOMZ
for_PIN
trading_GER
or_CC
speculative_JJ
purposes_NN
._.
Derivative_JJ
financial_JJ
instruments_NOMZ
are_VPRT [SPAU] [PASS]
initially_TIME
recognized_VBN [PRIV]
in_PIN
the_DT
balance_NN
sheet_NN
at_PIN
cost_NN
and_CC
then_RB
remeasured_VBD
at_PIN
subsequent_JJ
reporting_GER
dates_NN
to_PIN
fair_JJ
value_NN
._.
Hedging_VBG
derivatives_NN
are_VPRT [PASS]
classified_VBN
on_PIN
inception_NOMZ
as_IN
fair_JJ
value_NN
hedges_NN
,_,
cash_NN
flow_NN
hedges_NN
or_CC
net_JJ
investment_NOMZ
hedges_NN
._.
Changes_NN
in_PIN
the_DT
fair_JJ
value_NN
of_PIN
derivatives_NN
designed_VBN
as_IN
fair_JJ
value_NN
hedges_NN
are_VPRT [PASS]
recorded_VBN
in_PIN
the_DT
income_NN
statement_NOMZ
,_,
with_PIN
the_DT
changes_NN
in_PIN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
hedged_JJ
asset_NN
or_CC
liability_NOMZ
._.
Changes_NN
in_PIN
the_DT
fair_JJ
value_NN
of_PIN
derivatives_NN
designed_VBN
as_IN
cash_NN
flow_NN
hedges_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
equity_NOMZ
._.
Amounts_NN
deferred_VBN [WZPAST]
in_PIN
equity_NOMZ
are_VPRT [PASS]
transferred_VBN
to_PIN
the_DT
income_NN
statement_NOMZ
in_PIN
line_NN
with_PIN
the_DT
hedged_VBN
forecast_NN
transaction_NOMZ
._.
Hedges_NN
of_PIN
net_JJ
investments_NOMZ
in_PIN
foreign_JJ
entities_NOMZ
are_VPRT [PASS]
accounted_VBN
for_PIN
in_PIN
a_DT
similar_JJ
way_NN
to_PIN
cash_NN
flow_NN
hedges_NN
._.
Changes_NN
in_PIN
the_DT
fair_JJ
value_NN
of_PIN
any_QUAN
derivative_JJ
instruments_NOMZ
that_TSUB
do_VPRT
not_XX0
qualify_VB
for_PIN
hedge_JJ
accounting_GER
are_VPRT [PASS]
recognized_VBN [PRIV]
immediately_TIME
in_PIN
the_DT
income_NN
statement_NOMZ
._.
Investments_NOMZ
Available_NN
for_PIN
sale_NN
investments_NOMZ
with_PIN
quoted_VBN
market_NN
prices_NN
are_VPRT [SPAU] [PASS]
initially_TIME
recognized_VBN [PRIV]
at_PIN
cost_NN
on_PIN
acquisition_NOMZ
and_CC
remeasured_VBD
to_PIN
their_TPP3
fair_JJ
values_NN
at_PIN
year-end_NN
._.
Gains_NN
or_CC
losses_NN
on_PIN
remeasurement_NOMZ
to_PIN
fair_JJ
value_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
shareholders_NN
equity_NOMZ
until_IN
the_DT
investments_NOMZ
are_VPRT [PASS]
sold_VBN
,_,
disposed_VBN [PASTP]
of_PIN [STPR]
,_,
or_CC
determined_VBN [SUAV] [PRIV]
to_TO
be_VB [PASS]
impaired_VBN
,_,
at_PIN
which_WDT [PIRE]
time_NN
the_DT
cumulative_JJ
gains_NN
or_CC
loss_NN
relating_VBG [WZPRES]
to_PIN
these_DEMO
investments_NOMZ
previously_TIME
recognized_VBN [PRIV]
in_PIN
equity_NOMZ
is_VPRT [PASS]
included_VBN
in_PIN
the_DT
income_NN
statement_NOMZ
._.
Available_JJ
for_PIN
sale_NN
financial_JJ
assets_NN
without_PIN
market_NN
prices_NN
and_CC
the_DT
fair_JJ
value_NN
of_PIN
which_WDT [PIRE]
can_POMD
not_XX0
be_VB [SPAU] [PASS]
reliably_RB
measured_VBN
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
cost_NN
,_,
less_JJ
a_DT
provision_NN
for_PIN
any_QUAN
impairment_NOMZ
loss_NN
,_,
which_WDT [SERE]
is_VPRT [PASS]
taken_VBN
to_PIN
the_DT
income_NN
statement_NOMZ
._.
The_DT
fair_JJ
value_NN
of_PIN
quoted_VBN
financial_JJ
assets_NN
represents_VPRT
the_DT
closing_GER
price_NN
in_PIN
the_DT
financial_JJ
markets_NN
at_PIN
the_DT
date_NN
of_PIN
the_DT
financial_JJ
statements_NOMZ
._.
However_CONJ
,_,
the_DT
fair_JJ
value_NN
of_PIN
unquoted_JJ
financial_JJ
assets_NN
,_,
or_CC
those_DEMO
with_PIN
no_DT
declared_VBN [PUBV] [THATD]
price_NN
are_VPRT [BYPA]
estimated_VBN [PRIV]
by_PIN
comparing_VBG
the_DT
fair_JJ
value_NN
of_PIN
a_DT
similar_JJ
financial_JJ
instrument_NOMZ
or_CC
through_PIN
a_DT
discounted_JJ
cash_NN
flow_NN
method_NN
._.
Accounts_NN
receivable_JJ
Trade_NN
receivables_NN
are_VPRT [PASS]
measured_VBN
at_PIN
initial_JJ
recognition_NOMZ
at_PIN
fair_JJ
value_NN
,_,
and_ANDC
are_VPRT [SPAU] [PASS]
subsequently_TIME
measured_VBN
at_PIN
amortised_JJ
cost_NN
using_VBG [WZPRES]
the_DT
effective_JJ
interest_NN
rate_NN
method_NN
._.
Appropriate_JJ
allowances_NN
for_PIN
estimated_VBN [PRIV] [THATD]
irrecoverable_JJ
amounts_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
profit_NN
or_CC
loss_NN
when_RB
there_EX
is_VPRT
objective_JJ
evidence_NN
that_TOBJ
the_DT
asset_NN
is_VPRT [PASS]
impaired_VBN
._.
The_DT
allowance_NN
recognized_VBN [PRIV] [WZPAST]
is_VPRT [PASS]
measured_VBN
as_IN
the_DT
difference_NN
between_PIN
the_DT
assets_NN
carrying_VBG [WZPRES]
amount_NN
and_CC
the_DT
present_JJ
value_NN
of_PIN
estimated_JJ
future_JJ
cash_NN
flows_VPRT
discounted_VBN
at_PIN
the_DT
effective_JJ
interest_NN
rate_NN
computed_VBD
at_PIN
initial_JJ
recognition_NOMZ
._.
Cash_NN
and_PHC
cash_NN
equivalents_NN
Cash_NN
and_PHC
cash_NN
equivalents_NN
include_VPRT
highly_AMP
liquid_JJ
investments_NOMZ
with_PIN
original_JJ
maturities_NOMZ
of_PIN
three_CD
months_NN
or_CC
less_JJ
and_CC
are_VPRT [BEMA]
subject_PRED
to_PIN
an_DT
insignificant_JJ
risk_NN
of_PIN
changes_NN
in_PIN
value_NN
._.
Bank_NN
borrowings_GER
Interest-bearing_JJ
bank_NN
loans_NN
and_PHC
overdrafts_NN
are_VPRT [PASS]
recorded_VBN
at_PIN
the_DT
proceeds_NN
received_VBD
,_,
net_NN
of_PIN
direct_JJ
issue_NN
costs_NN
._.
Finance_NN
charges_NN
,_,
including_VBG
premiums_NN
payable_JJ
on_PIN
settlement_NOMZ
or_CC
redemption_NOMZ
and_CC
direct_JJ
issue_NN
costs_NN
,_,
are_VPRT [PASS]
accounted_VBN
for_PIN
on_PIN
an_DT
accrual_NN
basis_NN
in_PIN
profit_NN
or_CC
loss_NN
account_NN
using_VBG [WZPRES]
the_DT
effective_JJ
interest_NN
method_NN
and_CC
are_VPRT [PASS]
added_VBN [PUBV]
to_PIN
the_DT
carrying_VBG
amount_NN
of_PIN
the_DT
instrument_NOMZ
to_PIN
the_DT
extent_NN
that_TOBJ
they_TPP3
are_VPRT [PASS]
not_XX0
settled_VBN
in_PIN
the_DT
period_NN
in_PIN
which_WDT [PIRE]
they_TPP3
arise_VPRT
._.
Trade_NN
payables_NN
Trade_NN
payables_NN
are_VPRT
not_XX0
interest_NN
bearing_GER
and_CC
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
fair_JJ
value_NN
._.
Equity_NOMZ
instruments_NOMZ
Equity_NOMZ
instruments_NOMZ
issued_VBN [WZPAST]
by_PIN
the_DT
Group_NN
are_VPRT [PASS]
recorded_VBN
at_PIN
the_DT
proceeds_NN
received_VBD
,_,
net_NN
of_PIN
direct_JJ
issue_NN
costs_NN
._.
Significant_JJ
accounting_GER
policies_NN
continued_VBD
Provisions_NN
Provisions_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
when_RB [WHCL]
the_DT
Group_NN
has_VPRT
a_DT
present_JJ
obligation_NOMZ
legal_JJ
or_CC
constructive_JJ
as_CONJ
a_NULL
result_NULL
of_PIN
a_DT
past_JJ
event_NN
,_,
it_PIT
is_VPRT [BEMA]
probable_PRED
that_THAC
an_DT
outflow_NN
of_PIN
resources_NN
embodying_VBG [WZPRES]
economic_JJ
benefits_NN
will_PRMD
be_VB [PASS]
required_VBN [SUAV]
to_TO
settle_VB
the_DT
obligation_NOMZ
and_CC
a_DT
reliable_JJ
estimate_NN
can_POMD
be_VB [PASS]
made_VBN
of_PIN
the_DT
amount_NN
of_PIN
the_DT
obligation_NOMZ
._.
Impairment_NOMZ
of_PIN
tangible_JJ
and_PHC
intangible_JJ
assets_NN
excluding_VBG [WZPRES]
goodwill_NN
At_PIN
each_QUAN
balance_NN
sheet_NN
date_NN
,_,
the_DT
Group_NN
reviews_VPRT
the_DT
carrying_VBG
amounts_NN
of_PIN
its_PIT
tangible_JJ
and_PHC
intangible_JJ
assets_NN
to_TO
determine_VB [SUAV] [PRIV]
whether_IN [WHCL]
there_EX
is_VPRT
any_QUAN
indication_NOMZ
that_TOBJ
those_DEMO
assets_NN
have_VPRT [PEAS]
suffered_VBN
an_DT
impairment_NOMZ
loss_NN
._.
If_COND
any_QUAN
such_JJ
indication_NOMZ
exists_VPRT
,_,
the_DT
recoverable_JJ
amount_NN
of_PIN
the_DT
asset_NN
is_VPRT [PASS]
estimated_VBN [PRIV]
in_PIN
order_NN
to_TO
determine_VB [SUAV] [PRIV]
the_DT
extent_NN
of_PIN
the_DT
impairment_NOMZ
loss_NN
._.
An_DT
intangible_JJ
asset_NN
with_PIN
an_DT
indefinite_JJ
useful_JJ
life_NN
is_VPRT [PASS]
tested_VBN
for_PIN
impairment_NOMZ
annually_RB
and_ANDC
whenever_RB
there_EX
is_VPRT
an_DT
indication_NOMZ
that_TOBJ
the_DT
asset_NN
may_POMD
be_VB [PASS]
impaired_VBN
._.
Recoverable_JJ
amount_NN
is_VPRT [BEMA]
the_DT
higher_JJ
of_PIN
fair_JJ
value_NN
less_RB
costs_NN
to_TO
sell_VB
and_CC
value_NN
in_PIN
use_NN
._.
In_PIN
assessing_VBG
value_NN
in_PIN
use_NN
,_,
the_DT
estimated_JJ
future_JJ
cash_NN
flows_NN
are_VPRT [PASS]
discounted_VBN
to_PIN
their_TPP3
present_JJ
value_NN
using_VBG [WZPRES]
a_DT
pre-tax_JJ
discount_NN
rate_NN
that_TSUB
reflects_VPRT [PRIV]
current_JJ
market_NN
assessments_NOMZ
of_PIN
the_DT
time_NN
value_NN
of_PIN
money_NN
and_CC
the_DT
risks_NN
specific_JJ
to_PIN
the_DT
asset_NN
for_PIN
which_WDT [PIRE]
the_DT
estimates_NN
of_PIN
future_JJ
cash_NN
flows_NN
have_VPRT [PEAS]
not_XX0
been_VBN [PASS]
adjusted_VBN
._.
If_COND
the_DT
recoverable_JJ
amount_NN
of_PIN
an_DT
asset_NN
or_CC
income-generating_JJ
unit_NN
is_VPRT [PASS]
estimated_VBN [PRIV]
to_TO
be_VB [BEMA]
less_PRED
than_PIN
its_PIT
carrying_VBG
amount_NN
,_,
the_DT
carrying_VBG
amount_NN
of_PIN
the_DT
asset_NN
income-generating_JJ
unit_NN
is_VPRT [PASS]
reduced_VBN
to_PIN
its_PIT
recoverable_JJ
amount_NN
._.
An_DT
impairment_NOMZ
loss_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
as_IN
an_DT
expense_NN
immediately_TIME
._.
Where_RB
an_DT
impairment_NOMZ
loss_NN
subsequently_TIME
reverses_VPRT
,_,
the_DT
carrying_VBG
amount_NN
of_PIN
the_DT
asset_NN
cash-generating_JJ
unit_NN
is_VPRT [PASS]
increased_VBN
to_PIN
the_DT
revised_VBN
estimate_NN
of_PIN
its_PIT
recoverable_JJ
amount_NN
,_,
but_CC
so_OSUB
that_NULL
the_DT
increased_VBN
carrying_VBG
amount_NN
does_VPRT
not_XX0
exceed_VB
the_DT
carrying_VBG
amount_NN
that_TSUB
would_PRMD
have_VB [PEAS]
been_VBN [PASS]
determined_VBN [SUAV] [PRIV]
had_VBD
no_SYNE
impairment_NOMZ
loss_NN
been_VBN [PASS]
recognized_VBN [PRIV]
for_PIN
the_DT
asset_NN
cash-generating_JJ
unit_NN
in_PIN
prior_JJ
years_NN
._.
A_DT
reversal_NN
of_PIN
an_DT
impairment_NOMZ
loss_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
as_IN
income_NN
immediately_TIME
._.
New_NN
accounting_GER
policies_NN
and_CC
future_JJ
requirements_NOMZ
The_DT
following_JJ
IFRS_NN
and_PHC
IFRIC_NN
interpretation_NOMZ
have_VPRT [PEAS]
been_VBN [BYPA]
issued_VBN
by_PIN
the_DT
IASB_NN
and_CC
are_VPRT [BEMA]
likely_PRED
to_TO
affect_VB
future_JJ
annual_JJ
reports_NN
._.
IFRS_NN
7_CD
Financial_NN
instruments_NOMZ
:_:
disclosures_NN
was_VBD [PASS]
issued_VBN
in_PIN
August_NN
2005_CD
and_CC
is_VPRT [PASS]
required_VBN [SUAV]
to_TO
be_VB [BYPA]
implemented_VBN
by_PIN
the_DT
Group_NN
from_PIN
1st_CD
January_NN
2007_CD
._.
This_DEMO
new_JJ
standard_JJ
incorporates_VPRT
the_DT
disclosure_NN
requirements_NOMZ
of_PIN
IAS_NN
32_CD
,_,
which_WDT [SERE]
it_PIT
supersedes_VPRT
,_,
and_ANDC
adds_VPRT [PUBV]
further_JJ
quantitative_JJ
and_PHC
qualitative_JJ
disclosures_NN
in_PIN
relation_NOMZ
to_PIN
financial_JJ
instruments_NOMZ
._.
IFRIC_NN
4_CD
Determining_VBG [SUAV] [PRIV]
whether_IN [WHCL]
an_DT
arrangement_NOMZ
contains_VPRT
a_DT
lease_NN
was_VBD [PASS]
issued_VBN
in_PIN
December_NN
2004_CD
and_CC
is_VPRT [PASS]
required_VBN [SUAV]
to_TO
be_VB [BYPA]
implemented_VBN
by_PIN
the_DT
Group_NN
from_PIN
1_CD
January_NN
2006_CD
._.
The_DT
interpretation_NOMZ
requires_VPRT [SUAV]
arrangements_NOMZ
which_WDT [WHSUB]
may_POMD
have_VB
the_DT
nature_NN
,_,
but_CC
not_XX0
the_DT
legal_JJ
form_NN
,_,
of_PIN
a_DT
lease_NN
to_TO
be_VB [PASS]
accounted_VBN
for_PIN
in_PIN
accordance_NN
with_PIN
IAS_NN
17_CD
Leases_NN
._.
This_DEMO
interpretation_NOMZ
is_VPRT [PASS]
not_XX0
expected_VBN [PRIV]
to_TO
have_VB
a_DT
material_NN
impact_NN
on_PIN
the_DT
Group_NN
._.
58_CD
Hikma_NN
Pharmaceuticals_NN
PLC_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
continued_VBD
3_CD
._.
Business_NOMZ
and_CC
geographical_JJ
segments_NOMZ
For_PIN
management_NOMZ
purposes_NN
,_,
the_DT
Group_NN
is_VPRT [PASS]
organised_VBN
into_PIN
three_CD
operating_GER
divisions_NN
Generics_NN
,_,
Branded_NN
and_PHC
Injectables_NN
._.
These_DEMO
divisions_NN
are_VPRT [BEMA]
the_DT
basis_NN
on_PIN
which_WDT [PIRE]
the_DT
Group_NN
reports_VPRT [PUBV]
its_PIT
primary_JJ
segment_NOMZ
information_NOMZ
._.
Segment_NOMZ
information_NOMZ
about_IN
these_DEMO
businesses_NOMZ
is_VPRT [PASS]
presented_VBN
below_PLACE
._.
Corporate_JJ
Generics_NN
Branded_NN
Injectable_NN
and_PHC
others_NN
Group_NN
2005200520052005_CD
2005_CD
$_$
000s_CD
$_$
000s_CD
$_$
000s_CD
$_$
000s_CD
$_$
000s_CD
Revenue_NN
115,208_CD
93,012_CD
49,303_CD
4,692_CD
262,215_CD
Cost_NN
of_PIN
sales_NN
52,861_CD
39,297_CD
30,883_CD
3,383_CD
126,424_CD
Gross_NN
profit_NN
62,347_CD
53,715_CD
18,420_CD
1,309_CD
135,791_CD
Result_NN
Segment_NOMZ
result_NN
38,765_CD
28,764_CD
8,486_CD
27_CD
75,988_CD
Unallocated_JJ
corporate_JJ
expenses_NN
8,229_CD
Share_NN
of_PIN
results_NN
of_PIN
associates_NN
1,449_CD
1,449_CD
Operating_GER
profit_NN
69,208_CD
Flotation_NOMZ
costs_NN
1,426_CD
Finance_NN
income_NN
1,562_CD
Finance_NN
costs_NN
5,211_CD
Other_JJ
income_NN
276_CD
Profit_NN
before_IN
tax_NN
64,409_CD
Tax_NN
19,452_CD
Minority_NOMZ
interest_NN
1,090_CD
Profit_NN
for_PIN
the_DT
year_NN
attributable_JJ
to_PIN
equity_NOMZ
shareholders_NN
43,867_CD
Corporate_JJ
Generics_NN
Branded_NN
Injectable_NN
and_PHC
others_NN
Group_NN
2005200520052005_CD
2005_CD
Other_JJ
information_NOMZ
$_$
000s_CD
$_$
000s_CD
$_$
000s_CD
$_$
000s_CD
$_$
000s_CD
Additions_NOMZ
to_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
assets_NN
cost_VPRT
4,385_CD
12,364_CD
7,770_CD
1,680_CD
26,199_CD
Acquisition_NOMZ
of_PIN
subsidiarys_NN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
9,857_CD
9,857_CD
Additions_NOMZ
to_PIN
intangible_JJ
assets_NN
282_CD
3,939_CD
4,221_CD
Total_JJ
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
and_CC
intangible_JJ
assets_NN
net_JJ
book_NN
value_NN
25,600_CD
33,844_CD
30,408_CD
9,092_CD
98,944_CD
Depreciation_NOMZ
and_PHC
amortisation_NOMZ
4,879_CD
2,273_CD
2,133_CD
1,040_CD
10,325_CD
Total_JJ
investment_NOMZ
in_PIN
associated_VBN
companies_NN
7,552_CD
7,552_CD
Balance_NN
sheet_NN
Assets_NN
Segment_NOMZ
assets_NN
122,831_CD
140,631_CD
50,219_CD
89,113_CD
402,794_CD
Liabilities_NOMZ
Segment_NOMZ
liabilities_NOMZ
13,207_CD
62,937_CD
25,237_CD
13,931_CD
115,312_CD
Hikma_NN
Pharmaceuticals_NN
PLC_NN
59_CD
3_CD
._.
Business_NOMZ
and_CC
geographical_JJ
segments_NOMZ
continued_VBD
Corporate_NN
Group_NN
Generics_NN
Branded_NN
Injectable_NN
and_PHC
others_NN
Restated_VBN
2004200420042004_CD
2004_CD
$_$
000s_CD
$_$
000s_CD
$_$
000s_CD
$_$
000s_CD
$_$
000s_CD
Revenue_NN
106,225_CD
74,013_CD
28,859_CD
3,280_CD
212,377_CD
Cost_NN
of_PIN
sales_NN
48,773_CD
34,312_CD
19,140_CD
1,712_CD
103,937_CD
Gross_NN
profit_NN
57,452_CD
39,701_CD
9,719_CD
1,568_CD
108,440_CD
Result_NN
Segment_NOMZ
result_NN
41,043_CD
22,441_CD
4,056_CD
986_CD
68,526_CD
Unallocated_JJ
corporate_JJ
expenses_NN
6,534_CD
Share_NN
of_PIN
results_NN
of_PIN
associates_NN
732_CD
732_CD
Operating_GER
profit_NN
62,724_CD
Flotation_NOMZ
costs_NN
425_CD
Finance_NN
income_NN
326_CD
Finance_NN
costs_NN
3,825_CD
Other_JJ
income_NN
224_CD
Profit_NN
before_IN
tax_NN
59,024_CD
Tax_NN
20,835_CD
Minority_NOMZ
interest_NN
731_CD
Profit_NN
for_PIN
the_DT
year_NN
attributable_JJ
to_PIN
equity_NOMZ
shareholders_NN
37,458_CD
Corporate_JJ
Generics_NN
Branded_NN
Injectable_NN
and_PHC
others_NN
Group_NN
2004200420042004_CD
2004_CD
Other_JJ
information_NOMZ
$_$
000s_CD
$_$
000s_CD
$_$
000s_CD
$_$
000s_CD
$_$
000s_CD
Additions_NOMZ
to_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
assets_NN
cost_VPRT
6,139_CD
8,340_CD
2,133_CD
1,432_CD
18,044_CD
Acquisition_NOMZ
of_PIN
subsidiarys_NN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
3,146_CD
3,146_CD
Additions_NOMZ
to_PIN
intangible_JJ
assets_NN
3,443_CD
778_CD
70_CD
4,291_CD
Total_JJ
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
and_CC
intangible_JJ
assets_NN
net_JJ
book_NN
value_NN
25,271_CD
25,256_CD
18,373_CD
7,604_CD
76,504_CD
Depreciation_NOMZ
and_PHC
amortisation_NOMZ
2,036_CD
2,505_CD
1,412_CD
727_CD
6,680_CD
Total_JJ
investment_NOMZ
in_PIN
associated_VBN
companies_NN
6,103_CD
6,103_CD
Balance_NN
sheet_NN
Assets_NN
Segment_NOMZ
assets_NN
104,411_CD
93,493_CD
29,953_CD
18,624_CD
246,481_CD
Liabilities_NOMZ
Segment_NOMZ
liabilities_NOMZ
16,818_CD
45,783_CD
18,998_CD
19,707_CD
101,306_CD
60_CD
Hikma_NN
Pharmaceuticals_NN
PLC_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
continued_VBD
3_CD
._.
Business_NOMZ
and_CC
geographical_JJ
segments_NOMZ
continued_VBD
The_DT
following_JJ
table_NN
provides_VPRT
an_DT
analysis_NN
of_PIN
the_DT
Groups_NN
sales_NN
by_PIN
geographical_JJ
market_NN
,_,
irrespective_RB
of_PIN
the_DT
origin_NN
of_PIN
the_DT
goods_NN
services_NN
:_:
Sales_NN
revenue_NN
by_PIN
geographical_JJ
market_NN
2005_CD
2004_CD
$_$
000s_CD
$_$
000s_CD
United_NN
States_NN
130,454_CD
113,101_CD
Europe_NN
20,445_CD
12,490_CD
Middle_NN
East_NN
and_PHC
North_NN
Africa_NN
111,283_CD
85,826_CD
Rest_VPRT
of_PIN
the_DT
world_NN
33960262_CD
,215_CD
212,377_CD
The_DT
following_GER
is_VPRT [BEMA]
an_DT
analysis_NN
of_PIN
the_DT
additions_NOMZ
to_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
and_CC
intangible_JJ
assets_NN
,_,
an_DT
analysis_NN
of_PIN
total_JJ
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
and_CC
intangible_JJ
assets_NN
and_CC
an_DT
analysis_NN
of_PIN
total_JJ
assets_NN
by_PIN
the_DT
geographical_JJ
area_NN
in_PIN
which_WDT [PIRE]
the_DT
assets_NN
are_VPRT [PASS]
located_VBN
:_:
Additions_NOMZ
to_PIN
property_NN
,_,
plant_NN
and_CC
Total_JJ
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
and_PHC
intangibles_NN
equipment_NOMZ
and_CC
intangibles_VPRT
Total_JJ
assets_NN
2005200420052004_CD
2005_CD
2004_CD
$_$
000s_CD
$_$
000s_CD
$_$
000s_CD
$_$
000s_CD
$_$
000s_CD
$_$
000s_CD
United_NN
States_NN
4,385_CD
9,582_CD
25,600_CD
25,271_CD
122,832_CD
104,411_CD
Europe_NN
21,573_CD
2,912_CD
31,431_CD
18,373_CD
115,587_CD
30,377_CD
Middle_NN
East_NN
and_PHC
North_NN
Africa_NN
14,319_CD
12,987_CD
41,913_CD
32,860_CD
164,375_CD
111,693_CD
40,277_CD
25,481_CD
98,944_CD
76,504_CD
402,794_CD
246,481_CD
Additions_NOMZ
include_VPRT
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
and_PHC
intangibles_NN
acquired_VBN [WZPAST]
with_PIN
and_CC
arising_VBG
on_PIN
the_DT
acquisition_NOMZ
of_PIN
subsidiary_NN
undertakings_GER
._.
Profit_NN
for_PIN
the_DT
year_NN
Profit_NN
for_PIN
the_DT
year_NN
has_VPRT [PEAS]
been_VBN [PASS]
arrived_VBN
at_PIN
after_IN
charging_VBG
crediting_VBG
:_:
For_PIN
the_DT
years_NN
ended_VBN
31_CD
December_NN
2005_CD
2004_CD
$_$
000s_CD
$_$
000s_CD
Net_JJ
foreign_JJ
exchange_NN
gains_NN
217_CD
282_CD
Research_NN
and_PHC
development_NOMZ
costs_NN
16,507_CD
9,672_CD
Loss_NN
on_PIN
sale_NN
of_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
440_CD
390_CD
Depreciation_NOMZ
of_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
8,909_CD
6,680_CD
Amortisation_NOMZ
and_PHC
impairment_NOMZ
of_PIN
intangibles_NN
1,416_CD
Cost_NN
of_PIN
inventories_NN
recognized_VBN [PRIV]
as_IN
expense_NN
83,648_CD
67,237_CD
Write-down_NN
of_PIN
inventories_NN
855_CD
921_CD
Staff_NN
costs_NN
see_VPRT [PRIV]
Note_NN
5_CD
51,889_CD
36,894_CD
Auditors_NN
remuneration_NOMZ
for_PIN
audit_NN
services_NN
see_VPRT [PRIV]
below_PLACE
1,059_CD
439_CD
A_DT
more_EMPH
detailed_JJ
analysis_NN
of_PIN
auditors_NN
remuneration_NOMZ
on_PIN
a_DT
worldwide_JJ
basis_NN
is_VPRT [PASS]
provided_VBN
below_PLACE
._.
2005_CD
2004_CD
$_$
000s_CD
$_$
000s_CD
Audit_NN
fees_NN
644_CD
409_CD
Fees_NN
in_PIN
connection_NOMZ
with_PIN
the_DT
float_NN
212_CD
Other_JJ
services_NN
203_CD
30_CD
1,059_CD
439_CD
In_CONJ
addition_NULL
,_,
$_$
1,995,000_CD
of_PIN
fees_NN
in_PIN
relation_NOMZ
to_PIN
the_DT
float_NN
has_VPRT [PEAS]
been_VBN [PASS]
set_VBN
off_PIN
against_PIN
the_DT
share_NN
premium_NN
account_NN
._.
Profit_NN
for_PIN
the_DT
year_NN
continued_VBD
A_DT
description_NOMZ
of_PIN
the_DT
work_NN
of_PIN
the_DT
Audit_NN
Committee_NN
is_VPRT [PASS]
set_VBN
out_PIN
in_PIN
the_DT
Audit_NN
Committee_NN
report_NN
on_PIN
pages_NN
35_CD
and_CC
36_CD
and_CC
includes_VPRT
an_DT
explanation_NOMZ
of_PIN
how_RB
auditor_NN
objectivity_NOMZ
and_PHC
independence_NN
is_VPRT [PASS]
safeguarded_VBN
when_RB
non-audit_JJ
services_NN
are_VPRT [BYPA]
provided_VBN
by_PIN
the_DT
auditors_NN
._.
Included_VBN [PASTP]
in_PIN
the_DT
amount_NN
for_PIN
audit_NN
services_NN
shown_VBN [PRIV] [WZPAST]
on_PIN
the_DT
previous_JJ
page_NN
are_VPRT [BEMA]
the_DT
audit_NN
fees_NN
of_PIN
Hikma_NN
Pharmaceuticals_NN
PLC_NN
company_NN
only_DWNT
of_PIN
$_$
50,000_CD
._.
Staff_NN
costs_NN
The_DT
average_JJ
monthly_JJ
number_NN
of_PIN
employees_NN
including_VBG [WZPRES]
Executive_NN
Directors_NN
was_VBD
:_:
2005_CD
2004_CD
Number_NN
Number_NN
Production_NOMZ
1,052_CD
818_CD
Selling_VBG
and_PHC
marketing_VBG
363_CD
292_CD
Research_NN
and_PHC
development_NOMZ
160_CD
122_CD
General_NN
and_CC
administrative_JJ
252_CD
195_CD
1,827_CD
1,427_CD
2005_CD
2004_CD
$_$
000s_CD
$_$
000s_CD
Their_TPP3
aggregate_JJ
remuneration_NOMZ
comprised_VBN
:_:
Wages_NN
and_PHC
salaries_NN
41,055_CD
29,662_CD
Social_NN
security_NOMZ
costs_NN
4,039_CD
2,702_CD
Post_NN
employment_NOMZ
benefits_NN
685_CD
615_CD
End_NN
of_PIN
service_NN
indemnity_NOMZ
843_CD
615_CD
Other_JJ
5,267_CD
3,300_CD
51,889_CD
36,894_CD
Other_JJ
staff_NN
costs_NN
mainly_RB
consist_VPRT
of_PIN
health_NN
insurance_NN
,_,
training_GER
,_,
housing_GER
and_CC
living_VBG
allowances_NN
._.
Other_JJ
operating_GER
expenses_NN
The_DT
other_JJ
operating_GER
expenses_NN
consist_VPRT
mainly_RB
of_PIN
damaged_VBN
and_CC
slow_JJ
moving_VBG [SUAV]
items_NN
and_CC
the_DT
cost_NN
of_PIN
setting_VBG
up_RP
the_DT
new_JJ
manufacturing_GER
facilities_NOMZ
in_PIN
Algeria_NN
that_TSUB
commenced_VBD
operations_NOMZ
early_TIME
in_PIN
2006_CD
._.
Other_JJ
operating_GER
income_NN
The_DT
other_JJ
operating_GER
income_NN
consists_VPRT
mainly_RB
of_PIN
management_NOMZ
fees_NN
from_PIN
Al-Jazeera_NN
Pharmaceuticals_NN
Industries_NN
Co._NN
._.
KSA_NN
and_CC
foreign_JJ
exchange_NN
gains_NN
._.
Flotation_NOMZ
costs_NN
The_DT
total_JJ
costs_NN
of_PIN
flotation_NOMZ
were_VBD
$_$
12,661,000_CD
,_,
of_PIN
which_WDT [PIRE]
costs_VPRT
incurred_VBN
in_PIN
issuing_VBG
shares_NN
amounting_VBG [WZPRES]
to_TO
$_$
10,810,000_CD
have_VPRT [PEAS]
been_VBN [PASS]
charged_VBN
against_PIN
the_DT
share_NN
premium_NN
account_NN
._.
The_DT
remaining_VBG
amount_NN
of_PIN
$_$
1,851,000_CD
incurred_VBN
as_CONJ
a_NULL
result_NULL
of_PIN
the_DT
listing_GER
exercise_NN
,_,
but_CC
which_WDT
was_VBD [BEMA]
not_XX0
eligible_PRED
to_TO
be_VB [PASS]
set_VBN
against_PIN
the_DT
share_NN
premium_NN
,_,
has_VPRT [PEAS]
been_VBN [PASS]
reflected_VBN [PRIV]
in_PIN
flotation_NOMZ
costs_NN
within_PIN
the_DT
income_NN
statement_NOMZ
,_,
of_PIN
which_WDT [PIRE]
$_$
1,426,000_CD
and_CC
$_$
425,000_CD
was_VBD [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
years_NN
ended_VBN
31_CD
December_NN
2005_CD
and_CC
2004_CD
,_,
respectively_RB
._.
Finance_NN
income_NN
For_PIN
the_DT
years_NN
ended_VBN
31_CD
December_NN
2005_CD
2004_CD
$_$
000s_CD
$_$
000s_CD
Interest_NN
income_NN
1,562_CD
313_CD
Net_JJ
foreign_JJ
exchange_NN
13_CD
1,562_CD
326_CD
62_CD
Hikma_NN
Pharmaceuticals_NN
PLC_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
continued_VBD
10_CD
._.
Finance_NN
costs_VPRT
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2005_CD
2004_CD
$_$
000s_CD
$_$
000s_CD
Interest_NN
on_PIN
bank_NN
overdrafts_NN
and_PHC
loans_NN
3,437_CD
2,498_CD
Interest_NN
on_PIN
obligations_NOMZ
under_IN
finance_NN
leases_NN
227_CD
436_CD
Other_JJ
bank_NN
charges_NN
1,547_CD
891_CD
5,211_CD
3,825_CD
11_CD
._.
Tax_NN
For_PIN
the_DT
years_NN
ended_VBN
31_CD
December_NN
2005_CD
2004_CD
$_$
000s_CD
$_$
000s_CD
Current_JJ
tax_NN
:_:
UK_NN
current_JJ
tax_NN
110_CD
Foreign_NN
tax_NN
19,596_CD
20,896_CD
Deferred_JJ
tax_NN
Note_NN
17_CD
254_CD
61_CD
19,452_CD
20,835_CD
UK_NN
corporation_NOMZ
tax_NN
is_VPRT [PASS]
calculated_VBN [PRIV]
at_PIN
30_CD
%_NN
of_PIN
the_DT
estimated_VBN [PRIV]
assessable_JJ
profit_NN
for_PIN
the_DT
year_NN
._.
At_PIN
31_CD
December_NN
2004_CD
the_DT
Group_NN
was_VBD [BYPA]
headed_VBN
by_PIN
Hikma_NN
Pharma_NN
Limited_NN
,_,
a_DT
company_NN
incorporated_VBN [WZPAST]
in_PIN
Jersey_NN
where_RB
the_DT
tax_NN
rate_NN
is_VPRT [BEMA]
zero_CD
._.
The_DT
charge_NN
for_PIN
the_DT
year_NN
can_POMD
be_VB [PASS]
reconciled_VBN
to_PIN
the_DT
profit_NN
per_PIN
the_DT
income_NN
statement_NOMZ
as_IN
follows_VPRT
:_:
2005_CD
$_$
000s_CD
Profit_NN
before_IN
tax_NN
64,409_CD
Tax_NN
at_PIN
the_DT
UK_NN
corporation_NOMZ
tax_NN
rate_NN
of_PIN
30_CD
%_NN
19,323_CD
Tax_NN
effect_NN
of_PIN
share_NN
of_PIN
results_NN
of_PIN
associates_NN
435_CD
Tax_NN
effect_NN
of_PIN
expenses_NN
that_TSUB
are_VPRT [BEMA]
not_XX0
deductible_PRED
in_PIN
determining_VBG [SUAV] [PRIV]
taxable_JJ
profit_NN
7_CD
Tax_NN
effect_NN
of_PIN
exempted_VBN
revenues_NN
3,023_CD
Tax_NN
effect_NN
of_PIN
losses_NN
for_PIN
which_WDT [PIRE]
no_SYNE
deferred_JJ
tax_NN
asset_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
1,520_CD
Effect_NN
of_PIN
different_JJ
tax_NN
rates_NN
of_PIN
subsidiaries_NN
operating_VBG [WZPRES]
in_PIN
other_JJ
jurisdictions_NOMZ
2,427_CD
Other_JJ
adjustments_NOMZ
367_CD
Tax_NN
expense_NN
for_PIN
the_DT
year_NN
19,452_CD
No_SYNE
reconciliation_NOMZ
is_VPRT [PASS]
provided_VBN
for_PIN
2004_CD
as_IN
the_DT
company_NN
was_VBD [PASS]
incorporated_VBN
in_PIN
Jersey_NN
where_RB
the_DT
tax_NN
rate_NN
is_VPRT [BEMA]
zero_CD
._.
Dividends_NN
2005_CD
2004_CD
$_$
000s_CD
$_$
000s_CD
Amounts_NN
recognized_VBN [PRIV]
as_IN
distributions_NOMZ
to_PIN
equity_NOMZ
holders_NN
in_PIN
the_DT
period_NN
:_:
Final_JJ
dividend_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
of_PIN
5.0_CD
cents_NN
per_PIN
share_NN
2003_CD
:_:
2.6_CD
cents_NN
per_PIN
share_NN
7,120_CD
3,766_CD
Pre-float_JJ
interim_JJ
dividend_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2005_CD
of_PIN
7.5_CD
cents_NN
per_PIN
share_NN
10,680_CD
17,800_CD
3,766_CD
Proposed_VBN [SUAV]
final_JJ
dividend_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2005_CD
of_PIN
0.89_CD
cents_NN
per_PIN
share_NN
2004_CD
:_:
5.0_CD
cents_NN
per_PIN
share_NN
1,500_CD
7,120_CD
The_DT
final_JJ
dividend_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
and_CC
the_DT
pre-float_JJ
interim_JJ
dividend_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2005_CD
were_VBD [BYPA]
paid_VBN
by_PIN
Hikma_NN
Pharma_NN
Limited_NN
which_WDT [WHSUB]
is_VPRT [PASS]
incorporated_VBN
in_PIN
Jersey_NN
._.
Earnings_GER
per_PIN
share_NN
The_DT
calculation_NOMZ
of_PIN
the_DT
basic_JJ
and_PHC
diluted_JJ
earnings_GER
per_PIN
share_NN
is_VPRT [PASS]
based_VBN
on_PIN
the_DT
following_VBG
data_NN
:_:
2005_CD
2004_CD
$_$
000s_CD
$_$
000s_CD
Earnings_GER
Earnings_GER
for_PIN
the_DT
purposes_NN
of_PIN
basic_JJ
and_PHC
diluted_JJ
earnings_GER
per_PIN
share_NN
being_VBG [WZPRES] [BEMA]
net_JJ
profit_NN
attributable_JJ
to_PIN
equity_NOMZ
holders_NN
of_PIN
the_DT
parent_NN
43,867_CD
37,458_CD
Number_NN
Number_NN
Number_NN
of_PIN
shares_NN
Weighted_VBN
average_JJ
number_NN
of_PIN
Ordinary_NN
Shares_NN
for_PIN
the_DT
purposes_NN
of_PIN
basic_JJ
earnings_GER
per_PIN
share_NN
000_CD
146,454_CD
142,400_CD
Effect_NN
of_PIN
dilutive_JJ
potential_JJ
Ordinary_NN
Shares_NN
:_:
Share_NN
options_NOMZ
000_CD
8,402_CD
7,843_CD
Weighted_VBN
average_JJ
number_NN
of_PIN
ordinary_JJ
shares_NN
for_PIN
the_DT
purposes_NN
of_PIN
diluted_JJ
earnings_GER
per_PIN
share_NN
000_CD
154,856_CD
150,243_CD
Basic_JJ
Cents_NN
30.0_CD
26.3_CD
Diluted_NN
Cents_NN
28.3_CD
24.8_CD
14_CD
._.
Goodwill_NN
of_PIN
$_$
70,000_CD
arose_VBD
on_PIN
the_DT
acquisition_NOMZ
of_PIN
the_DT
Groups_NN
shares_NN
of_PIN
IPRC_NN
and_PHC
SPRC_NN
in_PIN
2004_CD
._.
The_DT
additions_NOMZ
to_PIN
goodwill_NN
in_PIN
2005_CD
represent_VPRT
the_DT
acquisition_NOMZ
of_PIN
the_DT
Italian_JJ
subsidiary_NN
IBPP_NN
see_VB [PRIV]
Note_VB [PRIV]
36_CD
._.
In_PIN
accordance_NN
with_PIN
International_NN
Accounting_GER
Standard_NN
38_CD
Intangible_NN
Assets_NN
IAS_NN
38_CD
the_DT
Group_NN
has_VPRT [PEAS]
tested_VBN
its_PIT
goodwill_NN
for_PIN
impairment_NOMZ
and_CC
assessed_VBN
that_DEMO
the_DT
fair_JJ
value_NN
exceeds_VPRT
its_PIT
book_NN
value_NN
,_,
therefore_CONJ
no_SYNE
impairment_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
taken_VBN
to_PIN
the_DT
income_NN
statement_NOMZ
._.
Marketing_GER
rights_NN
were_VBD [PASS]
acquired_VBN
in_PIN
2005_CD
and_CC
2004_CD
and_CC
are_VPRT
being_VBG [PASS]
amortised_VBN
over_IN
a_DT
period_NN
of_PIN
three_CD
to_PIN
five_CD
years_NN
from_PIN
the_DT
time_NN
they_TPP3
generate_VPRT
sales_NN
._.
Product_NN
files_NN
were_VBD [PASS]
acquired_VBN
at_PIN
14_CD
March_NN
2005_CD
on_PIN
the_DT
acquisition_NOMZ
of_PIN
the_DT
Italian_JJ
subsidiary_NN
IBPP_NN
._.
The_DT
product_NN
files_NN
have_VPRT
an_DT
indefinite_JJ
useful_JJ
life_NN
and_CC
are_VPRT
being_VBG [PASS]
reviewed_VBN
for_PIN
impairment_NOMZ
test_NN
at_PIN
least_JJ
annually_RB
._.
Software_NN
represents_VPRT
the_DT
new_JJ
Enterprise_NN
Resource_NN
Planning_GER
solution_NOMZ
ERP_NN
that_TOBJ
the_DT
Company_NN
implemented_VBN [WZPAST]
in_PIN
January_NN
2005_CD
._.
An_DT
impairment_NOMZ
charge_NN
of_PIN
$_$
250,000_CD
has_VPRT [PEAS]
been_VBN [PASS]
recognized_VBN [PRIV]
during_PIN
2005_CD
in_PIN
relation_NOMZ
to_PIN
software_NN
which_WDT [WHSUB]
no_RB
longer_RB
has_VPRT
any_QUAN
beneficial_JJ
interest_NN
to_PIN
the_DT
Group_NN
._.
64_CD
Hikma_NN
Pharmaceuticals_NN
PLC_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
continued_VBD
15_CD
._.
As_IN
at_PIN
31_CD
December_NN
2005_CD
the_DT
Group_NN
had_VBD [PEAS]
pledged_VBN [SUAV]
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
,_,
having_VBG [PRESP]
a_DT
carrying_VBG
value_NN
of_PIN
$_$
31,538,000_CD
of_PIN
which_WDT [PIRE]
an_DT
amount_NN
of_PIN
$_$
6,743,000_CD
was_VBD [PASS]
pledged_VBN [SUAV]
to_PIN
International_NN
Finance_NN
Corporation_NOMZ
._.
In_PIN
1994_CD
,_,
the_DT
Portuguese_NN
Government_NOMZ
granted_VBD [SUAV]
Hikma_NN
Farmacutica_NN
an_DT
amount_NN
of_PIN
Euro_NN
1,600,000_CD
to_TO
build_VB
the_DT
Companys_NN
factory_NN
in_PIN
accordance_NN
with_PIN
the_DT
SINPEDIP_NN
program_NN
._.
The_DT
grant_NN
amount_NN
is_VPRT
being_VBG [PASS]
released_VBN
to_PIN
the_DT
income_NN
statement_NOMZ
over_IN
the_DT
period_NN
necessary_JJ
to_TO
match_VB
it_PIT
with_PIN
the_DT
assets_NN
life_NN
._.
The_DT
carrying_VBG
value_NN
of_PIN
the_DT
grant_NN
as_IN
of_PIN
31_CD
December_NN
2005_CD
was_VBD
$_$
416,000_CD
31_CD
December_NN
2004_CD
:_:
$_$
591,000_CD
._.
The_DT
Directors_NN
were_VBD [BEMA]
not_XX0
aware_PRED
of_PIN
any_QUAN
significant_JJ
contractual_JJ
commitments_NOMZ
other_JJ
than_PIN
those_DEMP
disclosed_VBN [PUBV]
in_PIN
the_DT
accounts_NN
as_IN
of_PIN
31_CD
December_NN
2005_CD
2004_CD
:_:
$_$
1,600,000_CD
._.
The_DT
amount_NN
of_PIN
borrowing_GER
costs_NN
that_TSUB
was_VBD [PASS]
capitalized_VBN
on_PIN
the_DT
projects_NN
under_IN
construction_NOMZ
is_VPRT
$_$
300,000_CD
2004_CD
:_:
nil_NN
._.
Interest_NN
in_PIN
associate_JJ
Summarised_JJ
financial_JJ
information_NOMZ
in_PIN
respect_NN
of_PIN
the_DT
Groups_NN
47.5_CD
%_NN
interest_NN
in_PIN
the_DT
Ordinary_NN
Shares_NN
of_PIN
Al-Jazeera_NN
Pharmaceutical_NN
Industries_NN
Co._NN
incorporated_VBN [WZPAST]
in_PIN
KSA_NN
is_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
:_:
For_PIN
the_DT
years_NN
ended_VBN
31_CD
December_NN
2005_CD
2004_CD
$_$
000s_CD
$_$
000s_CD
Total_JJ
assets_NN
47,773_CD
40,690_CD
Total_JJ
liabilities_NOMZ
31,874_CD
27,842_CD
Net_JJ
assets_NN
15,899_CD
12,848_CD
Interest_NN
in_PIN
associate_JJ
7,552_CD
6,103_CD
Revenues_NN
30,371_CD
23,347_CD
Profit_NN
3,050_CD
1,541_CD
Share_NN
of_PIN
result_NN
of_PIN
associate_JJ
1,449_CD
732_CD
Profit_NN
is_VPRT [PASS]
stated_VBN [PUBV]
after_IN
management_NOMZ
fees_NN
of_PIN
$_$
1,061,000_CD
2004_CD
:_:
$_$
333,000_CD
paid_VBN
to_PIN
the_DT
Group_NN
._.
Deferred_JJ
tax_NN
The_DT
following_VBG
are_VPRT [BEMA]
the_DT
major_JJ
deferred_JJ
tax_NN
liabilities_NOMZ
and_PHC
assets_NN
recognized_VBN [PRIV] [WZPAST]
by_PIN
the_DT
Group_NN
and_PHC
movements_NOMZ
thereon_NN
during_PIN
the_DT
current_JJ
and_PHC
prior_JJ
reporting_GER
period_NN
._.
AmortisSoftware_NN
Deferred_NN
Reserves_NN
Interest_NN
able_JJ
Fixed_NN
Stock_NN
developTax_NN
losses_NN
R&D_NN
costs_NN
and_PHC
others_NN
rate_NN
swaps_NN
assets_NN
assets_NN
options_NOMZ
ment_NOMZ
Total_JJ
$_$
000s_CD
$_$
000s_CD
$_$
000s_CD
$_$
000s_CD
$_$
000s_CD
$_$
000s_CD
$_$
000s_CD
$_$
000s_CD
$_$
000s_CD
At_PIN
1_CD
January_NN
2004129482_CD
91_CD
50_CD
1,284_CD
532_CD
Charge_NN
to_PIN
income_NN
28_CD
1,620_CD
91_CD
6_CD
300_CD
1,312_CD
61_CD
Exchange_NN
differences_NN
14_CD
6_CD
20_CD
At_PIN
1_CD
January_NN
2005_CD
171_CD
2,102_CD
44_CD
1,578_CD
1,312_CD
573_CD
Charge_NN
credit_NN
to_PIN
income_NN
128_CD
213_CD
1917287214_CD
410_CD
254_CD
Charge_NN
credit_NN
to_PIN
equity_NOMZ
960_CD
960_CD
Acquisition_NOMZ
of_PIN
subsidiary_NN
357651294_CD
Exchange_NN
differences_NN
43_CD
29_CD
69_CD
3_CD
As_IN
31_CD
December_NN
2005314270_CD
1,889_CD
19_CD
27_CD
2,447_CD
1,174_CD
902_CD
344_CD
Certain_NN
deferred_VBN
tax_NN
assets_NN
and_PHC
liabilities_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
offset_VBN
._.
The_DT
following_GER
is_VPRT [BEMA]
the_DT
analysis_NN
of_PIN
the_DT
deferred_JJ
tax_NN
balances_NN
after_IN
offset_VBN
for_PIN
financial_JJ
reporting_GER
purposes_NN
:_:
2005_CD
2004_CD
$_$
$_$
Deferred_JJ
tax_NN
liabilities_NOMZ
1,162_CD
744_CD
Deferred_JJ
tax_NN
assets_NN
1,506_CD
171344573_CD
A_DT
deferred_JJ
tax_NN
asset_NN
on_PIN
unused_JJ
tax_NN
losses_NN
totalling_VBG [WZPRES]
$_$
226,000_CD
has_VPRT [PEAS]
not_XX0
been_VBN [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
year_NN
due_JJ
to_PIN
the_DT
unpredictability_NOMZ
of_PIN
future_JJ
profit_NN
streams_NN
._.
These_DEMO
losses_NN
may_POMD
be_VB [PASS]
carried_VBN
forward_RB
indefinitely_RB
._.
In_CONJ
addition_NULL
there_EX
is_VPRT
a_DT
deferred_JJ
tax_NN
asset_NN
of_PIN
approximately_RB
$_$
310,000_CD
on_PIN
other_JJ
deductible_JJ
temporary_JJ
differences_NN
which_WDT [WHSUB]
has_VPRT [PEAS]
not_XX0
been_VBN [PASS]
recognized_VBN [PRIV]
due_JJ
to_PIN
uncertainty_NN
regarding_VBG [WZPRES]
the_DT
tax_NN
treatment_NOMZ
of_PIN
the_DT
profits_NN
against_PIN
which_WDT [PIRE]
these_DEMO
differences_NN
will_PRMD
reverse_VB
._.
66_CD
Hikma_NN
Pharmaceuticals_NN
PLC_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
continued_VBD
18_CD
._.
Available_JJ
for_PIN
sale_NN
investments_NOMZ
The_DT
investment_NOMZ
in_PIN
available_JJ
for_PIN
sale_NN
securities_NOMZ
represents_VPRT
investments_NOMZ
in_PIN
listed_VBN
equity_NOMZ
securities_NOMZ
and_CC
unlisted_JJ
securities_NOMZ
that_TSUB
are_VPRT [PASS]
recorded_VBN
at_PIN
the_DT
fair_JJ
value_NN
based_VBN [WZPAST]
on_PIN
either_DT
quoted_VBN
market_NN
price_NN
for_PIN
listed_VBN
companies_NN
or_CC
using_VBG
other_JJ
valuation_NOMZ
methods_NN
for_PIN
unlisted_JJ
companies_NN
._.
As_IN
at_PIN
31_CD
December_NN
2005_CD
2004_CD
$_$
000s_CD
$_$
000s_CD
Listed_VBN
companies_NN
1,185_CD
171_CD
Non-listed_JJ
companies_NN
254_CD
254_CD
1,439_CD
425_CD
Included_VBN
in_PIN
this_DEMO
amount_NN
is_VPRT [BEMA]
an_DT
investment_NOMZ
in_PIN
a_DT
non-listed_JJ
US_FPP1
company_NN
MENA_NN
Innovative_JJ
Technologies_NN
Inc._NN
of_PIN
$_$
141,000_CD
2004_CD
:_:
$_$
141,000_CD
that_DEMP
represents_VPRT
32.5_CD
%_NN
of_PIN
its_PIT
common_JJ
share_NN
for_PIN
which_WDT [PIRE]
the_DT
management_NOMZ
does_VPRT
not_XX0
exert_VB
significant_JJ
influence_NN
as_IN
it_PIT
has_VPRT
no_SYNE
representation_NOMZ
on_PIN
the_DT
Board_NN
of_PIN
Directors_NN
of_PIN
the_DT
company_NN
._.
Financial_NN
and_CC
other_JJ
non-current_JJ
assets_NN
As_IN
at_PIN
31_CD
December_NN
2005_CD
2004_CD
$_$
000s_CD
$_$
000s_CD
Investments_NOMZ
recorded_VBN [WZPAST]
at_PIN
cost_NN
488_CD
488_CD
Amounts_NN
due_JJ
from_PIN
investments_NOMZ
recorded_VBN [WZPAST]
at_PIN
cost_NN
511_CD
554_CD
Other_JJ
financial_JJ
assets_NN
277_CD
147_CD
1,276_CD
1,189_CD
Investments_NOMZ
at_PIN
cost_NN
represent_VPRT
the_DT
Groups_NN
share_NN
of_PIN
32_CD
%_NN
2004_CD
:_:
32_CD
%_NN
and_CC
49_CD
%_NN
2004_CD
:_:
49_CD
%_NN
in_PIN
Societe_NN
Hikma_NN
Pharma_NN
Tunisia_NN
and_PHC
Societe_NN
DIndustries_NN
Pharmaceutiques_NN
Ibn_NN
Al_NN
Baytar_NN
S._NN
A._NN
Tunisia_NN
,_,
over_IN
which_WDT
the_DT
Company_NN
does_VPRT
not_XX0
exert_VB
significant_JJ
influence_NN
due_JJ
to_PIN
a_DT
number_NN
of_PIN
factors_NN
including_VBG [WZPRES]
its_PIT
limited_JJ
representation_NOMZ
on_PIN
the_DT
Board_NN
of_PIN
Directors_NN
of_PIN
these_DEMO
companies_NN
._.
On_PIN
17_CD
March_NN
2005_CD
the_DT
Group_NN
signed_VBD
an_DT
agreement_NOMZ
with_PIN
Societe_NN
DIndustries_NN
Pharmaceutiques_NN
Ibn_NN
Al_NN
Baytar_NN
S._NN
A._NN
Tunisia_NN
,_,
to_TO
sell_VB
the_DT
Groups_NN
share_NN
in_PIN
Societe_NN
Hikma_NN
Ibn_NN
Al_NN
Baytar_NN
Limited_NN
Tunisia_NN
for_PIN
a_DT
total_JJ
value_NN
equivalent_NN
to_PIN
Tunisian_NN
Dinar_NN
400,000_CD
$_$
333,000_CD
to_TO
be_VB [PASS]
paid_VBN
in_PIN
four_CD
instalments_NOMZ
within_PIN
nine_CD
months_NN
from_PIN
17_CD
March_NN
2005_CD
._.
In_PIN
the_DT
year_NN
to_PIN
31_CD
December_NN
2005_CD
the_DT
Group_NN
has_VPRT [PEAS]
received_VBN
three_CD
instalments_NOMZ
totalling_VBG [WZPRES]
$_$
241,000_CD
,_,
which_WDT [SERE]
have_VPRT [PEAS]
been_VBN [PASS]
recognized_VBN [PRIV]
as_IN
other_JJ
income_NN
in_PIN
the_DT
income_NN
statement_NOMZ
as_IN
the_DT
net_JJ
book_NN
value_NN
of_PIN
the_DT
investment_NOMZ
amounted_VBD
to_PIN
one_CD
US_FPP1
Dollar_NN
._.
Amounts_NN
due_RB
from_PIN
investments_NOMZ
recorded_VBN [WZPAST]
at_PIN
cost_NN
include_VPRT
$_$
162,000_CD
2004_CD
:_:
$_$
162,000_CD
,_,
and_ANDC
$_$
459,000_CD
2004_CD
:_:
$_$
554,000_CD
due_JJ
from_PIN
Societe_NN
Hikma_NN
Pharma_NN
Tunisia_NN
and_PHC
Societe_NN
DIndustries_NN
Pharmaceutiques_NN
Ibn_NN
Al_NN
Baytar_NN
S._NN
A._NN
Tunisia_NN
,_,
respectively_RB
._.
While_OSUB
the_DT
remaining_VBG
amount_NN
of_PIN
$_$
188,000_CD
2004_CD
:_:
$_$
514,000_CD
represents_VPRT
the_DT
amount_NN
due_JJ
form_NN
Societe_NN
Hikma_NN
Ibn_NN
Al_NN
Baytar_NN
Limited_NN
Tunisia_NN
,_,
which_WDT [SERE]
was_VBD [PASS]
sold_VBN
to_PIN
Societe_NN
DIndustries_NN
Pharmaceutiques_NN
Ibn_NN
Al_NN
Baytar_NN
S._NN
A._NN
Tunisia_NN
as_IN
mentioned_VBN [PUBV]
above_PLACE
._.
The_DT
amounts_NN
due_RB
from_PIN
Societe_NN
Hikma_NN
Pharma_NN
Tunisia_NN
and_PHC
Societe_NN
Hikma_NN
Ibn_NN
Al_NN
Baytar_NN
Limited_NN
Tunisia_NN
are_VPRT [PASS]
stated_VBN [PUBV]
after_IN
provision_NN
for_PIN
doubtful_JJ
debts_NN
of_PIN
$_$
298,000_CD
2004_CD
:_:
$_$
676,000_CD
._.
Inventories_NN
As_IN
at_PIN
31_CD
December_NN
2005_CD
2004_CD
$_$
000s_CD
$_$
000s_CD
Finished_VBN
goods_NN
14,868_CD
14,777_CD
Work-in-progress_JJ
13,150_CD
7,890_CD
Raw_NN
and_CC
packing_VBG
materials_NN
24,247_CD
17,791_CD
Goods_NN
in_PIN
transit_NN
5,752_CD
3,907_CD
58,017_CD
44,365_CD
Goods_NN
in_PIN
transit_NN
include_VPRT
inventory_NN
held_VBN [PRIV] [WZPAST]
at_PIN
third_JJ
parties_NN
whilst_OSUB
in_PIN
transit_NN
between_PIN
Group_NN
companies_NN
._.
Trade_NN
and_CC
other_JJ
receivables_NN
As_IN
at_PIN
31_CD
December_NN
2005_CD
2004_CD
$_$
000s_CD
$_$
000s_CD
Trade_NN
receivables_NN
77,441_CD
60,151_CD
Other_JJ
prepayments_NOMZ
5,389_CD
1,762_CD
Interest_NN
receivable_NN
217_CD
30_CD
Employee_NN
advances_NN
68_CD
29_CD
Value_NN
added_VBD [PUBV]
tax_NN
recoverable_JJ
3,889_CD
1,733_CD
Other_JJ
receivables_NN
462_CD
27_CD
87,466_CD
63,732_CD
Trade_NN
receivables_NN
are_VPRT [PASS]
stated_VBN [PUBV]
net_NN
of_PIN
provisions_NN
for_PIN
chargebacks_NN
in_PIN
the_DT
US_FPP1
,_,
doubtful_JJ
debts_NN
and_CC
expired_VBD
goods_NN
as_IN
follows_VPRT
:_:
As_IN
at_PIN
31_CD
December_NN
2005_CD
2004_CD
$_$
000s_CD
$_$
000s_CD
Charge_NN
backs_NN
15,828_CD
18,125_CD
Doubtful_JJ
debts_NN
4,408_CD
3,432_CD
Expired_VBN
goods_NN
1,693_CD
1,216_CD
21,929_CD
22,773_CD
22_CD
._.
Collateralised_NN
cash_NN
Collateralised_NN
cash_NN
represents_VPRT
an_DT
amount_NN
equal_JJ
to_PIN
105_CD
%_NN
of_PIN
bank_NN
facilities_NOMZ
granted_VBN [SUAV] [WZPAST]
to_PIN
the_DT
Groups_NN
Algerian_NN
operations_NOMZ
._.
Cash_NN
and_PHC
cash_NN
equivalents_NN
As_IN
at_PIN
31_CD
December_NN
2005_CD
2004_CD
$_$
000s_CD
$_$
000s_CD
Cash_NN
on_PIN
hand_NN
and_CC
at_PIN
banks_NN
33,405_CD
13,864_CD
Time_NN
deposits_NN
1,194_CD
2,562_CD
Money_NN
market_NN
deposits_NN
101,025_CD
24,980_CD
Restricted_VBN
cash_NN
335_CD
9_CD
135,959_CD
41,415_CD
Cash_NN
and_PHC
cash_NN
equivalents_NN
include_VPRT
highly_AMP
liquid_JJ
investments_NOMZ
with_PIN
maturities_NOMZ
of_PIN
three_CD
months_NN
or_CC
less_JJ
._.
Bank_NN
overdrafts_NN
and_PHC
loans_NN
As_IN
at_PIN
31_CD
December_NN
2005_CD
2004_CD
$_$
000s_CD
$_$
000s_CD
Overdrafts_NN
866_CD
13,283_CD
Import_NN
and_PHC
export_NN
financing_GER
5,208_CD
13,013_CD
Short-term_JJ
loans_NN
7,267_CD
103_CD
Current_JJ
portion_NOMZ
of_PIN
long-term_JJ
loans_NN
Note_VPRT [PRIV]
27_CD
7,805_CD
8,619_CD
Fair_NN
value_NN
of_PIN
derivative_JJ
financial_JJ
instruments_NOMZ
90_CD
21,146_CD
35,108_CD
68_CD
Hikma_NN
Pharmaceuticals_NN
PLC_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
continued_VBD
24_CD
._.
Bank_NN
overdrafts_NN
and_PHC
loans_NN
continued_VBD
2005_CD
2004_CD
%_NN
%_NN
The_DT
weighted_JJ
average_JJ
interest_NN
rates_NN
paid_VBN [WZPAST]
were_VBD
as_IN
follows_VPRT
:_:
Bank_NN
overdrafts_NN
4.16_CD
3.30_CD
Bank_NN
loans_NN
including_VBG [WZPRES]
the_DT
non-current_JJ
bank_NN
loans_NN
5.14_CD
4.89_CD
Import_NN
and_PHC
export_NN
financing_GER
represent_VPRT
short-term_JJ
financing_GER
for_PIN
the_DT
ordinary_JJ
trading_GER
activities_NOMZ
of_PIN
the_DT
business_NOMZ
._.
Trade_NN
and_CC
other_JJ
payables_NN
As_IN
at_PIN
31_CD
December_NN
2005_CD
2004_CD
$_$
000s_CD
$_$
000s_CD
Trade_NN
payables_NN
26,738_CD
16,612_CD
Accrued_VBN
expenses_NN
16,537_CD
10,332_CD
Employees_NN
provident_JJ
fund_NN
2,301_CD
1,563_CD
VAT_NN
and_PHC
sales_NN
tax_NN
payables_NN
1,425_CD
854_CD
Dividends_NN
payable_JJ
841_CD
93_CD
Social_NN
security_NOMZ
withholdings_GER
416_CD
118_CD
Income_NN
tax_NN
withholdings_GER
378_CD
182_CD
Other_JJ
payables_NN
213_CD
58_CD
48,849_CD
29,812_CD
The_DT
employees_NN
provident_JJ
fund_NN
liability_NOMZ
represents_VPRT
outstanding_JJ
contributions_NOMZ
to_PIN
the_DT
Hikma_NN
Pharmaceuticals_NN
Limited_NN
Jordan_NN
retirement_NOMZ
benefit_NN
plan_NN
on_PIN
which_WDT [PIRE]
the_DT
fund_NN
receive_VB
5_CD
%_NN
interest_NN
._.
Other_JJ
provisions_NN
Other_JJ
provisions_NN
represent_VPRT
the_DT
end_NN
of_PIN
service_NN
indemnity_NOMZ
provisions_NN
of_PIN
Hikma_NN
Pharmaceuticals_NN
Limited_NN
Jordan_NN
,_,
Istituto_NN
Biochimico_NN
Pavese_NN
Pharma_NN
S._NN
P._NN
A_NN
Italy_NN
,_,
and_ANDC
Pharma_NN
Ixir_NN
Co._NN
._.
Ltd_NN
Sudan_NN
._.
This_DEMO
provision_NN
represents_VPRT
a_DT
one_CD
month_NN
salary_NN
payable_JJ
for_PIN
each_QUAN
year_NN
employed_VBN [WZPAST]
for_PIN
certain_JJ
individuals_NN
in_PIN
accordance_NN
with_PIN
the_DT
agreements_NOMZ
for_PIN
the_DT
Group_NN
employees_NN
for_PIN
Hikma_NN
Pharmaceuticals_NN
Limited_NN
Jordan_NN
and_PHC
Pharma_NN
Ixir_NN
Co_NN
,_,
Ltd._NN
._.
Regarding_VBG
IBPP_NN
,_,
the_DT
staff_NN
leaving_VBG [WZPRES]
indemnity_NOMZ
is_VPRT [PASS]
not_XX0
funded_VBN
,_,
and_ANDC
all_QUAN
calculations_NOMZ
necessary_JJ
to_TO
determine_VB [SUAV] [PRIV] [THATD]
the_DT
annual_JJ
expense_NN
are_VPRT [PASS]
determined_VBN [SUAV] [PRIV]
in_PIN
accordance_NN
with_PIN
Italian_JJ
law_NN
._.
The_DT
annual_JJ
accrual_NN
for_PIN
staff_NN
indemnity_NOMZ
is_VPRT [BYPA]
calculated_VBN [PRIV]
by_PIN
dividing_VBG
the_DT
employees_NN
remuneration_NOMZ
for_PIN
the_DT
year_NN
by_PIN
13.5_CD
and_CC
it_PIT
is_VPRT [BEMA]
subject_PRED
to_PIN
revaluation_NOMZ
on_PIN
a_DT
yearly_JJ
basis_NN
._.
Movements_NOMZ
on_PIN
the_DT
provision_NN
of_PIN
end_NN
of_PIN
service_NN
indemnity_NOMZ
:_:
2005_CD
$_$
000s_CD
1_CD
January_NN
829_CD
Addition_NOMZ
733_CD
Utilisation_NOMZ
300_CD
Translation_NOMZ
adjustments_NOMZ
29_CD
31_CD
December_NN
1,233_CD
As_IN
at_PIN
31_CD
December_NN
2005_CD
,_,
the_DT
balance_NN
of_PIN
IBPPs_NN
provision_NN
for_PIN
end_NN
of_PIN
service_NN
indemnity_NOMZ
was_VBD
$_$
327,000_CD
._.
Long-term_JJ
financial_JJ
debts_NN
As_IN
at_PIN
31_CD
December_NN
2005_CD
2004_CD
$_$
000s_CD
$_$
000s_CD
Total_JJ
debts_NN
38,596_CD
32,910_CD
Less_RB
:_:
current_JJ
portion_NOMZ
of_PIN
debts_NN
7,805_CD
8,619_CD
Long-term_JJ
financial_JJ
debts_NN
30,791_CD
24,291_CD
As_IN
at_PIN
31_CD
December_NN
2005_CD
2004_CD
$_$
000s_CD
$_$
000s_CD
Breakdown_VBN
by_PIN
maturity_NOMZ
:_:
Under_IN
one_CD
year_NN
7,805_CD
8,619_CD
In_PIN
the_DT
second_JJ
year_NN
8,737_CD
7,901_CD
In_PIN
third_JJ
year_NN
8,357_CD
5,683_CD
In_PIN
the_DT
fourth_JJ
year_NN
7,532_CD
4,634_CD
In_PIN
the_DT
fifth_JJ
year_NN
4,065_CD
3,302_CD
Thereafter_RB
2,100_CD
2,771_CD
38,596_CD
32,910_CD
Breakdown_NN
by_PIN
currency_NN
:_:
US_FPP1
Dollar_NN
22,302_CD
19,846_CD
Euro_NN
6,184_CD
6,255_CD
Jordanian_NN
Dinar_NN
9,989_CD
6,446_CD
Algerian_NN
Dinar_NN
121_CD
363_CD
Long-term_JJ
financial_JJ
debts_NN
38,596_CD
32,910_CD
At_PIN
31_CD
December_NN
2005_CD
,_,
import_NN
and_PHC
export_NN
financing_GER
,_,
short-term_JJ
loans_NN
and_CC
the_DT
current_JJ
and_PHC
long-term_JJ
portion_NOMZ
of_PIN
long-term_JJ
loans_NN
total_VPRT
$_$
51,071,000_CD
2004_CD
:_:
$_$
46,026,000_CD
._.
At_PIN
31_CD
December_NN
2005_CD
,_,
loans_NN
and_PHC
import_NN
and_PHC
export_NN
financing_GER
of_PIN
$_$
36,344,000_CD
2004_CD
:_:
$_$
22,985,000_CD
,_,
were_VBD [PASS]
arranged_VBN [SUAV]
at_PIN
fixed_JJ
interest_NN
rates_NN
._.
The_DT
other_JJ
borrowings_GER
at_PIN
31_CD
December_NN
2005_CD
of_PIN
$_$
14,727,000_CD
2004_CD
:_:
$_$
23,041,000_CD
are_VPRT [PASS]
arranged_VBN [SUAV]
at_PIN
floating_VBG
rates_NN
,_,
thus_CONJ
exposing_VBG
the_DT
Group_NN
to_PIN
cash_NN
flow_NN
interest_NN
rate_NN
risk_NN
._.
Loans_NN
amounting_VBG [WZPRES]
to_TO
$_$
9,993,000_CD
2004_CD
:_:
$_$
13,475,000_CD
are_VPRT [PASS]
secured_VBN
on_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
._.
Obligations_NOMZ
under_IN
finance_NN
leases_NN
Present_JJ
value_NN
of_PIN
Minimum_NN
lease_NN
payments_NOMZ
minimum_JJ
lease_NN
payments_NOMZ
2005200420052004_CD
$_$
000s_CD
$_$
000s_CD
$_$
000s_CD
$_$
000s_CD
Amounts_NN
payable_JJ
under_IN
finance_NN
leases_NN
:_:
Within_PIN
one_CD
year_NN
838_CD
1,297_CD
797_CD
1,165_CD
In_PIN
the_DT
second_JJ
to_PIN
fifth_JJ
years_NN
inclusive_JJ
1,441_CD
2,595_CD
1,411_CD
2,448_CD
2,279_CD
3,892_CD
2,208_CD
3,613_CD
Less_RB
:_:
interest_NN
lease_NN
charges_NN
71_CD
279_CD
Present_JJ
value_NN
of_PIN
minimum_JJ
lease_NN
payments_NOMZ
payable_JJ
2,208_CD
3,613_CD
2,208_CD
3,613_CD
Its_PIT
the_DT
Groups_NN
policy_NN
to_TO
lease_VB
certain_JJ
of_PIN
its_PIT
fixtures_NN
and_PHC
equipment_NOMZ
under_IN
finance_NN
leases_NN
._.
The_DT
average_JJ
lease_NN
term_NN
is_VPRT [BEMA]
two_CD
years_NN
2004_CD
:_:
two_CD
years_NN
._.
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2005_CD
,_,
the_DT
average_JJ
effective_JJ
borrowings_GER
rate_NN
was_VBD [BEMA]
between_PIN
5.4_CD
%_NN
and_CC
6_CD
%_NN
2004_CD
:_:
between_PIN
4.8_CD
%_NN
and_CC
5.95_CD
%_NN
._.
All_QUAN
leases_NN
are_VPRT [BEMA]
on_PIN
fixed_VBN
repayment_NOMZ
basis_NN
and_CC
no_SYNE
arrangement_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
entered_VBN
into_PIN
for_PIN
contingent_JJ
rental_JJ
payment_NOMZ
._.
70_CD
Hikma_NN
Pharmaceuticals_NN
PLC_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
continued_VBD
29_CD
._.
Financial_JJ
policies_NN
for_PIN
risk_NN
management_NOMZ
and_CC
their_TPP3
objectives_NN
Credit_NN
risk_NN
The_DT
Groups_NN
principal_JJ
financial_JJ
assets_NN
are_VPRT
bank_NN
balances_NN
and_PHC
cash_NN
,_,
trade_NN
and_CC
other_JJ
receivables_NN
,_,
finance_NN
lease_NN
receivables_NN
and_PHC
investments_NOMZ
._.
The_DT
Groups_NN
credit_NN
risk_NN
is_VPRT [BEMA]
primarily_RB
attributable_PRED
to_PIN
its_PIT
trade_NN
and_PHC
finance_NN
lease_NN
receivables_NN
._.
The_DT
amounts_NN
presented_VBN [WZPAST]
in_PIN
the_DT
balance_NN
sheet_NN
are_VPRT
net_NN
of_PIN
allowances_NN
for_PIN
doubtful_JJ
receivables_NN
._.
An_DT
allowance_NN
for_PIN
impairment_NOMZ
is_VPRT [PASS]
made_VBN
where_RB
there_EX
is_VPRT
an_DT
identified_VBN
loss_NN
event_NN
which_WDT [WHOBJ]
,_,
based_VBN [PASTP]
on_PIN
previous_JJ
experience_NN
,_,
is_VPRT
evidence_NN
of_PIN
a_DT
reduction_NOMZ
in_PIN
the_DT
recoverability_NOMZ
of_PIN
the_DT
cash_NN
flows_VPRT
._.
The_DT
credit_NN
risk_NN
on_PIN
liquid_JJ
funds_NN
and_CC
derivative_JJ
financial_JJ
instruments_NOMZ
is_VPRT [PASS]
limited_VBN
because_CAUS
the_DT
counterparties_NN
are_VPRT
banks_NN
with_PIN
high_JJ
credit-ratings_GER
assigned_VBN [WZPAST]
by_PIN
international_JJ
credit-rating_NN
agencies_NN
._.
The_DT
Group_NN
has_VPRT
no_SYNE
significant_JJ
concentration_NOMZ
of_PIN
credit_NN
risk_NN
,_,
with_PIN
exposure_NN
spread_NN
over_IN
a_DT
large_JJ
number_NN
of_PIN
counterparties_NN
and_PHC
customers_NN
._.
Market_NN
risk_NN
The_DT
Group_NN
is_VPRT [PASS]
exposed_VBN
to_PIN
foreign_JJ
exchange_NN
and_PHC
interest_NN
rates_NN
risk_NN
._.
Management_NOMZ
actively_RB
monitors_VPRT
these_DEMO
exposures_NN
to_TO
manage_VB
the_DT
volatility_NOMZ
relating_VBG [WZPRES]
to_PIN
these_DEMO
exposures_NN
by_PIN
entering_VBG
into_PIN
a_DT
variety_NN
of_PIN
derivatives_NN
financial_JJ
instruments_NOMZ
._.
The_DT
Groups_NN
objective_NN
is_VPRT
to_TO
reduce_VB
,_,
where_RB
it_PIT
is_VPRT [PASS]
deemed_VBN [PRIV]
appropriate_JJ
to_TO
do_VB
so_RB
,_,
fluctuations_NOMZ
in_PIN
earnings_GER
and_PHC
cash_NN
flow_NN
associated_VBN [WZPAST]
with_PIN
changes_NN
in_PIN
interest_NN
rates_NN
and_CC
foreign_JJ
currency_NN
rates_NN
._.
It_PIT
is_VPRT [BEMA]
the_DT
Group_NN
policy_NN
and_PHC
practice_NN
to_TO
use_VB
derivative_JJ
financial_JJ
instruments_NOMZ
to_TO
manage_VB
exposures_NN
to_PIN
interest_NN
rates_NN
and_CC
foreign_JJ
currency_NN
fluctuations_NOMZ
._.
Foreign_JJ
exchange_NN
risk_NN
The_DT
Group_NN
uses_VPRT
the_DT
US_FPP1
Dollar_NN
as_IN
its_PIT
reporting_GER
currency_NN
and_CC
is_VPRT [SPAU] [PASS]
therefore_CONJ
exposed_VBN
to_PIN
foreign_JJ
exchange_NN
movements_NOMZ
primarily_RB
in_PIN
European_JJ
,_,
Algerian_NN
and_CC
Japanese_JJ
currencies_NN
._.
Consequently_CONJ
it_PIT
enters_VPRT
into_PIN
various_JJ
contracts_NN
,_,
which_WDT [SERE]
change_VPRT
in_PIN
value_NN
as_IN
foreign_JJ
exchange_NN
rates_NN
change_VPRT
to_TO
hedge_VB
against_PIN
the_DT
risk_NN
of_PIN
movement_NOMZ
in_PIN
foreign_JJ
denominated_VBN
assets_NN
and_PHC
liabilities_NOMZ
._.
Interest_NN
rate_NN
risk_NN
The_DT
Group_NN
manages_VPRT
its_PIT
exposures_NN
to_PIN
interest_NN
rate_NN
risks_NN
by_PIN
changing_VBG
the_DT
proportion_NOMZ
of_PIN
fixed_JJ
rate_NN
debt_NN
and_CC
variable_JJ
rate_NN
debt_NN
in_PIN
its_PIT
total_JJ
debt_NN
portfolio_NN
._.
To_TO
manage_VB
this_DEMO
mix_NN
,_,
the_DT
Group_NN
may_POMD
enter_VB
into_PIN
interest_NN
rates_NN
swap_VPRT
agreements_NOMZ
,_,
in_PIN
which_WDT [PIRE]
it_PIT
exchanges_NN
the_DT
periodic_JJ
payments_NOMZ
based_VBN [WZPAST]
on_PIN
notional_JJ
amounts_NN
and_CC
agreed_VBD [SUAV] [PUBV]
upon_PIN
fixed_VBN
and_CC
variable_JJ
interest_NN
rates_NN
._.
Using_VBG [PRESP]
the_DT
above-mentioned_JJ
derivative_JJ
financial_JJ
instruments_NOMZ
has_VPRT [PEAS]
not_XX0
had_VBD
a_DT
material_NN
impact_NN
on_PIN
the_DT
Groups_NN
financial_JJ
position_NOMZ
at_PIN
31_CD
December_NN
2005_CD
or_CC
the_DT
Groups_NN
results_NN
of_PIN
operations_NOMZ
for_PIN
the_DT
year_NN
then_RB
ended_VBD
._.
Fair_NN
value_NN
of_PIN
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
:_:
The_DT
fair_JJ
value_NN
of_PIN
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
are_VPRT [PASS]
included_VBN
at_PIN
the_DT
amount_NN
at_PIN
which_WDT [PIRE]
the_DT
instrument_NOMZ
could_POMD
be_VB [PASS]
exchanged_VBN
in_PIN
a_DT
current_JJ
transaction_NOMZ
between_PIN
willing_JJ
parties_NN
,_,
other_JJ
than_PIN
in_PIN
a_DT
forced_VBN
or_CC
liquidation_NOMZ
sale_NN
._.
The_DT
following_VBG
methods_NN
and_PHC
assumptions_NOMZ
were_VBD [PASS]
used_VBN
to_TO
estimate_VB [PRIV]
the_DT
fair_JJ
value_NN
:_:
Cash_NN
and_PHC
cash_NN
equivalents_NN
approximates_VPRT
to_PIN
the_DT
carrying_VBG
amount_NN
._.
Short-term_JJ
loans_NN
and_PHC
overdrafts_NN
approximates_VPRT
to_PIN
the_DT
carrying_VBG
amount_NN
because_CAUS
of_PIN
the_DT
short_JJ
maturity_NOMZ
of_PIN
these_DEMO
instruments_NOMZ
._.
Long-term_JJ
loans_NN
approximates_VPRT
to_PIN
the_DT
carrying_VBG
amount_NN
in_PIN
the_DT
case_NN
of_PIN
floating_VBG
rate_NN
bank_NN
loans_NN
and_CC
other_JJ
loans_NN
._.
Forward_RB
exchange_NN
contracts_NN
based_VBN [WZPAST]
on_PIN
market_NN
prices_NN
and_PHC
exchange_NN
rates_NN
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
Receivables_NN
and_PHC
payables_NN
approximates_VPRT
to_PIN
the_DT
carrying_VBG
amount_NN
._.
Provisions_NN
approximates_VPRT
to_PIN
the_DT
carrying_VBG
amount_NN
._.
Lease_NN
obligations_NOMZ
approximates_VPRT
to_PIN
the_DT
carrying_VBG
value_NN
._.
The_DT
fair_JJ
value_NN
of_PIN
the_DT
Groups_NN
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
do_VPRT
not_XX0
materially_RB
differ_VPRT
form_VB
their_TPP3
fair_JJ
value_NN
._.
Derivative_JJ
financial_JJ
instruments_NOMZ
Currency_NN
derivatives_NN
The_DT
Group_NN
utilises_VPRT
currency_NN
derivatives_NN
to_TO
hedge_VB
significant_JJ
future_JJ
transactions_NOMZ
and_PHC
cash_NN
flows_NN
._.
The_DT
Group_NN
is_VPRT [BEMA]
a_DT
party_NN
to_PIN
a_DT
variety_NN
of_PIN
foreign_JJ
currency_NN
forward_RB
contracts_NN
and_PHC
options_NOMZ
in_PIN
the_DT
management_NOMZ
of_PIN
its_PIT
exchange_NN
rate_NN
exposures_NN
._.
The_DT
instruments_NOMZ
purchased_VBN [WZPAST]
are_VPRT [SPAU] [PASS]
primarily_RB
denominated_VBN
in_PIN
the_DT
currencies_NN
of_PIN
the_DT
Groups_NN
principal_JJ
markets_NN
._.
At_PIN
the_DT
balance_NN
sheet_NN
date_NN
,_,
total_JJ
notional_JJ
amount_NN
of_PIN
outstanding_JJ
forward_RB
foreign_JJ
exchange_NN
contracts_NN
that_TOBJ
the_DT
Group_NN
has_VPRT [PEAS]
committed_VBN
are_VPRT
as_RB
below_PLACE
:_:
2005_CD
2004_CD
$_$
000s_CD
$_$
000s_CD
Foreign_JJ
exchange_NN
forward_RB
contracts_NN
Euro_NN
414_CD
Foreign_JJ
exchange_NN
forward_RB
contracts_NN
Yen_NN
300_CD
Foreign_JJ
exchange_NN
option_NOMZ
contracts_NN
Euro_NN
1,020_CD
These_DEMO
arrangements_NOMZ
are_VPRT [PASS]
designed_VBN
to_TO
address_VB
significant_JJ
exchange_NN
exposures_NN
._.
At_PIN
31_CD
December_NN
2005_CD
and_CC
2004_CD
,_,
the_DT
fair_JJ
value_NN
of_PIN
the_DT
Groups_NN
currency_NN
derivatives_NN
is_VPRT [PASS]
estimated_VBN [PRIV]
to_TO
be_VB
$_$
709,648_CD
and_CC
$_$
1,016,647_CD
respectively_RB
._.
The_DT
fair_JJ
valuation_NOMZ
of_PIN
the_DT
currency_NN
derivatives_NN
that_TSUB
are_VPRT [PASS]
designated_VBN
and_CC
effective_JJ
as_IN
cash_NN
flow_NN
hedge_NN
resulted_VBD
in_PIN
a_DT
loss_NN
of_PIN
$_$
4,847_CD
and_CC
a_DT
loss_NN
of_PIN
$_$
3,128_CD
for_PIN
the_DT
years_NN
ended_VBN
31_CD
December_NN
2005_CD
and_CC
2004_CD
respectively_RB
that_DEMP
has_VPRT [PEAS]
been_VBN [PASS]
deferred_VBN
in_PIN
equity_NOMZ
._.
These_DEMO
amounts_NN
are_VPRT [PASS]
based_VBN
on_PIN
market_NN
values_NN
of_PIN
equivalent_JJ
instruments_NOMZ
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
Interest_NN
rate_NN
swaps_NN
The_DT
Group_NN
uses_VPRT
interest_NN
rate_NN
swaps_NN
to_TO
manage_VB
its_PIT
exposure_NN
to_PIN
interest_NN
rate_NN
movements_NOMZ
on_PIN
its_PIT
bank_NN
borrowings_GER
._.
Contracts_NN
with_PIN
original_JJ
nominal_JJ
values_NN
of_PIN
$_$
19.5_CD
million_CD
as_IN
at_PIN
31_CD
December_NN
2004_CD
increased_VBD
to_TO
$_$
28_CD
million_CD
as_IN
at_PIN
31_CD
December_NN
2005_CD
have_VPRT [PEAS]
fixed_VBN
interest_NN
payments_NOMZ
at_PIN
rates_NN
ranging_VBG [WZPRES]
from_PIN
2.8_CD
%_NN
to_PIN
5.4_CD
%_NN
for_PIN
periods_NN
up_IN
until_IN
2012_CD
and_CC
have_VPRT
floating_VBG
interest_NN
receipts_NN
ranging_VBG [WZPRES]
from_PIN
LIBOR_NN
to_PIN
LIBOR_NN
plus_PIN
1.5_CD
%_NN
._.
The_DT
fair_JJ
value_NN
of_PIN
swaps_NN
entered_VBN [WZPAST]
into_PIN
by_PIN
the_DT
Group_NN
is_VPRT [PASS]
estimated_VBN [PRIV]
at_PIN
a_DT
favourable_JJ
value_NN
of_PIN
$_$
208,310_CD
and_CC
a_DT
favourable_JJ
value_NN
of_PIN
$_$
121,892_CD
as_IN
at_PIN
31_CD
December_NN
2005_CD
and_CC
2004_CD
respectively_RB
._.
These_DEMO
amounts_NN
are_VPRT [PASS]
based_VBN
on_PIN
market_NN
values_VPRT
provided_VBN
by_PIN
the_DT
banks_NN
that_TSUB
originated_VPRT
the_DT
swaps_NN
and_CC
are_VPRT [PASS]
based_VBN
on_PIN
equivalent_JJ
instruments_NOMZ
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
Some_QUAN
of_PIN
these_DEMO
interest_NN
rate_NN
swaps_NN
are_VPRT [PASS]
designated_VBN
as_IN
effective_JJ
cash_NN
flow_NN
hedges_NN
and_CC
the_DT
fair_JJ
value_NN
thereof_RB
has_VPRT [PEAS]
been_VBN [PASS]
deferred_VBN
in_PIN
equity_NOMZ
totalling_VBG [WZPRES]
$_$
126,333_CD
and_CC
$_$
32,386_CD
for_PIN
the_DT
years_NN
ended_VBN
31_CD
December_NN
2005_CD
and_CC
2004_CD
respectively_RB
,_,
and_ANDC
the_DT
remainder_NN
are_VPRT [PASS]
designated_VBN
as_IN
ineffective_JJ
cash_NN
flow_NN
hedges_NN
of_PIN
which_WDT [PIRE]
the_DT
change_NN
in_PIN
their_TPP3
fair_JJ
value_NN
has_VPRT [PEAS]
been_VBN [PASS]
taken_VBN
to_PIN
earnings_GER
._.
A_DT
gain_NN
of_PIN
$_$
171,483_CD
and_CC
$_$
81,328_CD
for_PIN
the_DT
years_NN
ended_VBN
31_CD
December_NN
2005_CD
and_CC
2004_CD
respectively_RB
have_VPRT [PEAS]
been_VBN [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
income_NN
statement_NOMZ
._.
Share_NN
capital_NN
2005_CD
2004_CD
$_$
000s_CD
$_$
000s_CD
Authorised_VBN
:_:
500,000,000_CD
Ordinary_NN
Shares_NN
of_PIN
10p_CD
each_QUAN
88,700_CD
88,700_CD
49,998_CD
non-voting_JJ
,_,
Redeemable_JJ
Preference_NN
Shares_NN
of_PIN
1_CD
each_QUAN
90_CD
90_CD
Issued_VBN
and_CC
fully_AMP
paid_VBN
included_VBN
in_PIN
shareholders_NN
equity_NOMZ
166,798,407_CD
Ordinary_NN
Shares_NN
of_PIN
10p_CD
each_QUAN
29,457_CD
25,269_CD
Issued_VBN
and_CC
fully_AMP
paid_VBN
included_VBN
in_PIN
liabilities_NOMZ
49,998_CD
non-voting_JJ
,_,
Redeemable_JJ
Preference_NN
Shares_NN
of_PIN
1_CD
each_QUAN
90_CD
The_DT
Company_NN
was_VBD [PASS]
incorporated_VBN
on_PIN
8_CD
September_NN
2005_CD
with_PIN
an_DT
authorised_JJ
share_NN
capital_NN
of_PIN
50,000_CD
divided_VBN
into_PIN
two_CD
Ordinary_NN
Shares_NN
of_PIN
1_CD
each_QUAN
and_CC
49,998_CD
non-voting_JJ
,_,
Redeemable_JJ
Preference_NN
Shares_NN
of_PIN
1_CD
each_QUAN
._.
The_DT
two_CD
Ordinary_NN
Shares_NN
of_PIN
1_CD
each_QUAN
were_VBD [PASS]
transferred_VBN
on_PIN
8_CD
September_NN
2005_CD
as_IN
subscriber_NN
shares_NN
at_PIN
a_DT
price_NN
of_PIN
1_CD
each_QUAN
to_PIN
the_DT
two_CD
Executive_NN
Directors_NN
,_,
and_ANDC
on_PIN
15_CD
September_NN
2005_CD
all_QUAN
the_DT
Preference_NN
Shares_NN
were_VBD [PASS]
allotted_VBN
to_PIN
the_DT
Executive_NN
Directors_NN
._.
The_DT
Company_NN
redeemed_VBD
the_DT
Preference_NN
Shares_NN
at_PIN
par_NN
on_PIN
9_CD
February_NN
2006_CD
._.
At_PIN
31_CD
December_NN
2005_CD
the_DT
Preference_NN
Shares_NN
were_VBD [PASS]
recorded_VBN
as_IN
a_DT
financial_JJ
liability_NOMZ
within_PIN
other_JJ
current_JJ
liabilities_NOMZ
._.
On_PIN
31_CD
October_NN
2005_CD
,_,
the_DT
two_CD
Ordinary_NN
Shares_NN
of_PIN
1_CD
each_QUAN
were_VBD [PASS]
subdivided_VBN
into_PIN
10_CD
Ordinary_NN
Shares_NN
of_PIN
10_CD
pence_NN
each_QUAN
and_CC
the_DT
authorised_JJ
Ordinary_NN
Share_NN
capital_NN
of_PIN
the_DT
Company_NN
was_VBD [PASS]
increased_VBN
to_PIN
50_CD
million_CD
by_PIN
the_DT
creation_NOMZ
of_PIN
an_DT
additional_JJ
499,999,980_CD
Ordinary_NN
Shares_NN
of_PIN
10_CD
pence_NN
each_QUAN
._.
72_CD
Hikma_NN
Pharmaceuticals_NN
PLC_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
continued_VBD
31_CD
._.
Share_NN
capital_NN
continued_VBD
On_PIN
31_CD
October_NN
2005_CD
,_,
the_DT
Company_NN
acquired_VBD
the_DT
entire_JJ
issued_JJ
share_NN
capital_NN
of_PIN
Hikma_NN
Pharma_NN
Limited_NN
pursuant_JJ
to_PIN
a_DT
share_NN
exchange_NN
offer_NN
,_,
following_VBG [PRESP]
which_WDT
it_PIT
became_VBD
the_DT
holding_VBG [PRIV]
company_NN
of_PIN
the_DT
Group_NN
._.
Under_IN
the_DT
terms_NN
of_PIN
the_DT
share_NN
exchange_NN
,_,
shareholders_NN
in_PIN
Hikma_NN
Pharma_NN
Limited_NN
received_VBD
four_CD
Ordinary_NN
Shares_NN
in_PIN
the_DT
Company_NN
for_PIN
every_QUAN
one_CD
share_NN
held_VBN [PRIV] [WZPAST]
in_PIN
Hikma_NN
Pharma_NN
Limited_NN
._.
Total_JJ
shares_NN
issued_VBN
and_CC
fully_AMP
paid_VBN
were_VBD [BEMA]
142,400,020_CD
Ordinary_NN
Shares_NN
of_PIN
10_CD
pence_NN
each_QUAN
._.
On_PIN
1_CD
November_NN
2005_CD
,_,
and_ANDC
as_CONJ
a_NULL
result_NULL
of_PIN
a_DT
placing_GER
,_,
24,137,931_CD
Ordinary_NN
Shares_NN
of_PIN
10_CD
pence_NN
each_QUAN
were_VBD [PASS]
issued_VBN
at_PIN
a_DT
price_NN
of_PIN
290p_JJ
per_PIN
Ordinary_NN
Share_NN
._.
On_PIN
30_CD
November_NN
2005_CD
,_,
the_DT
Company_NN
allotted_VBD
260,456_CD
Ordinary_NN
Shares_NN
at_PIN
a_DT
price_NN
of_PIN
290_CD
pence_NN
per_PIN
Ordinary_NN
Share_NN
pursuant_JJ
to_PIN
the_DT
exercise_NN
of_PIN
an_DT
over-allotment_NOMZ
option_NOMZ
._.
Share_NN
premium_NN
Share_NN
premium_NN
$_$
000s_CD
Balance_NN
at_PIN
1_CD
January_NN
2004_CD
,_,
31_CD
December_NN
2004_CD
and_CC
1_CD
January_NN
2005_CD
Premium_NN
arising_VBG [WZPRES]
on_PIN
issue_NN
of_PIN
Equity_NOMZ
Shares_NN
120,725_CD
Expenses_NN
of_PIN
issue_NN
of_PIN
Equity_NOMZ
Shares_NN
10,810_CD
Treasury_NN
Shares_NN
159_CD
Balance_NN
at_PIN
31_CD
December_NN
2005_CD
110,074_CD
33_CD
._.
Treasury_NN
shares_NN
2005_CD
2004_CD
$_$
000s_CD
$_$
000s_CD
Balance_NN
at_PIN
1_CD
January_NN
187_CD
193_CD
Sale_NN
of_PIN
Treasury_NN
Shares_NN
346_CD
4,841_CD
Purchase_NN
of_PIN
Treasury_NN
Shares_NN
4,835_CD
Transfer_NN
to_TO
share_VB
premium_JJ
159_CD
Balance_NN
at_PIN
31_CD
December_NN
187_CD
The_DT
number_NN
of_PIN
shares_NN
held_VBN [PRIV] [WZPAST]
at_PIN
31_CD
December_NN
2004_CD
was_VBD [BEMA]
91,743_CD
shares_NN
._.
Reserves_NN
Cumulative_JJ
Merger_NN
Retained_VBD
translation_NOMZ
Total_JJ
reserve_NN
earnings_GER
reserve_NN
reserve_NN
$_$
000s_CD
$_$
000s_CD
$_$
000s_CD
$_$
000s_CD
At_PIN
1_CD
January_NN
2004_CD
33,920_CD
48,043_CD
190_CD
82,153_CD
Cost_NN
of_PIN
equity_NOMZ
settled_VBN
employee_NN
share_NN
scheme_NN
145_CD
145_CD
Dividends_NN
on_PIN
Ordinary_NN
Shares_NN
3,766_CD
3,766_CD
Profit_NN
for_PIN
the_DT
year_NN
37,458_CD
37,458_CD
Cumulative_JJ
effect_NN
of_PIN
change_NN
in_PIN
fair_JJ
value_NN
of_PIN
available_JJ
for_PIN
sale_NN
investments_NOMZ
92_CD
92_CD
Cumulative_JJ
effect_NN
of_PIN
change_NN
in_PIN
fair_JJ
value_NN
of_PIN
financial_JJ
derivatives_NN
168_CD
168_CD
Currency_NN
translation_NOMZ
gain_NN
1,158_CD
1,158_CD
At_PIN
31_CD
December_NN
2004_CD
33,920_CD
82,140_CD
1,348_CD
117,408_CD
Cost_NN
of_PIN
equity_NOMZ
settled_VBN
employee_NN
share_NN
scheme_NN
712_CD
712_CD
Deferred_JJ
tax_NN
arising_VBG [WZPRES]
on_PIN
stock_NN
options_NOMZ
960_CD
960_CD
Dividends_NN
on_PIN
Ordinary_NN
Shares_NN
17,800_CD
17,800_CD
Profit_NN
for_PIN
the_DT
year_NN
43,867_CD
43,867_CD
Cumulative_JJ
effect_NN
of_PIN
change_NN
in_PIN
fair_JJ
value_NN
of_PIN
available_JJ
for_PIN
sale_NN
investments_NOMZ
980_CD
980_CD
Cumulative_JJ
effect_NN
of_PIN
change_NN
in_PIN
fair_JJ
value_NN
of_PIN
financial_JJ
derivatives_NN
164_CD
164_CD
Currency_NN
translation_NOMZ
gain_NN
1,941_CD
1,941_CD
At_PIN
31_CD
December_NN
2005_CD
33,920_CD
111,023_CD
593_CD
144,350_CD
Hikma_NN
Pharmaceuticals_NN
PLC_NN
73_CD
35_CD
._.
Minority_NOMZ
interest_NN
2005_CD
2004_CD
$_$
000s_CD
$_$
000s_CD
At_PIN
1_CD
January_NN
2,685_CD
697_CD
Minority_NOMZ
interest_NN
share_NN
of_PIN
profit_NN
1,090_CD
731_CD
Other_JJ
movements_NOMZ
including_VBG [WZPRES]
foreign_JJ
exchange_NN
174_CD
1,257_CD
At_PIN
31_CD
December_NN
3,601_CD
2,685_CD
36_CD
._.
Acquisition_NOMZ
of_PIN
subsidiary_NN
On_PIN
14_CD
March_NN
2005_CD
,_,
the_DT
Group_NN
acquired_VBD
100_CD
%_NN
of_PIN
the_DT
issued_VBN
share_NN
capital_NN
of_PIN
Istituto_NN
Biochimico_NN
Pavese_NN
Pharma_NN
S._NN
P._NN
A_NN
IBPP_NN
located_VBN [WZPAST]
in_PIN
Italy_NN
for_PIN
cash_NN
consideration_NOMZ
of_PIN
Euro_NN
500,000_CD
$_$
673,100_CD
and_CC
deferred_VBN
consideration_NOMZ
of_PIN
Euro_NN
500,000_CD
to_TO
be_VB [PASS]
paid_VBN
in_PIN
2006_CD
subject_JJ
to_PIN
certain_JJ
conditions_NOMZ
._.
The_DT
IBPP_NN
business_NOMZ
concerns_VPRT
the_DT
antiseptic_JJ
manufacturing_GER
of_PIN
injectable_JJ
products_NN
solutions_NOMZ
and_CC
lyophilized_VBN
powders_NN
in_PIN
vials_NN
and_PHC
ampoules_NN
._.
The_DT
net_JJ
assets_NN
acquired_VBN [WZPAST]
in_PIN
the_DT
transaction_NOMZ
and_CC
the_DT
goodwill_NN
arising_VBG [WZPRES]
are_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
:_:
Fair_NN
value_NN
Book_NN
value_NN
adjustment_NOMZ
Fair_NN
value_NN
$_$
000s_CD
$_$
000s_CD
$_$
000s_CD
Net_JJ
assets_NN
acquired_VBD
Product_NN
files_NN
1,222_CD
1,359_CD
2,581_CD
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
5,464_CD
1,148_CD
6,612_CD
Deferred_JJ
taxes_NN
357651294_CD
Financial_JJ
assets_NN
1_CD
1_CD
Inventory_NN
346_CD
346_CD
Other_JJ
current_JJ
assets_NN
159_CD
159_CD
Accounts_NN
receivable_NN
,_,
net_JJ
1,529_CD
106_CD
1,423_CD
Cash_NN
and_PHC
cash_NN
equivalents_NN
4_CD
4_CD
Trade_NN
accounts_NN
payable_JJ
1,207_CD
1,207_CD
Capital_NN
lease_NN
obligations_NOMZ
541_CD
541_CD
Bank_NN
overdrafts_NN
and_PHC
loans_NN
2,164_CD
2,164_CD
Provision_NN
for_PIN
end_NN
of_PIN
service_NN
indemnity_NOMZ
288_CD
288_CD
Other_JJ
current_JJ
liabilities_NOMZ
1,797_CD
1,256_CD
3,053_CD
Long-term_JJ
financial_JJ
debts_NN
1,894_CD
1,894_CD
Capital_NN
lease_NN
obligations_NOMZ
1,163_CD
1,163_CD
28494522_CD
Goodwill_NN
976_CD
Total_JJ
consideration_NOMZ
1,498_CD
Satisfied_VBN
by_PIN
:_:
Cash_NN
673_CD
Deferred_JJ
consideration_NOMZ
673_CD
Directly_RB
attributable_JJ
costs_NN
152_CD
1,498_CD
Net_JJ
cash_NN
outflow_NN
arising_VBG [WZPRES]
on_PIN
acquisition_NOMZ
Cash_NN
consideration_NOMZ
673_CD
Cash_NN
and_PHC
cash_NN
equivalents_NN
acquired_VBD
4_CD
669_CD
Directly_RB
attributable_JJ
acquisition_NOMZ
costs_NN
include_VPRT
legal_JJ
and_CC
accounting_GER
costs_NN
incurred_VBN [WZPAST]
in_PIN
the_DT
preparation_NOMZ
of_PIN
the_DT
acquisition_NOMZ
contracts_NN
and_CC
in_PIN
performing_VBG
due_JJ
diligence_NN
activities_NOMZ
._.
The_DT
Group_NN
placed_VBD
significant_JJ
emphasis_NN
on_PIN
the_DT
value_NN
of_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
in_PIN
making_VBG
the_DT
decision_NN
to_TO
acquire_VB
IBPP_NN
._.
The_DT
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
of_PIN
IBPP_NN
complement_VPRT
the_DT
Groups_NN
Injectables_NN
business_NOMZ
._.
74_CD
Hikma_NN
Pharmaceuticals_NN
PLC_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
continued_VBD
36_CD
._.
Acquisition_NOMZ
of_PIN
subsidiary_NN
continued_VBD
The_DT
losses_NN
of_PIN
IBPP_NN
from_PIN
the_DT
date_NN
of_PIN
acquisition_NOMZ
that_TSUB
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
Groups_NN
income_NN
statement_NOMZ
for_PIN
the_DT
period_NN
amounted_VBD
to_TO
$_$
526,000_CD
._.
If_COND
the_DT
acquisition_NOMZ
of_PIN
IBPP_NN
had_VBD [PEAS]
been_VBN [PASS]
completed_VBN
on_PIN
the_DT
first_JJ
day_NN
of_PIN
the_DT
financial_JJ
year_NN
,_,
Group_NN
revenues_NN
for_PIN
the_DT
year_NN
would_PRMD
have_VB [PEAS]
been_VBN
$_$
262,914,000_CD
and_CC
the_DT
Groups_NN
profit_NN
attributable_JJ
to_PIN
equity_NOMZ
holders_NN
of_PIN
the_DT
parent_NN
would_PRMD
have_VB [PEAS]
been_VBN
$_$
42,986,000_CD
._.
Net_JJ
cash_NN
from_PIN
operating_VBG
activities_NOMZ
2005_CD
2004_CD
$_$
000s_CD
$_$
000s_CD
Profit_NN
before_IN
tax_NN
and_PHC
minority_NOMZ
interest_NN
64,409_CD
59,024_CD
Adjustments_NOMZ
for_PIN
:_:
Depreciation_NOMZ
,_,
amortisation_NOMZ
and_PHC
impairment_NOMZ
of_PIN
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
8,909_CD
6,680_CD
Intangible_JJ
assets_NN
1,416_CD
Financial_JJ
assets_NN
92_CD
Results_NN
from_PIN
associated_VBN
companies_NN
1,449_CD
732_CD
Losses_NN
on_PIN
disposal_NN
of_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
440_CD
390_CD
Movement_NOMZ
on_PIN
provisions_NN
404_CD
372_CD
Deferred_JJ
income_NN
174_CD
54_CD
Cumulative_JJ
effect_NN
of_PIN
change_NN
in_PIN
fair_JJ
value_NN
of_PIN
derivatives_NN
164_CD
168_CD
Stock_NN
options_NOMZ
granted_VBD [SUAV]
713_CD
145_CD
Deferred_JJ
tax_NN
252_CD
41_CD
Interest_NN
and_PHC
bank_NN
charges_NN
5,211_CD
3,826_CD
Cash_NN
flow_NN
before_IN
working_VBG
capital_NN
79,791_CD
69,952_CD
Change_NN
in_PIN
trade_NN
and_CC
other_JJ
receivables_NN
22,311_CD
10,426_CD
Change_NN
in_PIN
due_JJ
from_PIN
associate_JJ
691_CD
1,080_CD
Change_NN
in_PIN
other_JJ
current_JJ
assets_NN
369_CD
1,700_CD
Income_NN
tax_NN
recoverable_JJ
588_CD
707_CD
Change_NN
in_PIN
inventories_NN
13,306_CD
4,563_CD
Change_NN
in_PIN
trade_NN
and_CC
other_JJ
payables_NN
16,064_CD
1,955_CD
Change_NN
in_PIN
other_JJ
current_JJ
liabilities_NOMZ
4,029_CD
6,532_CD
Cash_NN
generated_VBN [WZPAST]
by_PIN
operations_NOMZ
55,737_CD
56,025_CD
Income_NN
tax_NN
paid_VBN
17,800_CD
19,458_CD
Interest_NN
paid_VBN
5,224_CD
3,725_CD
Net_JJ
cash_NN
generated_VBD
from_PIN
operating_VBG
activities_NOMZ
32,713_CD
32,842_CD
38_CD
._.
Contingent_JJ
liabilities_NOMZ
The_DT
Group_NN
was_VBD [BEMA]
contingently_RB
liable_PRED
for_PIN
letters_NN
of_PIN
guarantee_NN
and_PHC
letters_NN
of_PIN
credit_NN
totalling_VBG [WZPRES]
$_$
11.1_CD
million_CD
and_CC
$_$
7.1_CD
million_CD
as_IN
of_PIN
31_CD
December_NN
2005_CD
and_CC
2004_CD
,_,
respectively_RB
._.
The_DT
Group_NN
guaranteed_VBN [PUBV]
47.5_CD
%_NN
of_PIN
a_DT
loan_NN
granted_VBN [SUAV] [WZPAST]
to_PIN
its_PIT
associate_JJ
Al-Jazeera_NN
Pharmaceutical_NN
Industries_NN
by_PIN
Saudi_NN
Industrial_NN
Development_NOMZ
Fund_NN
SIDF_NN
for_PIN
a_DT
total_JJ
equivalent_JJ
value_NN
of_PIN
$_$
11.2_CD
million_CD
and_CC
$_$
13.3_CD
million_CD
for_PIN
the_DT
years_NN
ended_VBN
31_CD
December_NN
2005_CD
and_CC
2004_CD
,_,
respectively_RB
._.
The_DT
integrated_JJ
nature_NN
of_PIN
the_DT
Groups_NN
worldwide_JJ
operations_NOMZ
,_,
involving_VBG
significant_JJ
investment_NOMZ
in_PIN
research_NN
and_CC
strategic_JJ
manufacture_NN
at_PIN
a_DT
limited_JJ
number_NN
of_PIN
locations_NOMZ
,_,
with_PIN
consequential_JJ
cross-border_JJ
supply_NN
routes_NN
into_PIN
numerous_JJ
end-markets_NN
,_,
gives_VPRT
rise_NN
to_PIN
complexity_NOMZ
and_PHC
delay_NN
in_PIN
negotiations_NOMZ
with_PIN
revenue_NN
authorities_NOMZ
as_IN
to_PIN
the_DT
profits_NN
on_PIN
which_WDT [PIRE]
individual_JJ
Group_NN
companies_NN
are_VPRT [BEMA]
liable_PRED
to_PIN
tax_NN
._.
Disagreements_NOMZ
with_PIN [STPR]
,_,
and_ANDC
between_PIN [STPR]
,_,
revenue_NN
authorities_NOMZ
as_IN
to_PIN
intra-Group_JJ
transactions_NOMZ
,_,
in_CONJ
particular_NULL
the_DT
price_NN
at_PIN
which_WDT [PIRE]
goods_NN
and_PHC
services_NN
should_NEMD
be_VB [PASS]
transferred_VBN
between_PIN
Group_NN
companies_NN
in_PIN
different_JJ
tax_NN
jurisdictions_NOMZ
,_,
can_POMD
produce_VB
conflicting_VBG
claims_NN
from_PIN
revenue_NN
authorities_NOMZ
as_IN
to_PIN
the_DT
profits_NN
to_TO
be_VB [PASS]
taxed_VBN
in_PIN
individual_JJ
territories_NN
._.
Resolution_NOMZ
of_PIN
such_JJ
issues_NN
is_VPRT [BEMA]
ongoing_PRED
._.
In_PIN
common_JJ
with_PIN
many_QUAN
other_JJ
companies_NN
in_PIN
the_DT
pharmaceutical_JJ
industries_NN
the_DT
Group_NN
is_VPRT [BEMA]
subject_PRED
to_PIN
certain_JJ
legal_JJ
and_CC
product_NN
liability_NOMZ
claims_NN
from_PIN
time_NN
to_PIN
time_NN
._.
Whilst_OSUB
provisions_NN
have_VPRT [PEAS]
been_VBN [PASS]
made_VBN
for_PIN
probable_JJ
losses_NN
that_DEMO
management_NOMZ
deems_VPRT [PRIV]
to_TO
be_VB [BEMA]
reasonable_PRED
or_CC
appropriate_JJ
there_EX
are_VPRT
inherent_JJ
uncertainties_NN
connected_VBN [WZPAST]
with_PIN
these_DEMO
estimates_NN
._.
The_DT
Group_NN
does_VPRT
not_XX0
expect_VB [PRIV]
the_DT
resolution_NOMZ
of_PIN
uncertainties_NN
to_TO
have_VB
a_DT
material_NN
effect_NN
on_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
._.
Hikma_NN
Pharmaceuticals_NN
PLC_NN
equity_NOMZ
settled_VBD
share_NN
option_NOMZ
scheme_NN
During_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2005_CD
,_,
the_DT
Company_NN
had_VBD
one_CD
share-based_JJ
compensation_NOMZ
scheme_NN
settled_VBN [WZPAST]
by_PIN
equity_NOMZ
instruments_NOMZ
._.
The_DT
options_NOMZ
over_IN
these_DEMO
instruments_NOMZ
are_VPRT [PASS]
settled_VBN
in_PIN
equity_NOMZ
once_TIME
exercised_VBN
._.
Details_NN
of_PIN
the_DT
grants_NN
under_IN
the_DT
scheme_NN
are_VPRT [PASS]
shown_VBN [PRIV]
below_PLACE
:_:
2005_CD
Type_NN
of_PIN
arrangement_NOMZ
General_NN
employee_NN
share_NN
option_NOMZ
plan_NN
Date_NN
of_PIN
grant_NN
13_CD
October_NN
2005_CD
Number_NN
granted_VBN [SUAV]
1,600,000_CD
Contractual_JJ
life_NN
Ten_CD
years_NN
Vesting_JJ
conditions_NOMZ
20_CD
%_NN
per_PIN
year_NN
for_PIN
five_CD
years_NN
beginning_VBG [WZPRES]
on_PIN
the_DT
first_JJ
anniversary_NN
of_PIN
the_DT
grant_NN
date_NN
The_DT
estimated_VBN [PRIV]
fair_JJ
value_NN
of_PIN
each_QUAN
share_NN
option_NOMZ
granted_VBN [SUAV] [WZPAST]
in_PIN
the_DT
general_JJ
employee_NN
share_NN
option_NOMZ
plan_NN
is_VPRT
$_$
0.74_CD
._.
This_DEMP
was_VBD [BYPA]
calculated_VBN [PRIV]
by_PIN
applying_VBG
a_DT
binomial_JJ
option_NOMZ
pricing_GER
model_NN
._.
The_DT
model_NN
inputs_NN
were_VBD [BEMA]
the_DT
share_NN
price_NN
at_PIN
grant_NN
date_NN
of_PIN
$_$
4.50_CD
,_,
exercise_NN
price_NN
of_PIN
$_$
4.50_CD
,_,
expected_VBN [PRIV]
volatility_NOMZ
of_PIN
26.2_CD
%_NN
,_,
expected_VBN [PRIV]
dividend_NN
yield_NN
of_PIN
6.67_CD
%_NN
,_,
expected_VBN [PRIV]
contractual_JJ
life_NN
of_PIN
7.5_CD
years_NN
,_,
and_ANDC
a_DT
risk-free_JJ
interest_NN
rate_NN
of_PIN
4.54_CD
%_NN
._.
To_TO
allow_VB [SUAV]
for_PIN
the_DT
effects_NN
of_PIN
early_TIME
exercise_NN
,_,
it_PIT
was_VBD [PASS]
assumed_VBN [PRIV]
that_THVC
the_DT
employees_NN
would_PRMD
exercise_VB
the_DT
options_NOMZ
immediately_TIME
after_IN
vesting_VBG
date_NN
._.
2004_CD
Type_NN
of_PIN
arrangement_NOMZ
General_NN
employee_NN
share_NN
option_NOMZ
plan_NN
Date_NN
of_PIN
grant_NN
12_CD
October_NN
2004_CD
Number_NN
granted_VBN [SUAV]
9,520,000_CD
Contractual_JJ
life_NN
Ten_CD
years_NN
Vesting_JJ
conditions_NOMZ
20_CD
%_NN
per_PIN
year_NN
for_PIN
five_CD
years_NN
beginning_VBG [WZPRES]
on_PIN
the_DT
first_JJ
anniversary_NN
of_PIN
the_DT
grant_NN
date_NN
The_DT
estimated_VBN [PRIV]
fair_JJ
value_NN
of_PIN
each_QUAN
share_NN
option_NOMZ
granted_VBN [SUAV] [WZPAST]
in_PIN
the_DT
general_JJ
employee_NN
share_NN
option_NOMZ
plan_NN
is_VPRT
$_$
0.35_CD
._.
The_DT
model_NN
inputs_NN
were_VBD [BEMA]
the_DT
share_NN
price_NN
at_PIN
grant_NN
date_NN
of_PIN
$_$
0.91_CD
,_,
exercise_NN
price_NN
of_PIN
$_$
0.91_CD
,_,
expected_VBN [PRIV]
volatility_NOMZ
of_PIN
44.8_CD
%_NN
,_,
expected_VBN [PRIV]
dividend_NN
yield_NN
of_PIN
3.85_CD
%_NN
,_,
expected_VBN [PRIV]
contractual_JJ
life_NN
of_PIN
7.5_CD
years_NN
,_,
and_ANDC
a_DT
risk-free_JJ
interest_NN
rate_NN
of_PIN
4.22_CD
%_NN
._.
To_TO
allow_VB [SUAV]
for_PIN
the_DT
effects_NN
of_PIN
early_TIME
exercise_NN
,_,
it_PIT
was_VBD [PASS]
assumed_VBN [PRIV]
that_THVC
the_DT
employees_NN
would_PRMD
exercise_VB
the_DT
options_NOMZ
after_IN
vesting_VBG
date_NN
._.
Further_JJ
details_NN
of_PIN
the_DT
general_JJ
employee_NN
share_NN
option_NOMZ
plan_NN
are_VPRT
as_IN
follows_VPRT
:_:
Weighted_JJ
average_JJ
Number_NN
of_PIN
exercise_NN
price_NN
options_NOMZ
$_$
Outstanding_JJ
at_PIN
1_CD
January_NN
2005_CD
9,520,000_CD
0.91_CD
Granted_VBN [SUAV]
during_PIN
the_DT
year_NN
1,600,000_CD
4.50_CD
Outstanding_JJ
at_PIN
31_CD
December_NN
2005_CD
11,120,000_CD
1.42_CD
Exercisable_JJ
at_PIN
31_CD
December_NN
2005_CD
1,904,000_CD
0.91_CD
A_DT
stock_NN
based_VBN
compensation_NOMZ
charge_NN
of_PIN
$_$
712,000_CD
2004_CD
:_:
$_$
145,000_CD
has_VPRT [PEAS]
been_VBN [PASS]
recorded_VBN
in_PIN
the_DT
income_NN
statement_NOMZ
as_IN
part_NN
of_PIN
general_JJ
and_PHC
administrative_JJ
costs_NN
._.
76_CD
Hikma_NN
Pharmaceuticals_NN
PLC_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
continued_VBD
40_CD
._.
Operating_VBG
lease_NN
arrangements_NOMZ
2005_CD
2004_CD
$_$
000s_CD
$_$
000s_CD
Minimum_NN
lease_NN
payments_NOMZ
under_IN
operating_VBG
leases_NN
recognized_VBN [PRIV] [WZPAST]
in_PIN
income_NN
for_PIN
the_DT
year_NN
655_CD
492_CD
At_PIN
the_DT
balance_NN
sheet_NN
date_NN
,_,
the_DT
Group_NN
had_VBD
outstanding_JJ
commitments_NOMZ
for_PIN
future_JJ
minimum_NN
lease_NN
payments_NOMZ
under_IN
non-cancellable_JJ
operating_GER
leases_NN
,_,
which_WDT [SERE]
fall_VPRT
due_JJ
as_IN
follows_VPRT
:_:
2005_CD
2004_CD
$_$
000s_CD
$_$
000s_CD
Within_PIN
one_CD
year_NN
1,421_CD
857_CD
In_PIN
the_DT
second_JJ
to_PIN
fifth_JJ
years_NN
inclusive_JJ
4,320_CD
1,689_CD
After_IN
five_CD
years_NN
4,726_CD
10,467_CD
2,546_CD
Operating_GER
lease_NN
payments_NOMZ
represent_VPRT
rentals_NN
payable_JJ
by_PIN
the_DT
Group_NN
for_PIN
certain_JJ
of_PIN
its_PIT
office_NN
properties_NN
._.
Leases_NN
are_VPRT [PASS]
negotiated_VBN
for_PIN
an_DT
average_JJ
term_NN
of_PIN
one_CD
to_PIN
7.5_CD
years_NN
._.
Related_VBN
party_NN
balances_NN
Transactions_NOMZ
between_PIN
the_DT
Company_NN
and_CC
its_PIT
subsidiaries_NN
have_VPRT [PEAS]
been_VBN [PASS]
eliminated_VBN
on_PIN
consolidation_NOMZ
and_CC
are_VPRT [PASS]
not_XX0
disclosed_VBN [PUBV]
in_PIN
this_DEMO
Note_NN
._.
Transactions_NOMZ
between_PIN
the_DT
Group_NN
and_CC
its_PIT
associate_NN
and_CC
other_JJ
related_JJ
parties_NN
are_VPRT [PASS]
disclosed_VBN [PUBV]
below_PLACE
._.
Trading_GER
transactions_NOMZ
:_:
During_PIN
the_DT
year_NN
,_,
Group_NN
companies_NN
entered_VBD
into_PIN
the_DT
following_JJ
transactions_NOMZ
with_PIN
related_JJ
parties_NN
:_:
Al-Jazeera_NN
Pharmaceuticals_NN
Industries_NN
:_:
is_VPRT [BEMA]
a_DT
related_JJ
party_NN
of_PIN
the_DT
Group_NN
because_CAUS
it_PIT
is_VPRT [PASS]
considered_VBN [PRIV]
an_DT
associate_JJ
company_NN
with_PIN
ownership_NN
percentage_NN
of_PIN
47.5_CD
%_NN
._.
Total_JJ
purchases_NN
from_PIN
Al-Jazeera_NN
Pharmaceuticals_NN
Industries_NN
during_PIN
2005_CD
amounted_VBD
to_TO
$_$
3,619,000_CD
and_CC
total_JJ
sales_NN
amounted_VBD
to_TO
$_$
1,905,000_CD
._.
Balances_NN
due_RB
from_PIN
Al-Jazeera_NN
Pharmaceuticals_NN
Industries_NN
at_PIN
the_DT
end_NN
of_PIN
2005_CD
amounted_VBD
to_TO
$_$
2,304,000_CD
._.
Management_NOMZ
fees_NN
due_JJ
to_PIN
the_DT
Group_NN
amounted_VBD
to_TO
$_$
1,016,000_CD
as_IN
at_PIN
31_CD
December_NN
2004_CD
:_:
$_$
333,000_CD
._.
Sales_NN
of_PIN
goods_NN
were_VBD [PASS]
made_VBN
at_PIN
the_DT
Groups_NN
usual_JJ
list_NN
prices_NN
and_PHC
purchases_NN
were_VBD [PASS]
made_VBN
at_PIN
market_NN
price_NN
discounted_VBN
to_TO
reflect_VB [PRIV]
the_DT
quantity_NOMZ
of_PIN
goods_NN
purchased_VBN
and_CC
the_DT
relationship_NN
between_PIN
the_DT
parties_NN
._.
Darhold_NN
Limited_NN
:_:
is_VPRT [BEMA]
a_DT
related_JJ
party_NN
of_PIN
the_DT
Group_NN
because_CAUS
it_PIT
is_VPRT [PASS]
considered_VBN [PRIV]
one_CD
of_PIN
the_DT
major_JJ
shareholders_NN
of_PIN
Hikma_NN
Pharmaceuticals_NN
PLC_NN
with_PIN
ownership_NN
percentage_NN
of_PIN
31.6_CD
%_NN
at_PIN
the_DT
end_NN
of_PIN
2005_CD
2004_CD
:_:
nil_NN
._.
During_PIN
the_DT
year_NN
2005_CD
,_,
the_DT
Group_NN
has_VPRT [PEAS]
paid_VBN
administrative_JJ
expense_NN
on_PIN
behalf_NN
of_PIN
Darhold_NN
Limited_NN
for_PIN
a_DT
total_JJ
amount_NN
of_PIN
$_$
34,000_CD
of_PIN
which_WDT [PIRE]
the_DT
balance_NN
due_JJ
to_PIN
the_DT
Group_NN
by_PIN
year_NN
end_NN
amounted_VBD
to_TO
$_$
21,000_CD
2004_CD
:_:
nil_NN
._.
Export_NN
&_CC
Finance_NN
Bank_NN
Jordan_NN
:_:
is_VPRT [BEMA]
a_DT
related_JJ
party_NN
of_PIN
the_DT
Group_NN
because_CAUS
two_CD
board_NN
members_NN
of_PIN
the_DT
Bank_NN
are_VPRT
also_RB
Board_NN
members_NN
at_PIN
Hikma_NN
Pharmaceuticals_NN
PLC_NN
total_JJ
cash_NN
balances_NN
at_PIN
Export_NN
&_CC
Finance_NN
Bank_NN
Jordan_NN
were_VBD
$_$
5,180,000_CD
2004_CD
:_:
$_$
40,774_CD
._.
Loans_NN
and_PHC
overdrafts_NN
granted_VBN [SUAV] [WZPAST]
by_PIN
Export_NN
&_CC
Finance_NN
Bank_NN
to_PIN
the_DT
Group_NN
amounted_VBD
to_TO
$_$
1,201,000_CD
2004_CD
:_:
$_$
1,028,000_CD
with_PIN
interest_NN
rates_NN
ranging_VBG [WZPRES]
between_PIN
1_CD
to_PIN
1.25_CD
%_NN
LIBOR_NN
._.
Total_JJ
interest_NN
expense_NN
incurred_VBN [WZPAST]
against_PIN
Group_NN
facilities_NOMZ
was_VBD
$_$
107,000_CD
2004_CD
:_:
$_$
102,000_CD
._.
Jordan_NN
International_NN
Insurance_NN
Co_NN
:_:
is_VPRT [BEMA]
a_DT
related_JJ
party_NN
of_PIN
the_DT
Group_NN
because_CAUS
one_CD
board_NN
member_NN
of_PIN
the_DT
company_NN
is_VPRT [BEMA]
also_RB
a_DT
Board_NN
member_NN
at_PIN
Hikma_NN
Pharmaceuticals_NN
PLC._NN
._.
Total_JJ
insurance_NN
premiums_NN
paid_VBN [WZPAST]
by_PIN
the_DT
Group_NN
to_PIN
Jordan_NN
International_NN
Insurance_NN
Co_NN
in_PIN
the_DT
year_NN
2005_CD
were_VBD
$_$
1,185,000_CD
2004_CD
:_:
$_$
834,000_CD
._.
The_DT
Groups_NN
insurance_NN
expense_NN
for_PIN
Jordan_NN
International_NN
Insurance_NN
Co_NN
contracts_NN
in_PIN
the_DT
year_NN
2005_CD
was_VBD
$_$
967,000_CD
2004_CD
:_:
$_$
928,000_CD
._.
The_DT
amounts_NN
due_JJ
to_PIN
Jordan_NN
International_NN
Insurance_NN
Co_NN
at_PIN
2005_CD
year_NN
end_NN
were_VBD
$_$
78,000_CD
2004_CD
:_:
$_$
284,000_CD
._.
Mena_NN
Innovative_JJ
Technology_NN
:_:
is_VPRT [BEMA]
a_DT
related_JJ
party_NN
of_PIN
the_DT
Group_NN
because_CAUS
the_DT
majority_NOMZ
shareholder_NN
is_VPRT
Mr._NN
Nabil_NN
Rizks_NN
wife_NN
the_DT
head_NN
of_PIN
the_DT
Generics_NN
business_NOMZ
._.
Total_JJ
purchases_NN
during_PIN
the_DT
year_NN
2005_CD
were_VBD
$_$
67,000_CD
._.
Purchases_NN
were_VBD [PASS]
made_VBN
at_PIN
market_NN
price_NN
discounted_VBN
to_TO
reflect_VB [PRIV]
the_DT
quantity_NOMZ
of_PIN
goods_NN
purchased_VBN
and_CC
the_DT
relationship_NN
between_PIN
the_DT
parties_NN
._.
The_DT
amounts_NN
due_JJ
to_PIN
Mena_NN
Innovation_NOMZ
Technology_NN
at_PIN
2005_CD
year_NN
end_NN
were_VBD
$_$
10,000_CD
2004_CD
:_:
$_$
6,000_CD
._.
Tunisian_JJ
Companies_NN
:_:
Amounts_NN
due_RB
from_PIN
Tunisian_JJ
companies_NN
include_VPRT
$_$
162,000_CD
2004_CD
:_:
$_$
162,000_CD
,_,
188,000_CD
2004_CD
:_:
$_$
514,000_CD
and_CC
$_$
459,000_CD
2004_CD
:_:
$_$
554,000_CD
due_JJ
form_NN
Societe_NN
Hikma_NN
Pharma_NN
Tunisia_NN
,_,
Societe_NN
Hikma_NN
Ibn_NN
Al_NN
Baytar_NN
Limited_NN
Tunisia_NN
and_PHC
Societe_NN
DIndustries_NN
Pharmaceutiques_NN
Ibn_NN
Al_NN
Baytar_NN
S._NN
A._NN
Tunisia_NN
,_,
respectively_RB
._.
West-ward_JJ
Pharmaceuticals_NN
USA_NN
:_:
Certain_NN
expenses_NN
of_PIN
the_DT
Chairman_NN
were_VBD [PASS]
paid_VBN
in_PIN
the_DT
USA_NN
by_PIN
West-ward_JJ
Pharmaceuticals_NN
and_CC
reimbursed_VBN
by_PIN
the_DT
Chairman_NN
._.
At_PIN
31_CD
December_NN
2005_CD
,_,
the_DT
balance_NN
outstanding_JJ
amounted_VBD
to_TO
$_$
120,000_CD
2004_CD
:_:
nil_NN
which_WDT [WHSUB]
has_VPRT [PEAS]
been_VBN [PASS]
repaid_VBN
since_OSUB
the_DT
year_NN
end_NN
._.
Related_VBN
party_NN
balances_NN
continued_VBD
Remuneration_NOMZ
of_PIN
key_JJ
management_NOMZ
personnel_NN
The_DT
remuneration_NOMZ
of_PIN
the_DT
two_CD
Executive_NN
Directors_NN
and_CC
the_DT
key_JJ
management_NOMZ
personnel_NN
of_PIN
the_DT
Group_NN
are_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
in_PIN
aggregate_NN
for_PIN
each_QUAN
of_PIN
the_DT
categories_NN
specified_VBN [WZPAST]
in_PIN
IAS_NN
24_CD
Related_NN
Party_NN
Disclosures_NN
._.
Further_JJ
information_NOMZ
about_IN
the_DT
remuneration_NOMZ
of_PIN
the_DT
individual_JJ
Directors_NN
is_VPRT [PASS]
provided_VBN
in_PIN
the_DT
audited_JJ
part_NN
of_PIN
the_DT
Board_NN
report_NN
on_PIN
remuneration_NOMZ
on_PIN
pages_NN
40_CD
to_PIN
42_CD
._.
Hikma_NN
Pharmaceuticals_NN
PLC_NN
main_JJ
subsidiaries_NN
The_DT
main_JJ
subsidiaries_NN
of_PIN
Hikma_NN
Pharmaceuticals_NN
PLC_NN
are_VPRT
as_IN
follows_VPRT
:_:
Ownership_NN
%_NN
Ownership_NN
%_NN
Ordinary_NN
Ordinary_NN
Shares_NN
Shares_NN
Companys_NN
name_NN
Established_VBN [PRIV] [WZPAST]
in_PIN
2005_CD
2004_CD
Hikma_NN
Pharmaceuticals_NN
Co._NN
._.
Jordan_NN
100_CD
100_CD
Trust_NN
Pharma_NN
Co._NN
._.
Algeria_NN
100_CD
100_CD
Hikma_NN
Farmacutica_NN
Portugal_NN
100_CD
100_CD
West-ward_JJ
Pharmaceutical_NN
Corp._NN
._.
USA_NN
100_CD
100_CD
Pharma_NN
Ixir_NN
Co._NN
._.
Sudan_NN
51_CD
51_CD
Istituto_NN
Biochimico_NN
Pavese_NN
Pharma_NN
S._NN
P._NN
A_NN
IBPP_NN
Italy_NN
100_CD
Acquired_VBN
during_PIN
the_DT
year_NN
._.
Hikma_NN
Pharmaceuticals_NN
PLC_NN
defined_VBD
contribution_NOMZ
retirement_NOMZ
benefit_NN
plan_NN
Hikma_NN
Pharmaceuticals_NN
PLC_NN
has_VPRT [PEAS]
defined_VBN
contribution_NOMZ
retirement_NOMZ
plans_NN
in_PIN
two_CD
of_PIN
its_PIT
subsidiaries_NN
:_:
West-ward_JJ
Pharmaceuticals_NN
USA_NN
and_PHC
Hikma_NN
Pharmaceuticals_NN
Jordan_NN
._.
The_DT
details_NN
of_PIN
each_QUAN
contribution_NOMZ
plan_NN
are_VPRT
as_IN
follows_VPRT
:_:
Hikma_NN
Pharmaceuticals_NN
Jordan_NN
:_:
The_NN
Group_NN
currently_RB
has_VPRT
an_DT
employee_NN
saving_VBG [WZPRES]
plan_NN
wherein_IN
the_DT
Group_NN
fully_AMP
matches_VPRT
employees_NN
contributions_NOMZ
,_,
which_WDT [SERE]
are_VPRT [PASS]
fixed_VBN
at_PIN
5_CD
%_NN
of_PIN
salary_NN
._.
Employees_NN
are_VPRT [PASS]
entitled_VBN
to_PIN
30_CD
%_NN
of_PIN
the_DT
Group_NN
contributions_NOMZ
after_IN
three_CD
years_NN
of_PIN
employment_NOMZ
with_PIN
the_DT
Group_NN
and_CC
10_CD
%_NN
for_PIN
each_QUAN
subsequent_JJ
year_NN
._.
Employees_NN
fully_AMP
vest_NN
in_PIN
the_DT
Group_NN
contributions_NOMZ
after_IN
ten_CD
years_NN
of_PIN
employment_NOMZ
._.
The_DT
Groups_NN
contributions_NOMZ
were_VBD
$_$
410,000_CD
and_CC
$_$
321,000_CD
for_PIN
the_DT
years_NN
ended_VBN
2005_CD
and_CC
2004_CD
respectively_RB
._.
West-ward_JJ
USA_NN
:_:
401_CD
k_NN
salary_NN
saving_VBG [WZPRES]
plan_NN
._.
Prior_RB
to_PIN
2001_CD
,_,
West-ward_JJ
USA_NN
established_VBD [PRIV]
a_DT
401_CD
k_NN
defined_VBN
contribution_NOMZ
plan_NN
,_,
which_WDT [SERE]
allows_VPRT [SUAV]
all_QUAN
eligible_JJ
employees_NN
to_TO
defer_VB
a_DT
portion_NOMZ
of_PIN
their_TPP3
income_NN
through_PIN
contributions_NOMZ
to_PIN
the_DT
plan_NN
._.
All_QUAN
employees_NN
not_XX0
covered_VBN
by_PIN
any_QUAN
collective_JJ
bargaining_GER
agreement_NOMZ
are_VPRT [BEMA]
eligible_PRED
after_IN
being_VBG [PASS]
employed_VBN
for_PIN
one_CD
year_NN
._.
Employees_NN
can_POMD
defer_VB
up_RP
to_PIN
25_CD
%_NN
of_PIN
their_TPP3
gross_JJ
salary_NN
into_PIN
the_DT
plan_NN
,_,
not_XX0
to_TO
exceed_VB
$_$
14,000_CD
and_CC
$_$
13,000_CD
for_PIN
2005_CD
and_CC
2004_CD
,_,
respectively_RB
,_,
not_XX0
including_VBG
catch-up_NN
contributions_NOMZ
available_JJ
to_PIN
eligible_JJ
employees_NN
as_IN
outlined_VBN
by_PIN
the_DT
Internal_NN
Revenue_NN
Service_NN
._.
The_DT
company_NN
matches_VPRT
40_CD
%_NN
of_PIN
the_DT
employees_NN
eligible_JJ
contribution_NOMZ
._.
Employer_NN
contributions_NOMZ
vest_NN
0_CD
%_NN
after_IN
one_CD
year_NN
of_PIN
service_NN
,_,
50_CD
%_NN
after_IN
two_CD
years_NN
of_PIN
service_NN
and_CC
100_CD
%_NN
after_IN
three_CD
years_NN
of_PIN
service_NN
._.
Employees_NN
are_VPRT [PASS]
considered_VBN [PRIV]
to_TO
have_VB [PEAS]
completed_VBN
one_CD
year_NN
of_PIN
service_NN
for_PIN
purposes_NN
of_PIN
vesting_VBG
upon_PIN
the_DT
completion_NOMZ
of_PIN
1,000_CD
hours_NN
of_PIN
service_NN
at_PIN
any_QUAN
time_NN
during_PIN
a_DT
plan_NN
year_NN
._.
Employer_NN
contributions_NOMZ
to_PIN
the_DT
plan_NN
as_IN
at_PIN
31_CD
December_NN
2005_CD
and_CC
2004_CD
amounted_VBD
to_TO
$_$
275,000_CD
and_CC
$_$
294,000_CD
respectively_RB
._.
The_DT
assets_NN
of_PIN
the_DT
plans_NN
are_VPRT [PASS]
held_VBN [PRIV]
separately_RB
from_PIN
those_DEMO
of_PIN
the_DT
Group_NN
._.
The_DT
only_DWNT
obligation_NOMZ
of_PIN
the_DT
Group_NN
with_PIN
respect_NN
to_PIN
the_DT
retirement_NOMZ
benefit_NN
plans_NN
is_VPRT
to_TO
make_VB
specified_VBN
contributions_NOMZ
._.
78_CD
Hikma_NN
Pharmaceuticals_NN
PLC_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
continued_VBD
44_CD
._.
Hikma_NN
Pharmaceuticals_NN
PLC_NN
Consolidated_NN
income_NN
statement_NOMZ
from_PIN
date_NN
of_PIN
incorporation_NOMZ
on_PIN
8_CD
September_NN
2005_CD
to_PIN
31_CD
December_NN
2005_CD
2005_CD
$_$
000s_CD
Net_JJ
sales_NN
90,822_CD
Cost_NN
of_PIN
sales_NN
45,600_CD
Gross_NN
profit_NN
45,222_CD
Sales_NN
and_PHC
marketing_GER
9,842_CD
General_NN
and_CC
administrative_JJ
9,182_CD
Research_NN
and_PHC
development_NOMZ
6,858_CD
Other_JJ
operating_GER
expenses_NN
,_,
net_JJ
2,867_CD
Share_NN
of_PIN
results_NN
of_PIN
associate_JJ
1,383_CD
Operating_GER
profit_NN
23,590_CD
Flotation_NOMZ
costs_NN
1,426_CD
Finance_NN
income_NN
831_CD
Finance_NN
cost_NN
1,789_CD
Other_JJ
expense_NN
1,088_CD
Profit_NN
before_IN
tax_NN
20,118_CD
Tax_NN
4,376_CD
Profit_NN
for_PIN
the_DT
period_NN
15,742_CD
Attributable_JJ
to_TO
:_:
Equity_NOMZ
holders_NN
of_PIN
the_DT
parent_NN
15,466_CD
Minority_NOMZ
interest_NN
276_CD
15,742_CD
The_DT
profit_NN
and_PHC
loss_NN
account_NN
above_PLACE
is_VPRT [BYPA]
required_VBN [SUAV]
by_PIN
the_DT
Companies_NN
Act_NN
1985_CD
and_CC
covers_VPRT
the_DT
first_JJ
statutory_JJ
accounting_GER
reference_NN
period_NN
of_PIN
Hikma_NN
Pharmaceuticals_NN
PLC_NN
from_PIN
its_PIT
date_NN
of_PIN
incorporation_NOMZ
on_PIN
8_CD
September_NN
2005_CD
to_PIN
31_CD
December_NN
2005_CD
._.
Disclosure_NN
notes_NN
for_PIN
this_DEMO
period_NN
are_VPRT [PASS]
not_XX0
presented_VBN
as_IN
the_DT
Directors_NN
do_VPRT
not_XX0
believe_VB [PRIV] [THATD]
they_TPP3
would_PRMD
provide_VB
meaningful_JJ
information_NOMZ
to_PIN
users_NN
of_PIN
the_DT
accounts_NN
._.
Directors_NN
remuneration_NOMZ
for_PIN
this_DEMO
period_NN
is_VPRT [PASS]
included_VBN
within_PIN
the_DT
amounts_NN
disclosed_VBN [PUBV] [WZPAST]
in_PIN
the_DT
Board_NN
report_NN
on_PIN
remuneration_NOMZ
on_PIN
pages_NN
37_CD
to_PIN
42_CD
which_WDT
include_VPRT
remuneration_NOMZ
for_PIN
the_DT
period_NN
from_PIN
8_CD
September_NN
or_CC
,_,
if_COND
later_TIME
,_,
date_NN
of_PIN
appointment_NOMZ
until_IN
the_DT
year_NN
end_NN
._.
Hikma_NN
Pharmaceuticals_NN
PLC_NN
continued_VBD
Consolidated_NN
cash_NN
flow_NN
statement_NOMZ
from_PIN
date_NN
of_PIN
incorporation_NOMZ
on_PIN
8_CD
September_NN
2005_CD
to_PIN
31_CD
December_NN
2005_CD
$_$
000s_CD
Net_JJ
cash_NN
from_PIN
operating_VBG
activities_NOMZ
20,847_CD
Cash_NN
flows_VPRT
from_PIN
investing_VBG
activities_NOMZ
Purchases_NN
of_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
14,747_CD
Proceeds_NN
from_PIN
disposal_NN
of_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
873_CD
Purchase_NN
of_PIN
intangible_JJ
assets_NN
89_CD
Investment_NOMZ
in_PIN
financial_JJ
and_PHC
other_JJ
assets_NN
593_CD
Investment_NOMZ
in_PIN
available_JJ
for_PIN
sale_NN
securities_NOMZ
16_CD
Acquisition_NOMZ
of_PIN
subsidiary_NN
40_CD
Net_JJ
cash_NN
used_VBN [WZPAST]
in_PIN
investing_VBG
activities_NOMZ
14,434_CD
Cash_NN
flows_VPRT
from_PIN
financing_VBG
activities_NOMZ
Increase_VPRT
in_PIN
collateralised_JJ
cash_NN
5,120_CD
Increase_VPRT
in_PIN
long-term_JJ
financial_JJ
debts_NN
5,471_CD
Repayment_NOMZ
of_PIN
long-term_JJ
financial_JJ
debts_NN
20,500_CD
Repayment_NOMZ
of_PIN
short-term_JJ
financial_JJ
debts_NN
15,041_CD
Payment_NOMZ
of_PIN
capital_NN
lease_NN
obligations_NOMZ
2,310_CD
Dividends_NN
paid_VBD
10,835_CD
Proceeds_NN
on_PIN
issue_NN
of_PIN
new_JJ
shares_NN
124,913_CD
Payments_NOMZ
on_PIN
issue_NN
of_PIN
new_JJ
shares_NN
10,810_CD
Net_JJ
cash_NN
generated_VBD
from_PIN
financing_VBG
activities_NOMZ
65,768_CD
Net_JJ
increase_NN
in_PIN
cash_NN
and_PHC
cash_NN
equivalents_NN
72,181_CD
Cash_NN
and_PHC
cash_NN
equivalents_NN
at_PIN
the_DT
beginning_GER
of_PIN
the_DT
period_NN
61,164_CD
Net_JJ
effect_NN
of_PIN
foreign_JJ
exchange_NN
rate_NN
changes_NN
2,297_CD
Cash_NN
and_PHC
cash_NN
equivalents_NN
at_PIN
period_NN
end_NN
135,642_CD
80_CD
Hikma_NN
Pharmaceuticals_NN
PLC_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
continued_VBD
44_CD
._.
Hikma_NN
Pharmaceuticals_NN
PLC_NN
continued_VBD
Consolidated_NN
cash_NN
flow_NN
statement_NOMZ
from_PIN
date_NN
of_PIN
incorporation_NOMZ
on_PIN
8_CD
September_NN
2005_CD
to_PIN
31_CD
December_NN
2005_CD
$_$
000s_CD
Profit_NN
before_IN
tax_NN
20,118_CD
Adjustments_NOMZ
for_PIN
:_:
Depreciation_NOMZ
,_,
amortisation_NOMZ
and_PHC
impairment_NOMZ
of_PIN
:_:
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
3,950_CD
Intangible_JJ
assets_NN
522_CD
Results_NN
from_PIN
associated_VBN
companies_NN
1,383_CD
Losses_NN
on_PIN
disposal_NN
of_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
556_CD
Movements_NOMZ
on_PIN
provision_NN
375_CD
Deferred_JJ
revenue_NN
46_CD
Cumulative_JJ
effect_NN
of_PIN
change_NN
in_PIN
fair_JJ
value_NN
of_PIN
derivatives_NN
236_CD
Stock_NN
options_NOMZ
granted_VBD [SUAV]
273_CD
Deferred_JJ
tax_NN
744_CD
Interest_NN
and_PHC
bank_NN
charges_NN
2,089_CD
Cash_NN
flow_NN
before_IN
working_VBG
capital_NN
25,946_CD
Change_NN
in_PIN
accounts_NN
receivables_NN
6,155_CD
Change_NN
in_PIN
other_JJ
current_JJ
assets_NN
3,484_CD
Change_NN
in_PIN
inventories_NN
992_CD
Change_NN
in_PIN
trade_NN
accounts_NN
payable_JJ
7,318_CD
Change_NN
in_PIN
other_JJ
current_JJ
liabilities_NOMZ
8,186_CD
Cash_NN
generated_VBN [WZPAST]
by_PIN
operations_NOMZ
28,493_CD
Income_NN
tax_NN
paid_VBN
5,545_CD
Interest_NN
paid_VBN
2,101_CD
Net_JJ
cash_NN
generated_VBD
from_PIN
operating_VBG
activities_NOMZ
20,847_CD
Hikma_NN
Pharmaceuticals_NN
PLC_NN
81_CD
Directors_NN
responsibilities_NOMZ
Company_NN
Law_NN
requires_VPRT [SUAV]
the_DT
Directors_NN
to_TO
prepare_VB
accounts_NN
and_PHC
Notes_NN
for_PIN
each_QUAN
financial_JJ
year_NN
,_,
which_WDT [SERE]
give_VPRT
a_DT
true_JJ
and_PHC
fair_JJ
view_NN
of_PIN
the_DT
state_NN
of_PIN
affairs_NN
of_PIN
the_DT
Company_NN
as_IN
at_PIN
the_DT
end_NN
of_PIN
the_DT
financial_JJ
year_NN
and_CC
the_DT
income_NN
statement_NOMZ
of_PIN
the_DT
Company_NN
for_PIN
that_DEMO
period_NN
._.
In_PIN
preparing_VBG
those_DEMO
accounts_NN
and_PHC
Notes_NN
the_DT
Directors_NN
are_VPRT [PASS]
required_VBN [SUAV]
to_TO
:_:
select_JJ
suitable_JJ
accounting_GER
policies_NN
and_CC
apply_VB
them_TPP3
consistently_RB
:_:
make_VB
judgements_NOMZ
and_PHC
estimates_NN
that_TSUB
are_VPRT [BEMA]
reasonable_PRED
and_PHC
prudent_PRED
:_:
and_ANDC
state_NN
whether_IN
applicable_JJ
accounting_GER
standards_NN
have_VPRT [PEAS]
been_VBN [PASS]
followed_VBN
._.
The_DT
Directors_NN
are_VPRT [BEMA]
responsible_PRED
for_PIN
ensuring_VBG [SUAV] [PRIV]
proper_JJ
accounting_GER
records_NN
are_VPRT [PASS]
kept_VBN
which_WDT
disclose_VPRT [PUBV]
with_PIN
reasonable_JJ
accuracy_NN
at_PIN
any_QUAN
time_NN
the_DT
financial_JJ
position_NOMZ
of_PIN
the_DT
Company_NN
and_CC
enable_VB
them_TPP3
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
the_DT
accounts_NN
and_PHC
Notes_NN
comply_VPRT
with_PIN
the_DT
Companies_NN
Act_NN
1985_CD
._.
They_TPP3
are_VPRT [BEMA]
also_RB
responsible_PRED
for_PIN
the_DT
Companys_NN
system_NN
of_PIN
internal_JJ
control_NN
,_,
for_PIN
safeguarding_VBG
of_PIN
the_DT
assets_NN
of_PIN
the_DT
Company_NN
and_ANDC
hence_CONJ
for_PIN
taking_VBG
reasonable_JJ
steps_NN
for_PIN
the_DT
prevention_NOMZ
and_PHC
detection_NOMZ
of_PIN
fraud_NN
and_CC
other_JJ
irregularities_NOMZ
After_IN
making_VBG
enquiries_NN
,_,
the_DT
Directors_NN
have_VPRT
a_DT
reasonable_JJ
expectation_NOMZ
that_TOBJ
the_DT
Company_NN
has_VPRT
adequate_JJ
resources_NN
to_TO
continue_VB
in_PIN
operational_JJ
existence_NN
for_PIN
the_DT
foreseeable_JJ
future_NN
._.
For_PIN
this_DEMO
reason_NN
,_,
they_TPP3
continue_VPRT
to_TO
adopt_VB
the_DT
going_VBG
concern_NN
basis_NN
in_PIN
preparing_VBG
the_DT
financial_JJ
statements_NOMZ
._.
82_CD
Hikma_NN
Pharmaceuticals_NN
PLC_NN
Independent_NN
auditors_NN
report_VPRT [PUBV]
to_PIN
the_DT
members_NN
of_PIN
Hikma_NN
Pharmaceuticals_NN
PLC_NN
We_FPP1
have_VPRT [PEAS]
audited_VBN
the_DT
individual_JJ
company_NN
financial_JJ
statements_NOMZ
of_PIN
Hikma_NN
Pharmaceuticals_NN
PLC_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2005_CD
which_WDT
comprise_VPRT
the_DT
balance_NN
sheet_NN
,_,
the_DT
cash_NN
flow_NN
statement_NOMZ
and_CC
the_DT
related_JJ
Notes_NN
1_CD
to_PIN
9_CD
._.
These_DEMO
individual_JJ
company_NN
financial_JJ
statements_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
under_IN
the_DT
accounting_GER
policies_NN
set_VBN [WZPAST]
out_PIN
therein_RB
._.
The_DT
corporate_JJ
governance_NN
statement_NOMZ
and_CC
the_DT
Directors_NN
remuneration_NOMZ
report_NN
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
Group_NN
annual_JJ
report_NN
of_PIN
Hikma_NN
Pharmaceuticals_NN
PLC_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2005_CD
._.
We_FPP1
have_VPRT [PEAS]
reported_VBN [PUBV]
separately_RB
on_PIN
the_DT
Group_NN
financial_JJ
statements_NOMZ
of_PIN
Hikma_NN
Pharmaceuticals_NN
PLC_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2005_CD
and_CC
on_PIN
the_DT
information_NOMZ
in_PIN
the_DT
Directors_NN
remuneration_NOMZ
report_NN
that_DEMP
is_VPRT [PASS]
described_VBN
as_IN
having_VBG [PEAS]
been_VBN [PASS]
audited_VBN
._.
This_DEMO
report_NN
is_VPRT [PASS]
made_VBN
solely_RB
to_PIN
the_DT
Companys_NN
members_NN
,_,
as_IN
a_DT
body_NN
,_,
in_PIN
accordance_NN
with_PIN
section_NOMZ
235_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
._.
Our_FPP1
audit_NN
work_NN
has_VPRT [PEAS]
been_VBN [PASS]
undertaken_VBN
so_OSUB
that_NULL
we_FPP1
might_POMD
state_VB [PUBV]
to_PIN
the_DT
Companys_NN
members_NN
those_DEMO
matters_NN
we_FPP1
are_VPRT [PASS]
required_VBN [SUAV]
to_PIN
state_NN
to_PIN
them_TPP3
in_PIN
an_DT
auditors_NN
report_NN
and_CC
for_PIN
no_SYNE
other_JJ
purpose_NN
._.
To_PIN
the_DT
fullest_JJ
extent_NN
permitted_VBN [WZPAST]
by_PIN
law_NN
,_,
we_FPP1
do_VPRT
not_XX0
accept_VB [PRIV]
or_CC
assume_VB [PRIV]
responsibility_NOMZ
to_PIN
anyone_QUPR
other_JJ
than_PIN
the_DT
Company_NN
and_CC
the_DT
Companys_NN
members_NN
as_IN
a_DT
body_NN
,_,
for_PIN
our_FPP1
audit_NN
work_NN
,_,
for_PIN
this_DEMO
report_NN
,_,
or_CC
for_PIN
the_DT
opinions_NN
we_FPP1
have_VPRT [PEAS]
formed_VBN
._.
Respective_JJ
responsibilities_NOMZ
of_PIN
Directors_NN
and_PHC
auditors_NN
The_DT
Directors_NN
responsibilities_NOMZ
for_PIN
preparing_VBG
the_DT
annual_JJ
report_NN
and_CC
the_DT
financial_JJ
statements_NOMZ
in_PIN
accordance_NN
with_PIN
applicable_JJ
law_NN
and_PHC
International_NN
Financial_NN
Reporting_GER
Standards_NN
IFRS_NN
as_IN
adopted_VBN
for_PIN
use_NN
in_PIN
the_DT
European_NN
Union_NN
are_VPRT [PASS]
set_VBN
out_PIN
in_PIN
the_DT
statement_NOMZ
of_PIN
Directors_NN
responsibilities_NOMZ
._.
Our_FPP1
responsibility_NOMZ
is_VPRT
to_TO
audit_VB
the_DT
individual_JJ
company_NN
financial_JJ
statements_NOMZ
in_PIN
accordance_NN
with_PIN
relevant_JJ
United_NN
Kingdom_NN
legal_JJ
and_PHC
regulatory_JJ
requirements_NOMZ
and_PHC
International_NN
Standards_NN
on_PIN
Auditing_GER
UK_NN
and_PHC
Ireland_NN
._.
We_FPP1
report_VPRT [PUBV]
to_PIN
you_SPP2
our_FPP1
opinion_NN
as_IN
to_PIN
whether_IN
the_DT
individual_JJ
company_NN
financial_JJ
statements_NOMZ
give_VPRT
a_DT
true_JJ
and_PHC
fair_JJ
view_NN
in_PIN
accordance_NN
with_PIN
the_DT
relevant_JJ
financial_JJ
reporting_GER
framework_NN
and_ANDC
whether_IN
the_DT
financial_JJ
statements_NOMZ
have_VPRT [PEAS]
been_VBN [SPAU] [PASS]
properly_RB
prepared_VBN
in_PIN
accordance_NN
with_PIN
the_DT
Companies_NN
Act_NN
1985_CD
and_CC
Article_NN
4_CD
of_PIN
the_DT
IAS_NN
Regulation_NOMZ
._.
We_FPP1
report_VPRT [PUBV]
to_PIN
you_SPP2
if_COND
,_,
in_PIN
our_FPP1
opinion_NN
,_,
the_DT
Directors_NN
report_NN
is_VPRT [BEMA]
not_XX0
consistent_PRED
with_PIN
the_DT
individual_JJ
company_NN
financial_JJ
statements_NOMZ
._.
We_FPP1
also_RB
report_VPRT [PUBV]
to_PIN
you_SPP2
if_COND
the_DT
Company_NN
has_VPRT [PEAS]
not_XX0
kept_VBN
proper_JJ
accounting_GER
records_NN
,_,
if_COND
we_FPP1
have_VPRT [PEAS]
not_XX0
received_VBN
all_QUAN
the_DT
information_NOMZ
and_PHC
explanations_NOMZ
we_FPP1
require_VPRT [SUAV]
for_PIN
our_FPP1
audit_NN
,_,
or_CC
if_COND
information_NOMZ
specified_VBN [WZPAST]
by_PIN
law_NN
regarding_VBG [WZPRES]
Directors_NN
remuneration_NOMZ
and_CC
other_JJ
transactions_NOMZ
is_VPRT [PASS]
not_XX0
disclosed_VBN [PUBV]
._.
We_FPP1
read_VPRT
the_DT
Directors_NN
report_NN
and_CC
the_DT
other_JJ
information_NOMZ
contained_VBN [WZPAST]
in_PIN
the_DT
annual_JJ
report_NN
for_PIN
the_DT
above_PLACE
year_NN
as_IN
described_VBN
in_PIN
the_DT
contents_NN
section_NOMZ
._.
We_FPP1
consider_VPRT [PRIV]
the_DT
implications_NOMZ
for_PIN
our_FPP1
report_NN
if_COND
we_FPP1
become_VPRT
aware_JJ
of_PIN
any_QUAN
apparent_JJ
misstatements_NOMZ
or_CC
material_NN
inconsistencies_NN
with_PIN
the_DT
individual_JJ
company_NN
financial_JJ
statements_NOMZ
._.
Basis_NN
of_PIN
audit_NN
opinion_NN
We_FPP1
conducted_VBD
our_FPP1
audit_NN
in_PIN
accordance_NN
with_PIN
International_NN
Standards_NN
on_PIN
Auditing_GER
UK_NN
and_PHC
Ireland_NN
issued_VBN [WZPAST]
by_PIN
the_DT
Auditing_GER
Practices_NN
Board_NN
._.
An_DT
audit_NN
includes_VPRT
examination_NOMZ
,_,
on_PIN
a_DT
test_NN
basis_NN
,_,
of_PIN
evidence_NN
relevant_JJ
to_PIN
the_DT
amounts_NN
and_PHC
disclosures_NN
in_PIN
the_DT
individual_JJ
company_NN
financial_JJ
statements_NOMZ
._.
It_PIT
also_RB
includes_VPRT
an_DT
assessment_NOMZ
of_PIN
the_DT
significant_JJ
estimates_NN
and_PHC
judgements_NOMZ
made_VBN [WZPAST]
by_PIN
the_DT
Directors_NN
in_PIN
the_DT
preparation_NOMZ
of_PIN
the_DT
financial_JJ
statements_NOMZ
,_,
and_ANDC
of_PIN
whether_IN
the_DT
accounting_GER
policies_NN
are_VPRT [BEMA]
appropriate_PRED
to_PIN
the_DT
Companys_NN
circumstances_NN
,_,
consistently_RB
applied_VBN
and_CC
adequately_RB
disclosed_VBN [PUBV]
._.
We_FPP1
planned_VBD
and_PHC
performed_VBD
our_FPP1
audit_NN
so_RB
as_IN
to_TO
obtain_VB
all_QUAN
the_DT
information_NOMZ
and_PHC
explanations_NOMZ
which_WDT [WHOBJ]
we_FPP1
considered_VBD [PRIV]
necessary_JJ
in_PIN
order_NN
to_TO
provide_VB
us_FPP1
with_PIN
sufficient_JJ
evidence_NN
to_TO
give_VB
reasonable_JJ
assurance_NN
that_TOBJ
the_DT
individual_JJ
company_NN
financial_JJ
statements_NOMZ
are_VPRT [BEMA]
free_PRED
from_PIN
material_NN
misstatement_NOMZ
,_,
whether_IN
caused_VBN
by_PIN
fraud_NN
or_CC
other_JJ
irregularity_NOMZ
or_CC
error_NN
._.
In_PIN
forming_VBG
our_FPP1
opinion_NN
we_FPP1
also_RB
evaluated_VBD
the_DT
overall_JJ
adequacy_NN
of_PIN
the_DT
presentation_NOMZ
of_PIN
information_NOMZ
in_PIN
the_DT
individual_JJ
company_NN
financial_JJ
statements_NOMZ
._.
Opinion_NN
In_PIN
our_FPP1
opinion_NN
:_:
the_DT
individual_JJ
company_NN
financial_JJ
statements_NOMZ
give_VPRT
a_DT
true_JJ
and_PHC
fair_JJ
view_NN
,_,
in_PIN
accordance_NN
with_PIN
IFRS_NN
as_IN
adopted_VBN
for_PIN
use_NN
in_PIN
the_DT
European_NN
Union_NN
as_IN
applied_VBN
in_PIN
accordance_NN
with_PIN
the_DT
requirements_NOMZ
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
,_,
of_PIN
the_DT
state_NN
of_PIN
the_DT
Companys_NN
affairs_NN
as_IN
at_PIN
31_CD
December_NN
2005_CD
:_:
and_ANDC
the_DT
individual_JJ
company_NN
financial_JJ
statements_NOMZ
have_VPRT [PEAS]
been_VBN [SPAU] [PASS]
properly_RB
prepared_VBN
in_PIN
accordance_NN
with_PIN
the_DT
Companies_NN
Act_NN
1985_CD
and_CC
Article_NN
4_CD
of_PIN
the_DT
IAS_NN
Regulation_NOMZ
._.
Deloitte_NN
&_CC
Touche_NN
LLP_NN
Chartered_NN
Accountants_NN
and_PHC
Registered_NN
Auditors_NN
London_NN
,_,
United_NN
Kingdom_NN
28_CD
March_NN
2006_CD
._.
Hikma_NN
Pharmaceuticals_NN
PLC_NN
83_CD
Company_NN
balance_NN
sheet_NN
as_IN
of_PIN
31_CD
December_NN
2005_CD
2005_CD
Notes_NN
$_$
000s_CD
Non-current_JJ
assets_NN
Investment_NOMZ
in_PIN
subsidiary_NN
2_CD
740,298_CD
Due_JJ
from_PIN
subsidiaries_NN
54,000_CD
794,298_CD
Current_JJ
assets_NN
Other_JJ
current_JJ
assets_NN
422_CD
Cash_NN
and_PHC
cash_NN
equivalents_NN
3_CD
58,732_CD
Dividends_NN
receivable_NN
1,500_CD
60,654_CD
Total_JJ
assets_NN
854,952_CD
Current_JJ
liabilities_NOMZ
Other_JJ
payables_NN
4_CD
994_CD
Other_JJ
current_JJ
liabilities_NOMZ
354_CD
Income_NN
tax_NN
provision_NN
110_CD
1,458_CD
Non-current_JJ
liabilities_NOMZ
Due_JJ
to_PIN
subsidiaries_NN
4,836_CD
Total_JJ
liabilities_NOMZ
6,294_CD
Net_JJ
assets_NN
848,658_CD
Equity_NOMZ
Share_NN
capital_NN
7_CD
29,457_CD
Share_NN
premium_NN
account_NN
8_CD
817,443_CD
Retained_VBN
earnings_GER
9_CD
1,758_CD
Equity_NOMZ
attributable_JJ
to_PIN
equity_NOMZ
holders_NN
to_PIN
the_DT
parent_NN
848,658_CD
The_DT
financial_JJ
statements_NOMZ
were_VBD [BYPA]
approved_VBN
by_PIN
the_DT
Board_NN
of_PIN
Directors_NN
and_CC
signed_VBN
on_PIN
its_PIT
behalf_NN
by_PIN
:_:
Samih_NN
Darwazah_NN
Director_NN
28_CD
March_NN
2006_CD
84_CD
Hikma_NN
Pharmaceuticals_NN
PLC_NN
Company_NN
statement_NOMZ
of_PIN
changes_NN
in_PIN
equity_NOMZ
for_PIN
the_DT
period_NN
ended_VBD
31_CD
December_NN
2005_CD
Paid_VBD
up_RP
Share_NN
Retained_VBN
capital_NN
premium_NN
earnings_GER
Total_JJ
Notes_NN
$_$
000s_CD
$_$
000s_CD
$_$
000s_CD
$_$
000s_CD
At_PIN
8_CD
September_NN
2005_CD
8_CD
Issue_NN
of_PIN
share_NN
capital_NN
29,457_CD
817,443_CD
846,900_CD
Net_JJ
income_NN
for_PIN
the_DT
period_NN
9_CD
1,758_CD
1,758_CD
At_PIN
31_CD
December_NN
2005_CD
29,457_CD
817,443_CD
1,758_CD
848,658_CD
As_IN
permitted_VBN
by_PIN
Section_NOMZ
230_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
,_,
the_DT
income_NN
statement_NOMZ
of_PIN
the_DT
Company_NN
is_VPRT [PASS]
not_XX0
presented_VBN
as_IN
part_NN
of_PIN
these_DEMO
accounts_NN
._.
Hikma_NN
Pharmaceuticals_NN
PLC_NN
85_CD
Cash_NN
flow_NN
statement_NOMZ
for_PIN
the_DT
period_NN
ended_VBD
31_CD
December_NN
2005_CD
2005_CD
$_$
000s_CD
Profit_NN
before_IN
tax_NN
1,695_CD
Stock_NN
options_NOMZ
granted_VBD [SUAV]
172_CD
Change_NN
in_PIN
other_JJ
current_JJ
assets_NN
422_CD
Change_NN
in_PIN
other_JJ
payables_NN
994_CD
Change_NN
in_PIN
other_JJ
current_JJ
liabilities_NOMZ
354_CD
Net_JJ
cash_NN
used_VBN [WZPAST]
in_PIN
operating_VBG
activities_NOMZ
2,793_CD
Investing_VBG
activities_NOMZ
Change_NN
in_PIN
amounts_NN
due_JJ
from_PIN
subsidiaries_NN
49,164_CD
Change_NN
in_PIN
dividends_NN
receivable_JJ
1,500_CD
Investment_NOMZ
in_PIN
subsidiary_NN
7,500_CD
Net_JJ
cash_NN
used_VBN [WZPAST]
in_PIN
investing_VBG
activities_NOMZ
58,164_CD
Financing_GER
activities_NOMZ
Proceeds_NN
from_PIN
share_NN
issuance_NN
124,913_CD
Costs_NN
of_PIN
share_NN
issue_NN
10,810_CD
Net_JJ
cash_NN
from_PIN
financing_VBG
activities_NOMZ
114,103_CD
Net_JJ
increase_NN
in_PIN
cash_NN
and_PHC
cash_NN
equivalents_NN
58,732_CD
Cash_NN
and_PHC
cash_NN
equivalents_NN
at_PIN
beginning_GER
of_PIN
period_NN
Cash_NN
and_PHC
cash_NN
equivalents_NN
at_PIN
end_NN
of_PIN
period_NN
58,732_CD
86_CD
Hikma_NN
Pharmaceuticals_NN
PLC_NN
Notes_NN
to_PIN
the_DT
separate_JJ
financial_JJ
statements_NOMZ
1_CD
._.
Significant_JJ
accounting_GER
policies_NN
The_DT
separate_JJ
financial_JJ
statements_NOMZ
of_PIN
the_DT
Company_NN
are_VPRT [PASS]
presented_VBN
as_IN
required_VBN [SUAV]
by_PIN
the_DT
Companies_NN
Act_NN
1985_CD
._.
As_IN
permitted_VBN
by_PIN
that_DEMO
Act_NN
,_,
the_DT
separate_JJ
financial_JJ
statements_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
in_PIN
accordance_NN
with_PIN
International_NN
Financial_NN
Reporting_GER
Standards_NN
and_PHC
UK_NN
law_NN
._.
The_DT
financial_JJ
statements_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
on_PIN
the_DT
historical_JJ
cost_NN
basis_NN
._.
The_DT
principal_JJ
accounting_GER
policies_NN
adopted_VBN [WZPAST]
are_VPRT [BEMA]
the_DT
same_JJ
as_IN
those_DEMP
set_VBN
out_PIN
in_PIN
Note_NN
2_CD
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
with_PIN
the_DT
addition_NOMZ
of_PIN
the_DT
policy_NN
as_IN
noted_VBN [PRIV]
below_PLACE
._.
Investments_NOMZ
in_PIN
subsidiaries_NN
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
cost_NN
less_RB
,_,
where_RB
appropriate_JJ
,_,
provisions_NN
for_PIN
impairment_NOMZ
._.
Investment_NOMZ
in_PIN
subsidiary_NN
Investment_NOMZ
in_PIN
subsidiary_NN
represents_VPRT
100_CD
%_NN
share_NN
in_PIN
Hikma_NN
Pharma_NN
Limited_NN
Jersey_NN
,_,
the_DT
cost_NN
method_NN
is_VPRT
being_VBG [PASS]
used_VBN
to_TO
account_VB
for_PIN
this_DEMO
investment_NOMZ
._.
Financial_JJ
assets_NN
Cash_NN
and_PHC
cash_NN
equivalents_NN
These_DEMP
comprise_VPRT
cash_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
company_NN
and_CC
short-term_JJ
bank_NN
deposits_NN
with_PIN
an_DT
original_JJ
maturity_NOMZ
of_PIN
three_CD
months_NN
or_CC
less_JJ
._.
The_DT
carrying_VBG
amount_NN
of_PIN
these_DEMO
assets_NN
approximates_VPRT
their_TPP3
fair_JJ
value_NN
._.
Financial_NN
liabilities_NOMZ
Other_JJ
payables_NN
The_DT
Directors_NN
consider_VPRT [PRIV]
that_THVC
the_DT
carrying_VBG
amount_NN
of_PIN
other_JJ
payables_NN
approximates_VPRT
to_PIN
their_TPP3
fair_JJ
value_NN
._.
Staff_NN
costs_NN
Hikma_NN
Pharmaceuticals_NN
PLC_NN
currently_RB
has_VPRT
two_CD
employees_NN
:_:
total_JJ
compensation_NOMZ
paid_VBN [WZPAST]
to_PIN
them_TPP3
amounted_VBD
to_TO
$_$
117,000_CD
of_PIN
which_WDT [PIRE]
salaries_NN
and_PHC
wages_NN
compromise_VB
an_DT
amount_NN
of_PIN
$_$
73,000_CD
the_DT
remaining_VBG
balance_NN
of_PIN
$_$
44,000_CD
represent_VPRT
social_JJ
security_NOMZ
and_CC
other_JJ
benefits_NN
._.
Stock_NN
options_NOMZ
The_DT
details_NN
of_PIN
the_DT
stock_NN
compensation_NOMZ
scheme_NN
were_VBD [PASS]
provided_VBN
in_PIN
Note_NN
39_CD
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
._.
The_DT
number_NN
of_PIN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
to_PIN
the_DT
employees_NN
of_PIN
the_DT
Company_NN
including_VBG [WZPRES]
Directors_NN
was_VBD [BEMA]
2,560,000_CD
and_CC
the_DT
total_JJ
amount_NN
of_PIN
the_DT
compensation_NOMZ
expenses_NN
charged_VBD
to_PIN
income_NN
statement_NOMZ
is_VPRT
$_$
172,000_CD
._.
Share_NN
capital_NN
2005_CD
$_$
000s_CD
Authorised_VBN
:_:
500,000,000_CD
Ordinary_NN
Shares_NN
of_PIN
10_CD
pence_NN
each_QUAN
88,700_CD
49,998_CD
non-voting_JJ
,_,
redeemable_JJ
preference_NN
shares_NN
of_PIN
1_CD
each_QUAN
90_CD
Issued_VBN
and_CC
fully_AMP
paid_VBN
included_VBN
in_PIN
shareholders_NN
equity_NOMZ
166,798,407_CD
Ordinary_NN
Shares_NN
of_PIN
10_CD
pence_NN
each_QUAN
29,457_CD
Issued_VBN
and_CC
fully_AMP
paid_VBN
included_VBN
in_PIN
liabilities_NOMZ
49,998_CD
non-voting_JJ
,_,
redeemable_JJ
preference_NN
shares_NN
of_PIN
1_CD
each_QUAN
90_CD
The_DT
details_NN
of_PIN
the_DT
issue_NN
of_PIN
the_DT
share_NN
capital_NN
in_PIN
the_DT
period_NN
are_VPRT [PASS]
given_VBN
in_PIN
Note_NN
31_CD
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
._.
Share_NN
premium_NN
Share_NN
premium_NN
$_$
000s_CD
Balance_NN
at_PIN
8_CD
September_NN
2005_CD
Premium_NN
arising_VBG [WZPRES]
on_PIN
issue_NN
of_PIN
equity_NOMZ
shares_NN
828,253_CD
Expenses_NN
of_PIN
issue_NN
of_PIN
equity_NOMZ
shares_NN
10,810_CD
Balance_NN
at_PIN
31_CD
December_NN
2005_CD
817,443_CD
9_CD
._.
Retained_VBN
earnings_GER
Included_VBD
in_PIN
the_DT
retained_VBN
earnings_GER
an_DT
amount_NN
of_PIN
$_$
172,000_CD
represents_VPRT
the_DT
current_JJ
year_NN
charge_NN
of_PIN
stock_NN
option_NOMZ
expenses_NN
._.
